The toxic $\hat{AI^2}$ oligomer and Alzheimer's disease: an emp

Nature Neuroscience 15, 349-357

DOI: 10.1038/nn.3028

Citation Report

#	Article	IF	CITATIONS
1	Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomarkers in Medicine, 2012, 6, 455-476.	0.6	100
2	Neurotoxicity and Memory Deficits Induced by Soluble Low-Molecular-Weight Amyloid-Â1-42 Oligomers Are Revealed In Vivo by Using a Novel Animal Model. Journal of Neuroscience, 2012, 32, 7852-7861.	1.7	156
3	The P's and Q's of cellular PrP-Aβ interactions. Prion, 2012, 6, 359-363.	0.9	10
4	Expression of the plant viral protease NIa in the brain of a mouse model of Alzheimer's disease mitigates AÎ ² pathology and improves cognitive function. Experimental and Molecular Medicine, 2012, 44, 740.	3.2	16
5	Putting a cap on AD. Science-Business EXchange, 2012, 5, 916-916.	0.0	0
6	Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood $A\hat{l}^2$ clearance in a mouse model of \hat{l}^2 -amyloidosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15502-15507.	3.3	138
7	Differential Regulation of Amyloid- \hat{l}^2 Endocytic Trafficking and Lysosomal Degradation by Apolipoprotein E Isoforms. Journal of Biological Chemistry, 2012, 287, 44593-44601.	1.6	156
8	Mitochondrion-mediated cell death: dissecting yeast apoptosis for a better understanding of neurodegeneration. Frontiers in Oncology, 2012, 2, 182.	1.3	36
9	Probing and Trapping a Sensitive Conformation: Amyloid- \hat{l}^2 Fibrils, Oligomers, and Dimers. Journal of Alzheimer's Disease, 2012, 32, 197-215.	1.2	23
10	The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update. Expert Opinion on Drug Discovery, 2012, 7, 281-297.	2.5	42
11	Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer's disease. Biochemical Society Transactions, 2012, 40, 721-727.	1.6	117
12	Lightâ€Controlled Toxicity of Engineered Amyloid βâ€Peptides. ChemBioChem, 2012, 13, 2657-2660.	1.3	10
13	Bioinformatics aggregation predictors in the study of protein conformational diseases of the human nervous system. Electrophoresis, 2012, 33, 3669-3679.	1.3	7
14	Fe65 matters: New light on an old molecule. IUBMB Life, 2012, 64, 936-942.	1.5	20
15	Determination of amyloid core structure using chemical shifts. Protein Science, 2012, 21, 1948-1953.	3.1	12
16	Pathogenesis and Disease-modifying Therapy in Alzheimer's Disease: The Flat Line of Progress. Archives of Medical Research, 2012, 43, 694-698.	1.5	85
17	Transient small molecule interactions kinetically modulate amyloid β peptide selfâ€assembly. FEBS Letters, 2012, 586, 3991-3995.	1.3	21
18	Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease. Alzheimer's Research and Therapy, 2012, 4, 32.	3.0	50

#	Article	IF	CITATIONS
19	Specific Recognition of Biologically Active Amyloid- \hat{l}^2 Oligomers by a New Surface Plasmon Resonance-based Immunoassay and an in Vivo Assay in Caenorhabditis elegans. Journal of Biological Chemistry, 2012, 287, 27796-27805.	1.6	52
20	Ligand-Gated Ion Channels: New Insights into Neurological Disorders and Ligand Recognition. Chemical Reviews, 2012, 112, 6285-6318.	23.0	133
21	pH-dependence of the specific binding of Cu(II) and Zn(II) ions to the amyloid- \hat{l}^2 peptide. Biochemical and Biophysical Research Communications, 2012, 421, 554-560.	1.0	46
22	Metal ions as modulators of protein conformation and misfolding in neurodegeneration. Coordination Chemistry Reviews, 2012, 256, 2253-2270.	9.5	147
23	Alzheimer Mechanisms and Therapeutic Strategies. Cell, 2012, 148, 1204-1222.	13.5	1,548
24	Alzheimerâ \in TM s disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory. Molecular Brain, 2012, 5, 25.	1.3	82
25	A protective mutation. Nature, 2012, 488, 38-39.	13.7	20
26	Reduction of Synaptojanin 1 Ameliorates Synaptic and Behavioral Impairments in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2012, 32, 15271-15276.	1.7	69
27	The epidemiological neuropathology of dementia and the implications for drug development. Neurodegenerative Disease Management, 2012, 2, 471-482.	1.2	7
28	Two-Step Mechanism of Membrane Disruption by ${\sf A}\hat{\sf I}^2$ through Membrane Fragmentation and Pore Formation. Biophysical Journal, 2012, 103, 702-710.	0.2	326
29	β-Amyloid (1–40) Peptide Interactions with Supported Phospholipid Membranes: A Single-Molecule Study. Biophysical Journal, 2012, 103, 1500-1509.	0.2	56
30	Hematopoietic MyD88-adaptor Protein Acts as a Natural Defense Mechanism for Cognitive Deficits in Alzheimer's Disease. Stem Cell Reviews and Reports, 2012, 8, 898-904.	5.6	27
31	Nerve Growth Factor and Alzheimer's Disease: New Facts for an Old Hypothesis. Molecular Neurobiology, 2012, 46, 588-604.	1.9	87
32	The Synaptic Accumulation of Hyperphosphorylated Tau Oligomers in Alzheimer Disease Is Associated With Dysfunction of the Ubiquitin-Proteasome System. American Journal of Pathology, 2012, 181, 1426-1435.	1.9	369
33	Multivariate Analyses of Amyloid-Beta Oligomer Populations Indicate a Connection between Pore Formation and Cytotoxicity. PLoS ONE, 2012, 7, e47261.	1.1	79
34	Modeling Amyloid-Beta as Homogeneous Dodecamers and in Complex with Cellular Prion Protein. PLoS ONE, 2012, 7, e49375.	1.1	11
35	Human Anti-A \hat{l}^2 IgGs Target Conformational Epitopes on Synthetic Dimer Assemblies and the AD Brain-Derived Peptide. PLoS ONE, 2012, 7, e50317.	1.1	13
36	Lysosomal Fusion Dysfunction as a Unifying Hypothesis for Alzheimer's Disease Pathology. International Journal of Alzheimer's Disease, 2012, 2012, 1-10.	1.1	37

#	Article	IF	Citations
37	Î ² -Amyloid: Enemy or Remedy?. Science Translational Medicine, 2012, 4, 145fs24.	5.8	3
38	Prion propagation, toxicity and degradation. Nature Neuroscience, 2012, 15, 936-939.	7.1	105
39	Differential Activation of the ER Stress Factor XBP1 by Oligomeric Assemblies. Neurochemical Research, 2012, 37, 1707-1717.	1.6	45
40	The role of α-synuclein in neurodegeneration — An update. Translational Neuroscience, 2012, 3, .	0.7	16
41	Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?. Immunity and Ageing, 2013, 10, 18.	1.8	97
42	Membrane trafficking in neuronal maintenance and degeneration. Cellular and Molecular Life Sciences, 2013, 70, 2919-2934.	2.4	62
43	Acetyl-CoA the Key Factor for Survival or Death of Cholinergic Neurons in Course of Neurodegenerative Diseases. Neurochemical Research, 2013, 38, 1523-1542.	1.6	89
44	Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochemistry International, 2013, 62, 540-555.	1.9	376
45	The case for soluble ${\rm A}\hat{\rm I}^2$ oligomers as a drug target in Alzheimer's disease. Trends in Pharmacological Sciences, 2013, 34, 261-266.	4.0	102
46	The neurodegeneration in Alzheimer disease and the prion protein. Prion, 2013, 7, 60-65.	0.9	12
47	Structures of Oligomers of a Peptide from \hat{l}^2 -Amyloid. Journal of the American Chemical Society, 2013, 135, 12460-12467.	6.6	50
48	Protein aggregation in bacteria: the thin boundary between functionality and toxicity. Microbiology (United Kingdom), 2013, 159, 1795-1806.	0.7	81
49	Role of Brain Iron Accumulation in Cognitive Dysfunction: Evidence from Animal Models and Human Studies. Journal of Alzheimer's Disease, 2013, 34, 797-812.	1.2	87
50	N-truncated amyloid \hat{I}^2 (\hat{AI}^2) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. Acta Neuropathologica, 2013, 126, 189-205.	3.9	153
51	Non-invasive infra-red therapy (1072nm) reduces β-amyloid protein levels in the brain of an Alzheimer's disease mouse model, TASTPM. Journal of Photochemistry and Photobiology B: Biology, 2013, 123, 13-22.	1.7	87
52	Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain, 2013, 136, 2510-2526.	3.7	294
53	Dietary cholesterol degrades rabbit long term memory for discrimination learning but facilitates acquisition of discrimination reversal. Neurobiology of Learning and Memory, 2013, 106, 238-245.	1.0	4
54	Fibrillar seeds alleviate amyloid- \hat{l}^2 cytotoxicity by omitting formation of higher-molecular-weight oligomers. Biochemical and Biophysical Research Communications, 2013, 439, 321-326.	1.0	13

#	Article	IF	CITATIONS
55	Structural Insights into A \hat{l}^2 42 Oligomers Using Site-directed Spin Labeling. Journal of Biological Chemistry, 2013, 288, 18673-18683.	1.6	70
56	Neuronal <scp>AChE</scp> splice variants and their nonâ€hydrolytic functions: redefining a target of <scp>AChE</scp> inhibitors?. British Journal of Pharmacology, 2013, 170, 953-967.	2.7	54
57	Engineered non-fluorescent Affibody molecules facilitate studies of the amyloid-beta ($A\hat{1}^2$) peptide in monomeric form: Low pH was found to reduce $A\hat{1}^2$ /Cu(II) binding affinity. Journal of Inorganic Biochemistry, 2013, 120, 18-23.	1.5	19
58	Multifunctional Cholinesterase and Amyloid Beta Fibrillization Modulators. Synthesis and Biological Investigation. ACS Medicinal Chemistry Letters, 2013, 4, 1178-1182.	1.3	40
59	Synaptic deficits in layer 5 neurons precede overt structural decay in 5xFAD mice. Neuroscience, 2013, 254, 152-159.	1.1	51
60	Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain, 2013, 136, 1383-1398.	3.7	384
61	Globular and Protofibrillar $\hat{Al^2}$ Aggregates Impair Neurotransmission by Different Mechanisms. Biochemistry, 2013, 52, 1466-1476.	1.2	20
62	Biology and Genetics of Prions Causing Neurodegeneration. Annual Review of Genetics, 2013, 47, 601-623.	3.2	384
63	Formation of Dynamic Soluble Surfactant-induced Amyloid \hat{l}^2 Peptide Aggregation Intermediates. Journal of Biological Chemistry, 2013, 288, 23518-23528.	1.6	43
64	Ligand Noninnocence of Thiolate/Disulfide in Dinuclear Copper Complexes: Solvent-Dependent Redox Isomerization and Proton-Coupled Electron Transfer. Journal of the American Chemical Society, 2013, 135, 18912-18919.	6.6	48
65	Single-Molecule Imaging Reveals A \hat{l}^2 42:A \hat{l}^2 40 Ratio-Dependent Oligomer Growth on Neuronal Processes. Biophysical Journal, 2013, 104, 894-903.	0.2	29
66	Free energy landscapes for initiation and branching of protein aggregation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20515-20520.	3.3	39
67	A stereoselective approach to peptidomimetic BACE1 inhibitors. European Journal of Medicinal Chemistry, 2013, 70, 233-247.	2.6	17
68	Aβ in Mitochondria—One Piece in the Alzheimer's Disease Puzzle. Oxidative Stress in Applied Basic Research and Clinical Practice, 2013, , 41-53.	0.4	0
69	Blood–brain-barriers in aging and in Alzheimer's disease. Molecular Neurodegeneration, 2013, 8, 38.	4.4	222
70	The airbag problem–a potential culprit for bench-to-bedside translational efforts: relevance for Alzheimer's disease. Acta Neuropathologica Communications, 2013, 1, 62.	2.4	31
71	N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody. Acta Neuropathologica Communications, 2013, 1, 56 .	2.4	36
72	The absence of myelin basic protein promotes neuroinflammation and reduces amyloid \hat{l}^2 -protein accumulation in Tg-5xFAD mice. Journal of Neuroinflammation, 2013, 10, 134.	3.1	30

#	Article	IF	Citations
73	SUMO and Alzheimer's Disease. NeuroMolecular Medicine, 2013, 15, 720-736.	1.8	82
74	Targeting the neural extracellular matrix in neurological disorders. Neuroscience, 2013, 253, 194-213.	1.1	198
75	Formation Kinetics and Structural Features of Betaâ€Amyloid Aggregates by Sedimented Solute NMR. ChemBioChem, 2013, 14, 1891-1897.	1.3	38
77	Promiscuous Alzheimer's Amyloid: Yet Another Partner. Science, 2013, 341, 1354-1355.	6.0	60
78	Alzheimer's Disease: Pathophysiology and Applications of Magnetic Nanoparticles as MRI Theranostic Agents. ACS Chemical Neuroscience, 2013, 4, 1417-1429.	1.7	95
79	Modification of a Small βâ€Barrel Protein, To Give Pseudoâ€Amyloid Structures, Inhibits Amyloid βâ€Peptide Aggregation. Chemistry - A European Journal, 2013, 19, 4525-4531.	1.7	6
80	A folding transition underlies the emergence of membrane affinity in amyloid- \hat{l}^2 . Physical Chemistry Chemical Physics, 2013, 15, 19129.	1.3	38
81	A General Way to Assay Protein by Coupling Peptide with Signal Reporter via Supermolecule Formation. Analytical Chemistry, 2013, 85, 1047-1052.	3.2	91
82	Alzheimer's Disease Modeling: Ups, Downs, and Perspectives for Human Induced Pluripotent Stem Cells. Journal of Alzheimer's Disease, 2013, 34, 563-588.	1.2	34
83	α-Synuclein Oligomers: an Amyloid Pore?. Molecular Neurobiology, 2013, 47, 613-621.	1.9	87
84	Cellular Polyamines Promote Amyloid-Beta (${\rm A\hat{I}^2}$) Peptide Fibrillation and Modulate the Aggregation Pathways. ACS Chemical Neuroscience, 2013, 4, 454-462.	1.7	89
85	Different Fates of Alzheimer's Disease Amyloid-β Fibrils Remodeled by Biocompatible Small Molecules. Biomacromolecules, 2013, 14, 264-274.	2.6	29
86	Different effects of soluble and aggregated amyloid \hat{l}^2 42 on gene/protein expression and enzyme activity involved in insulin and APP pathways. Journal of Neural Transmission, 2013, 120, 113-120.	1.4	15
87	αâ€Synuclein oligomers and clinical implications for Parkinson disease. Annals of Neurology, 2013, 73, 155-169.	2.8	255
88	Recent developments in targeting protein misfolding diseases. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1935-1944.	1.0	38
89	Beta amyloid peptide plaques fail to alter evoked neuronal calcium signals in APP/PS1 Alzheimer's disease mice. Neurobiology of Aging, 2013, 34, 1632-1643.	1.5	20
90	Nucleotide excision repair in chronic neurodegenerative diseases. DNA Repair, 2013, 12, 568-577.	1.3	25
91	Advances in ion mobility spectrometry–mass spectrometry reveal key insights into amyloid assembly. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 1257-1268.	1.1	76

#	ARTICLE	IF	CITATIONS
92	Further characterization of a putative serine protease contributing to the \hat{l}^3 -secretase cleavage of \hat{l}^2 -amyloid precursor protein. Bioorganic and Medicinal Chemistry, 2013, 21, 1018-1029.	1.4	3
93	Novel approaches for studying amyloidogenic peptides/proteins. Current Opinion in Pharmacology, 2013, 13, 797-801.	1.7	15
94	Abundant pyroglutamate-modified ABri and ADan peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias. Neurobiology of Aging, 2013, 34, 1416-1425.	1.5	14
95	Resolution of Oligomeric Species during the Aggregation of Aβ _{1–40} Using ¹⁹ F NMR. Biochemistry, 2013, 52, 1903-1912.	1.2	97
96	Amyloid- \hat{l}^2 induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. Prion, 2013, 7, 37-41.	0.9	114
97	Extracellular Chaperones and Proteostasis. Annual Review of Biochemistry, 2013, 82, 295-322.	5.0	156
99	Natural Compounds May Open New Routes to Treatment of Amyloid Diseases. Neurotherapeutics, 2013, 10, 429-439.	2.1	75
100	Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease. Journal of Neurochemistry, 2013, 126, 191-202.	2.1	145
101	Mechanical Resistance in Unstructured Proteins. Biophysical Journal, 2013, 104, 2725-2732.	0.2	15
102	Beta-amyloid peptides undergo regulated co-secretion with neuropeptide and catecholamine neurotransmitters. Peptides, 2013, 46, 126-135.	1.2	26
103	Rational heterodoxy: Cholesterol reformation of the amyloid doctrine. Ageing Research Reviews, 2013, 12, 282-288.	5.0	33
104	Axonal degeneration in Alzheimer's disease: When signaling abnormalities meet the axonal transport system. Experimental Neurology, 2013, 246, 44-53.	2.0	171
105	Differential contribution of isoaspartate post-translational modifications to the fibrillization and toxic properties of amyloid \hat{l}^2 and the Asn23 lowa mutation. Biochemical Journal, 2013, 456, 347-360.	1.7	39
106	Exosomes neutralize synaptic-plasticity-disrupting activity of $\hat{Al^2}$ assemblies in vivo. Molecular Brain, 2013, 6, 47.	1.3	155
107	On the subject of rigor in the study of amyloid \hat{l}^2 -protein assembly. Alzheimer's Research and Therapy, 2013, 5, 39.	3.0	64
108	Treating Alzheimer $\hat{a} \in \mathbb{N}$ s disease with monoclonal antibodies: current status and outlook for the future. Alzheimer's Research and Therapy, 2013, 5, 56.	3.0	51
109	Amyloid β-protein oligomers and Alzheimer's disease. Alzheimer's Research and Therapy, 2013, 5, 60.	3.0	209
110	Cellular Prion Protein as a Therapeutic Target in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 38, 227-244.	1.2	46

#	ARTICLE	IF	CITATIONS
111	The role of amyloid \hat{l}^2 in the pathogenesis of Alzheimer's disease. Journal of Clinical Pathology, 2013, 66, 362-366.	1.0	97
112	Correlation of Specific Amyloid- \hat{l}^2 Oligomers With Tau in Cerebrospinal Fluid From Cognitively Normal Older Adults. JAMA Neurology, 2013, 70, 594.	4.5	54
113	Non-toxic amyloid beta formed in the presence of glypican-1 or its deaminatively generated heparan sulfate degradation products. Glycobiology, 2013, 23, 1510-1519.	1.3	14
114	Using neurolipidomics to identify phospholipid mediators of synaptic (dys)function in Alzheimer's Disease. Frontiers in Physiology, 2013, 4, 168.	1.3	60
115	Breaking the Code of Amyloid- <mml:math id="M1" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi mathvariant="bold-italic">$\hat{1}^2$</mml:mi></mml:mrow></mml:math> Oligomers. International Journal of Cell Biology, 2013, 2013, 1-6.	1.0	25
116	Thermodynamically stable amyloid- \hat{l}^2 monomers have much lower membrane affinity than the small oligomers. Frontiers in Physiology, 2013, 4, 84.	1.3	47
117	New Genes and New Insights from Old Genes. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 358-371.	0.4	15
118	Amyloid imaging in dementia. Reviews in Clinical Gerontology, 2013, 23, 43-60.	0.5	O
119	Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology, 2013, 80, 1341-1348.	1.5	290
121	Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Scientific Reports, 2013, 3, 1472.	1.6	83
122	Amyloid- \hat{l}^2 oligomers induce tau-independent disruption of BDNF axonal transport via calcineurin activation in cultured hippocampal neurons. Molecular Biology of the Cell, 2013, 24, 2494-2505.	0.9	57
124	Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease. Current Opinion in Psychiatry, 2013, 26, 276-282.	3.1	20
125	Mechanism of amyloid $\hat{l}^2\hat{a}$ protein dimerization determined using singlea molecule AFM force spectroscopy. Scientific Reports, 2013, 3, 2880.	1.6	66
126	Factor V Activator from Daboia russelli russelli Venom Destabilizes \hat{l}^2 -Amyloid Aggregate, the Hallmark of Alzheimer Disease. Journal of Biological Chemistry, 2013, 288, 30559-30570.	1.6	20
127	Localization of Allâ€reactive oligomeric species in prion diseases. Histopathology, 2013, 62, 994-1001.	1.6	9
128	<scp>CHF</scp> 5074 restores visual memory ability and preâ€synaptic cortical acetylcholine release in preâ€plaque Tg2576 mice. Journal of Neurochemistry, 2013, 124, 613-620.	2.1	16
129	Molecular Pathology of Alzheimer's Disease. Colloquium Series on Neurobiology of Alzheimer S Disease, 2013, 1, 1-91.	0.0	4
130	Tissue-type plasminogen activator binds to $\hat{Al^2}$ and AIAPP amyloid fibrils with multiple domains. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 113-121.	1.4	5

#	Article	IF	CITATIONS
131	Amyloid- \hat{l}^2 nanotubes are associated with prion protein-dependent synaptotoxicity. Nature Communications, 2013, 4, 2416.	5.8	112
133	A Lipoprotein Receptor Cluster IV Mutant Preferentially Binds Amyloid- \hat{l}^2 and Regulates Its Clearance from the Mouse Brain. Journal of Biological Chemistry, 2013, 288, 15154-15166.	1.6	33
134	Deletion of $\langle i \rangle$ Abca7 $\langle i \rangle$ Increases Cerebral Amyloid- \hat{l}^2 Accumulation in the J20 Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2013, 33, 4387-4394.	1.7	165
135	Memantine Rescues Transient Cognitive Impairment Caused by High-Molecular-Weight AÂ Oligomers But Not the Persistent Impairment Induced by Low-Molecular-Weight Oligomers. Journal of Neuroscience, 2013, 33, 9626-9634.	1.7	160
136	Aftins Increase Amyloid-Î ² 42, Lower Amyloid-Î ² 38, and Do Not Alter Amyloid-Î ² 40 Extracellular Production in vitro: Toward a Chemical Model of Alzheimer's Disease?. Journal of Alzheimer's Disease, 2013, 35, 107-120.	1.2	18
137	Cessation of Neoangiogenesis in Alzheimer's Disease Follows Amyloid-beta Immunization. Scientific Reports, 2013, 3, 1354.	1.6	30
138	Functional and Molecular Characterization of the Effect of Amyloid- \hat{l}^2 42 on an in vitro Epithelial Barrier Model. Journal of Alzheimer's Disease, 2013, 38, 787-798.	1.2	21
139	Soluble Oligomers of Amyloid-Î ² Cause Changes in Redox State, DNA Methylation, and Gene Transcription by Inhibiting EAAT3 Mediated Cysteine Uptake. Journal of Alzheimer's Disease, 2013, 36, 197-209.	1.2	76
140	Oxidative stress and neurodegeneration: the yeast model system. Frontiers in Bioscience - Landmark, 2013, 18, 1174.	3.0	16
141	Pathoetiology of multiple sclerosis: are we barking up the wrong tree?. F1000prime Reports, 2013, 5, 20.	5.9	37
142	Intravenous Immunglobulin Binds Beta Amyloid and Modifies Its Aggregation, Neurotoxicity and Microglial Phagocytosis In Vitro. PLoS ONE, 2013, 8, e63162.	1.1	10
143	A Luminex Assay Detects Amyloid β Oligomers in Alzheimer's Disease Cerebrospinal Fluid. PLoS ONE, 2013, 8, e67898.	1.1	59
144	Visualization and Quantification of APP Intracellular Domain-Mediated Nuclear Signaling by Bimolecular Fluorescence Complementation. PLoS ONE, 2013, 8, e76094.	1.1	10
145	Synergistic Interactions between Alzheimer's Aβ40 and Aβ42 on the Surface of Primary Neurons Revealed by Single Molecule Microscopy. PLoS ONE, 2013, 8, e82139.	1.1	22
146	Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review. Frontiers in Aging Neuroscience, 2013, 5, 25.	1.7	12
147	Amyloid Beta-Protein and Neural Network Dysfunction. Journal of Neurodegenerative Diseases, 2013, 2013, 1-8.	1.1	23
148	Therapy in Prion Diseases. Current Topics in Medicinal Chemistry, 2013, 13, 2465-2476.	1.0	41
149	Increased Efflux of Amyloid- \hat{l}^2 Peptides through the Blood-Brain Barrier by Muscarinic Acetylcholine Receptor Inhibition Reduces Pathological Phenotypes in Mouse Models of Brain Amyloidosis. Journal of Alzheimer's Disease, 2013, 38, 767-786.	1.2	11

#	Article	IF	CITATIONS
150	Studies cast doubt on cancer drug as Alzheimer's treatment. Nature, 2013, , .	13.7	0
152	A Lifespan Observation of a Novel Mouse Model: In Vivo Evidence Supports $\hat{Al^2}$ Oligomer Hypothesis. PLoS ONE, 2014, 9, e85885.	1.1	35
153	Alum and Squalene-Oil-in-Water Emulsion Enhance the Titer and Avidity of Anti-Aβ Antibodies Induced by Multimeric Protein Antigen (1–11)E2, Preserving the Igg1-Skewed Isotype Distribution. PLoS ONE, 2014, 9, e101474.	1.1	16
154	\hat{l}^2 2-Microglobulin Amyloid Fibril-Induced Membrane Disruption Is Enhanced by Endosomal Lipids and Acidic pH. PLoS ONE, 2014, 9, e104492.	1.1	30
155	Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity. PLoS ONE, 2014, 9, e111899.	1.1	151
156	Early Onset Alzheimer's Disease and Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-14.	1.9	46
157	Xanthoceraside Ameliorates Mitochondrial Dysfunction Contributing to the Improvement of Learning and Memory Impairment in Mice with Intracerebroventricular Injection of A <mml:math id="M1" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>1/2</mml:mi>1/2</mml:math> 1-42. Evidence-based Complementary	0.5	24
158	and Alternative Medicine, 2014, 2014, 1-11. Pinocembrin Protects Human Brain Microvascular Endothelial Cells against Fibrillar Amyloid- <i>β</i> _{1â^'40} Injury by Suppressing the MAPK/NF- <i>β</i> B Inflammatory Pathways. BioMed Research International, 2014, 2014, 1-14.	0.9	32
159	Hijacking PrPc-dependent signal transduction: when prions impair $\hat{Al^2}$ clearance. Frontiers in Aging Neuroscience, 2014, 6, 25.	1.7	20
160	Deciphering the Molecular Profile of Plaques, Memory Decline and Neuron Loss in Two Mouse Models for Alzheimerââ,¬â"¢s Disease by Deep Sequencing. Frontiers in Aging Neuroscience, 2014, 6, 75.	1.7	78
161	Therapeutic and diagnostic challenges for frontotemporal dementia. Frontiers in Aging Neuroscience, 2014, 6, 204.	1.7	17
162	Coffee and caffeine potentiate the antiamyloidogenic activity of melatonin via inhibition of Aβ oligomerization and modulation of the Tau-mediated pathway in N2a/APP cells. Drug Design, Development and Therapy, 2014, 9, 241.	2.0	18
163	Increased Levels of Plasma p3-Alcî \pm 35, a Major Fragment of Alcadeinî \pm by î ³ -Secretase Cleavage, in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 39, 861-870.	1.2	13
165	N-terminal Domain of Prion Protein Directs Its Oligomeric Association. Journal of Biological Chemistry, 2014, 289, 25497-25508.	1.6	20
166	Stages and Conformations of the Tau Repeat Domain during Aggregation and Its Effect on Neuronal Toxicity. Journal of Biological Chemistry, 2014, 289, 20318-20332.	1.6	77
167	Oligomer Formation of Tau Protein Hyperphosphorylated in Cells. Journal of Biological Chemistry, 2014, 289, 34389-34407.	1.6	132
168	Peripheral Administration of a Humanized Anti-PrP Antibody Blocks Alzheimer's Disease A \hat{l}^2 Synaptotoxicity. Journal of Neuroscience, 2014, 34, 6140-6145.	1.7	68
169	Unfolded protein response signaling by transcription factor XBPâ€1 regulates ADAM10 and is affected in Alzheimer's disease. FASEB Journal, 2014, 28, 978-997.	0.2	86

#	ARTICLE	IF	CITATIONS
170	Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease. Acta Neuropathologica Communications, 2014, 2, 135.	2.4	246
171	Neuritin can normalize neural deficits of Alzheimer's disease. Cell Death and Disease, 2014, 5, e1523-e1523.	2.7	26
172	Amyloid Beta, TNFÃŽÂ \pm and FAIM-L; Approaching New Therapeutic Strategies for AD. Frontiers in Neurology, 2014, 5, 276.	1.1	5
173	Effect of Metals on Kinetic Pathways of Amyloid-β Aggregation. Biomolecules, 2014, 4, 101-116.	1.8	94
174	Misfolding of Amyloidogenic Proteins and Their Interactions with Membranes. Biomolecules, 2014, 4, 20-55.	1.8	23
175	Unlocking truths of \hat{I}^3 -secretase in Alzheimer's disease: what is the translational potential?. Future Neurology, 2014, 9, 419-429.	0.9	12
176	Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer's disease mouse model. Brain, 2014, 137, 3319-3326.	3.7	36
177	Stability of Amyloid Oligomers. Advances in Protein Chemistry and Structural Biology, 2014, 96, 113-141.	1.0	19
179	Immunolesionâ€induced loss of cholinergic projection neurones promotes βâ€amyloidosis and tau hyperphosphorylation in the hippocampus of tripleâ€transgenic mice. Neuropathology and Applied Neurobiology, 2014, 40, 106-120.	1.8	28
180	Elucidating Molecular Mass and Shape of a Neurotoxic AÎ ² Oligomer. ACS Chemical Neuroscience, 2014, 5, 1238-1245.	1.7	24
181	Learning To Fold Proteins Using Energy Landscape Theory. Israel Journal of Chemistry, 2014, 54, 1311-1337.	1.0	57
182	Conformational targeting of intracellular $\hat{A^2}$ oligomers demonstrates their pathological oligomerization inside the endoplasmic reticulum. Nature Communications, 2014, 5, 3867.	5 . 8	49
183	Beta-amyloid oligomers induce early loss of presynaptic proteins in primary neurons by caspase-dependent and proteasome-dependent mechanisms. NeuroReport, 2014, 25, 1281-1288.	0.6	20
184	Emerging Î ² -Amyloid Pathology and Accelerated Cortical Atrophy. JAMA Neurology, 2014, 71, 725.	4.5	51
185	Brain Intraventricular Injection of Amyloid- \hat{l}^2 in Zebrafish Embryo Impairs Cognition and Increases Tau Phosphorylation, Effects Reversed by Lithium. PLoS ONE, 2014, 9, e105862.	1.1	64
186	Targeting mRNA for Alzheimer's and Related Dementias. Scientifica, 2014, 2014, 1-13.	0.6	10
187	From Single Target to Multitarget/Network Therapeutics in Alzheimer's Therapy. Pharmaceuticals, 2014, 7, 113-135.	1.7	94
188	Amyloid \hat{l}^2 peptide cleavage by kallikrein 7 attenuates fibril growth and rescues neurons from A \hat{l}^2 -mediated toxicity in vitro. Biological Chemistry, 2014, 395, 109-118.	1.2	16

#	Article	IF	CITATIONS
189	Critical analysis of the use of β-site amyloid precursor protein-cleaving enzyme 1 inhibitors in the treatment of Alzheimer's disease. Degenerative Neurological and Neuromuscular Disease, 2014, 4, 1.	0.7	7
190	A Sensitive $\hat{Al^2}$ Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid. Journal of Neuroscience, 2014, 34, 2884-2897.	1.7	138
191	Calcium regulates the interaction of amyloid precursor protein with Homer3 protein. Neurobiology of Aging, 2014, 35, 2053-2063.	1.5	12
192	Spreading of amyloid- \hat{l}^2 peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. Neurobiology of Disease, 2014, 65, 82-92.	2.1	135
193	FLZ inhibited \hat{I}^3 -secretase selectively and decreased A \hat{I}^2 mitochondrial production in APP-SH-SY5Y cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 75-85.	1.4	9
194	Signature Amyloid \hat{l}^2 Profiles Are Produced by Different \hat{l}^3 -Secretase Complexes. Journal of Biological Chemistry, 2014, 289, 4346-4355.	1.6	74
195	Republished: The role of amyloid \hat{l}^2 in the pathogenesis of Alzheimer $\hat{a} \in \mathbb{N}$ s disease. Postgraduate Medical Journal, 2014, 90, 113-117.	0.9	15
196	Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochemical Pharmacology, 2014, 88, 508-516.	2.0	196
197	Differential ubiquitination and degradation of huntingtin fragments modulated by ubiquitin-protein ligase E3A. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5706-5711.	3.3	91
198	Gly25-Ser26 Amyloid \hat{I}^2 -Protein Structural Isomorphs Produce Distinct A \hat{I}^2 42 Conformational Dynamics and Assembly Characteristics. Journal of Molecular Biology, 2014, 426, 2422-2441.	2.0	30
199	Ceramides and sphingomyelinases in senile plaques. Neurobiology of Disease, 2014, 65, 193-201.	2.1	49
200	Significant Structural Differences between Transient Amyloidâ€Î² Oligomers and Lessâ€Toxic Fibrils in Regions Known To Harbor Familial Alzheimer′s Mutations. Angewandte Chemie - International Edition, 2014, 53, 6888-6892.	7.2	84
201	Potent Î ³ -secretase inhibitors/modulators interact with amyloid-Î ² fibrils but do not inhibit fibrillation: A high-resolution NMR study. Biochemical and Biophysical Research Communications, 2014, 447, 590-595.	1.0	17
202	Nrf2 Regulates Neurogenesis and Protects Neural Progenitor Cells Against A \hat{l}^2 Toxicity. Stem Cells, 2014, 32, 1904-1916.	1.4	110
203	Intraneuronal accumulation of A \hat{l}^2 42 induces age-dependent slowing of neuronal transmission in Drosophila. Neuroscience Bulletin, 2014, 30, 185-190.	1.5	12
204	Antioxidant gene therapy against neuronal cell death. , 2014, 142, 206-230.		120
205	Amyloid β-Peptide 1–42 Modulates the Proliferation of Mouse Neural Stem Cells: Upregulation of Fucosyltransferase IX and Notch Signaling. Molecular Neurobiology, 2014, 50, 186-196.	1.9	28
206	Differences between amyloid- \hat{l}^2 aggregation in solution and on the membrane: insights into elucidation of the mechanistic details of Alzheimer's disease. Chemical Society Reviews, 2014, 43, 6692-6700.	18.7	341

#	Article	IF	CITATIONS
207	Integrating the molecular and the population approaches to dementia research to help guide the future development of appropriate therapeutics. Biochemical Pharmacology, 2014, 88, 652-660.	2.0	6
208	Alzheimer's disease and CADASIL are heritable, adult-onset dementias that both involve damaged small blood vessels. Cellular and Molecular Life Sciences, 2014, 71, 949-955.	2.4	19
209	On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis. Ageing Research Reviews, 2014, 13, 10-12.	5.0	72
210	Experimental Traumatic Brain Injury Induces Rapid Aggregation and Oligomerization of Amyloid-Beta in an Alzheimer's Disease Mouse Model. Journal of Neurotrauma, 2014, 31, 125-134.	1.7	90
211	Accelerated microglial pathology is associated with $\langle scp \rangle A \langle scp \rangle \hat{l}^2$ plaques in mouse models of $\langle scp \rangle A \langle scp \rangle l$ zheimer's disease. Aging Cell, 2014, 13, 584-595.	3.0	113
212	Microspectroscopy (νFTIR) Reveals Co-localization of Lipid Oxidation and Amyloid Plaques in Human Alzheimer Disease Brains. Analytical Chemistry, 2014, 86, 12047-12054.	3.2	87
213	Monoclonal Antibodies against A \hat{l}^2 42 Fibrils Distinguish Multiple Aggregation State Polymorphisms in Vitro and in Alzheimer Disease Brain. Journal of Biological Chemistry, 2014, 289, 32131-32143.	1.6	103
214	Inactivation of brain Cofilin-1 by age, Alzheimer's disease and γ-secretase. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 2500-2509.	1.8	50
215	Mitochondrial dysfunction induced by a post-translationally modified amyloid linked to a familial mutation in an alternative model of neurodegeneration. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 2457-2467.	1.8	14
216	${\sf A\hat{l}^2}$ dimers differ from monomers in structural propensity, aggregation paths and population of synaptotoxic assemblies. Biochemical Journal, 2014, 461, 413-426.	1.7	71
217	Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients. Nature Communications, 2014, 5, 4824.	5.8	153
218	Genetics of Alzheimer's Disease. Advances in Genetics, 2014, 87, 245-294.	0.8	159
219	The Alzheimer Disease Protective Mutation A2T Modulates Kinetic and Thermodynamic Properties of Amyloid- \hat{l}^2 (A \hat{l}^2) Aggregation. Journal of Biological Chemistry, 2014, 289, 30977-30989.	1.6	132
220	Mapping amyloid- \hat{l}^2 (16-22) nucleation pathways using fluorescence lifetime imaging microscopy. Soft Matter, 2014, 10, 4162-4172.	1.2	23
221	Direct electrochemical and AFM detection of amyloid- \hat{l}^2 peptide aggregation on basal plane HOPG. Nanoscale, 2014, 6, 7853-7857.	2.8	41
222	Molecular Mechanisms of Alzheimer Disease Protection by the A673T Allele of Amyloid Precursor Protein. Journal of Biological Chemistry, 2014, 289, 30990-31000.	1.6	153
223	Early amyloid \hat{l}^2 -protein aggregation precedes conformational change. Chemical Communications, 2014, 50, 5373-5375.	2.2	58
224	Comparison of alternative nucleophiles for Sortase A-mediated bioconjugation and application in neuronal cell labelling. Organic and Biomolecular Chemistry, 2014, 12, 2675-2685.	1.5	19

#	Article	IF	CITATIONS
225	Endogenous Polyamines Reduce the Toxicity of Soluble Aβ Peptide Aggregates Associated with Alzheimer's Disease. Biomacromolecules, 2014, 15, 1985-1991.	2.6	30
226	Amyloid Precursor Protein (APP)/APP-like Protein 2 (APLP2) Expression Is Required to Initiate Endosome-Nucleus-Autophagosome Trafficking of Glypican-1-derived Heparan Sulfate. Journal of Biological Chemistry, 2014, 289, 20871-20878.	1.6	25
227	Beta-Amyloid Oligomers Activate Apoptotic BAK Pore for Cytochrome c Release. Biophysical Journal, 2014, 107, 1601-1608.	0.2	29
228	Pyroglutamylated Amyloid- \hat{l}^2 Peptide Reverses Cross \hat{l}^2 -Sheets by a Prion-Like Mechanism. Journal of Physical Chemistry B, 2014, 118, 5637-5643.	1.2	22
229	Hydrogen/Deuterium Exchange-Protected Oligomers Populated during A \hat{l}^2 Fibril Formation Correlate with Neuronal Cell Death. ACS Chemical Biology, 2014, 9, 2678-2685.	1.6	19
230	Nuclear Translocation Uncovers the Amyloid Peptide A \hat{l}^2 42 as a Regulator of Gene Transcription*. Journal of Biological Chemistry, 2014, 289, 20182-20191.	1.6	65
231	A Fibril-Like Assembly of Oligomers of a Peptide Derived from \hat{l}^2 -Amyloid. Journal of the American Chemical Society, 2014, 136, 12682-12690.	6.6	31
233	The C-Terminal Threonine of $\hat{Al^2}43$ Nucleates Toxic Aggregation via Structural and Dynamical Changes in Monomers and Protofibrils. Biochemistry, 2014, 53, 3095-3105.	1.2	36
234	Is Alzheimer's disease related to metabolic syndrome? A Wnt signaling conundrum. Progress in Neurobiology, 2014, 121, 125-146.	2.8	87
235	Mixed oligomers and monomeric amyloid-β disrupts endothelial cells integrity and reduces monomeric amyloid-β transport across hCMEC/D3 cell line as an in vitro blood–brain barrier model. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1806-1815.	1.8	46
236	Amyloid Fibrils: Formation, Polymorphism, and Inhibition. Journal of Physical Chemistry Letters, 2014, 5, 607-614.	2.1	42
237	A novel function for pro <scp>SAAS</scp> as an amyloid antiâ€aggregant in Alzheimer's disease. Journal of Neurochemistry, 2014, 128, 419-430.	2.1	44
238	Alzheimer Peptides Aggregate into Transient Nanoglobules That Nucleate Fibrils. Biochemistry, 2014, 53, 6302-6308.	1.2	32
239	A label-free electrical assay of fibrous amyloid \hat{l}^2 based on semiconductor biosensing. Chemical Communications, 2014, 50, 3476-3479.	2.2	15
240	Maintenance of Amyloid β Peptide Homeostasis by Artificial Chaperones Based on Mixedâ€Shell Polymeric Micelles. Angewandte Chemie - International Edition, 2014, 53, 8985-8990.	7.2	132
241	Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β. Alzheimer's Research and Therapy, 2014, 6, 14.	3.0	30
242	Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. Alzheimer's Research and Therapy, 2014, 6, 42.	3.0	140
243	Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer's disease. BMC Neurology, 2014, 14, 169.	0.8	59

#	Article	IF	Citations
244	Conformation-specific antibodies to target amyloid \hat{l}^2 oligomers and their application to immunotherapy for Alzheimerâ \in TM s disease. Bioscience, Biotechnology and Biochemistry, 2014, 78, 1293-1305.	0.6	37
245	Intracellular Accumulation of Amyloid-Â (AÂ) Protein Plays a Major Role in AÂ-Induced Alterations of Glutamatergic Synaptic Transmission and Plasticity. Journal of Neuroscience, 2014, 34, 12893-12903.	1.7	101
246	Transient dynamics of Aβ contribute to toxicity in Alzheimer's disease. Cellular and Molecular Life Sciences, 2014, 71, 3507-3521.	2.4	76
247	Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease. Acta Neuropathologica, 2014, 127, 787-801.	3.9	129
248	The hairpin conformation of the amyloid \hat{l}^2 peptide is an important structural motif along the aggregation pathway. Journal of Biological Inorganic Chemistry, 2014, 19, 623-634.	1.1	88
249	Structural evolution and membrane interactions of Alzheimer's amyloidâ€beta peptide oligomers: New knowledge from singleâ€molecule fluorescence studies. Protein Science, 2014, 23, 869-883.	3.1	27
250	Lipocalin 2 modulates the cellular response to amyloid beta. Cell Death and Differentiation, 2014, 21, 1588-1599.	5.0	59
251	Soluble AÎ ² Oligomers Are Rapidly Sequestered from Brain ISF InÂVivo and Bind GM1 Ganglioside on Cellular Membranes. Neuron, 2014, 82, 308-319.	3.8	174
252	Microglia convert aggregated amyloid- \hat{l}^2 into neurotoxic forms through the shedding of microvesicles. Cell Death and Differentiation, 2014, 21, 582-593.	5.0	219
253	Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10323-10328.	3.3	247
254	The Potential Role of Rho GTPases in Alzheimer's Disease Pathogenesis. Molecular Neurobiology, 2014, 50, 406-422.	1.9	36
255	Protective action of glutamate antibodies on increased expression of genes of programmed death of rat brain cells induced by injection of a β-amyloid fragment (25–35). Biology Bulletin, 2014, 41, 118-125.	0.1	3
256	Abundance of AÎ ² 5-xlike immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's disease. Molecular Neurodegeneration, 2014, 9, 13.	4.4	19
257	Non-chaperone Proteins Can Inhibit Aggregation and Cytotoxicity of Alzheimer Amyloid \hat{l}^2 Peptide. Journal of Biological Chemistry, 2014, 289, 27766-27775.	1.6	53
258	Surface Effects Mediate Self-Assembly of Amyloid-β Peptides. ACS Nano, 2014, 8, 10178-10186.	7.3	46
259	Neurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease $Al^2 < i > in vivo < /i >$. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130147.	1.8	23
260	Antiparallel Triple-strand Architecture for Prefibrillar A \hat{l}^2 42 Oligomers. Journal of Biological Chemistry, 2014, 289, 27300-27313.	1.6	60
261	Pathogenesis of Alzheimer's Disease. , 2014, , 2327-2337.		1

#	Article	IF	CITATIONS
262	A glucan isolated from flowers of Lonicera japonica Thunb. inhibits aggregation and neurotoxicity of A \hat{l}^2 42. Carbohydrate Polymers, 2014, 110, 142-147.	5.1	82
263	Simultaneous measurement of a range of particle sizes during Aβ1–42 fibrillogenesis quantified using fluorescence correlation spectroscopy. Biochemical and Biophysical Research Communications, 2014, 448, 195-199.	1.0	25
264	APP Homodimers Transduce an Amyloid- \hat{l}^2 -Mediated Increase in Release Probability at Excitatory Synapses. Cell Reports, 2014, 7, 1560-1576.	2.9	109
265	Hydroxy-safflor yellow A inhibits neuroinflammation mediated by Aβ1–42 in BV-2 cells. Neuroscience Letters, 2014, 562, 39-44.	1.0	34
266	Polymorphism of Oligomers of a Peptide from \hat{l}^2 -Amyloid. Journal of the American Chemical Society, 2014, 136, 5432-5442.	6.6	24
267	Transglutaminase 2 accelerates neuroinflammation in amyotrophic lateral sclerosis through interaction with misfolded superoxide dismutase 1. Journal of Neurochemistry, 2014, 128, 403-418.	2.1	28
268	Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's disease model. Nature Communications, 2014, 5, 4159.	5.8	215
269	Factors Influencing Compact–Extended Structure Equilibrium in Oligomers of Aβ1–40 Peptide—An Ion Mobility Mass Spectrometry Study. Journal of Molecular Biology, 2014, 426, 2871-2885.	2.0	37
270	A comparison of frailty of primary neurons, embryonic, and aging mouse cortical layers. Neurobiology of Aging, 2014, 35, 322-330.	1.5	5
271	Sustained Alzheimer's Amyloid Pathology in Myeloid Differentiation Protein-88-Deficient APPswe/PS1 Mice. Neurodegenerative Diseases, 2014, 13, 58-60.	0.8	7
273	Review: Prionâ€like mechanisms of transactive response DNA binding protein of 43 kDa (<scp>TDP</scp> â€43) in amyotrophic lateral sclerosis (<scp>ALS</scp>). Neuropathology and Applied Neurobiology, 2015, 41, 578-597.	1.8	76
274	New Targets of Molecular Imaging in Atherosclerosis: Prehension of Current Status. Analytical Sciences, 2015, 31, 245-255.	0.8	2
275	Electron Microscopy of the Brains of Drosophila Models of Alzheimer's Diseases. Neuromethods, 2015, , 105-123.	0.2	1
278	SDS-PAGE analysis of ${\rm A}\hat{\rm I}^2$ oligomers is disserving research into Alzheimer $\hat{\rm A}$'s disease: appealing for ESI-IM-MS. Scientific Reports, 2015, 5, 14809.	1.6	88
279	Orexin receptors exert a neuroprotective effect in Alzheimer's disease (AD) via heterodimerization with GPR103. Scientific Reports, 2015, 5, 12584.	1.6	58
280	Ultraviolet light triggers the conversion of Cu2+-bound A \hat{l}^2 42 aggregates into cytotoxic species in a copper chelation-independent manner. Scientific Reports, 2015, 5, 13897.	1.6	3
281	Construction of Sensor Protein That Responses to Amyloid \hat{l}^2 -Peptide Oligomers and Demonstration of Screening Capabilities for Oligomer Inhibitors. Chemistry Letters, 2015, 44, 67-69.	0.7	0
284	Reactivity of Metal-Free and Metal-Associated Amyloid- \hat{l}^2 with Glycosylated Polyphenols and Their Esterified Derivatives. Scientific Reports, 2015, 5, 17842.	1.6	44

#	Article	IF	CITATIONS
285	Intranasal Delivery of NEMO-Binding Domain Peptide Prevents Memory Loss inÂaÂMouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 385-402.	1.2	41
286	A \hat{l}^2 42-oligomer Interacting Peptide (AIP) neutralizes toxic amyloid- \hat{l}^2 42 species and protects synaptic structure and function. Scientific Reports, 2015, 5, 15410.	1.6	23
287	A Second Pedigree with Amyloid-less Familial Alzheimer's Disease Harboring an Identical Mutation in the Amyloid Precursor Protein Gene (E693delta). Internal Medicine, 2015, 54, 205-208.	0.3	12
288	Oxidative Stress and Aberrant Cell Cycle in Alzheimer's Disease Lymphocytes: Diagnostic Prospects. Journal of Alzheimer's Disease, 2015, 46, 329-350.	1.2	45
289	N-Truncated Aβ2-X Starting with Position Two in Sporadic Alzheimer's Disease Cases and Two Alzheimer Mouse Models. Journal of Alzheimer's Disease, 2015, 49, 101-110.	1.2	9
290	Tau and Amyloid- \hat{l}^2 Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 47, 965-975.	1.2	18
291	Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X. Scientific Reports, 2015, 5, 17338.	1.6	34
292	Synthesis and characterization of the amyloid \hat{l}^2 40 dimer model with a linker at position 30 adjacent to the intermolecular \hat{l}^2 -sheet region. Biochemical and Biophysical Research Communications, 2015, 466, 463-467.	1.0	6
293	Biophysical characterization data on ${\hat A}^2$ soluble oligomers produced through a method enabling prolonged oligomer stability and biological buffer conditions. Data in Brief, 2015, 4, 650-658.	0.5	1
294	Opposite effect of Ca2+/Mg2+ ions on the aggregation of native and precursor-derived A \hat{l}^2 42. Structural Chemistry, 2015, 26, 1389-1403.	1.0	2
295	Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain $A\hat{l}^2$ accumulation and memory deficits. Molecular Neurodegeneration, 2015, 10, 58.	4.4	322
296	The domestic cat as a natural animal model of Alzheimer's disease. Acta Neuropathologica Communications, 2015, 3, 78.	2.4	62
297	Does loss of the normal protein function contribute to the pathogenesis of Huntington's disease?. Bioscience Horizons, 2015, 8, hzv005.	0.6	7
298	Octarepeat region flexibility impacts prion function, endoproteolysis and disease manifestation. EMBO Molecular Medicine, 2015, 7, 339-356.	3.3	26
299	Liquid Crystal Enabled Early Stage Detection of Beta Amyloid Formation on Lipid Monolayers. Advanced Functional Materials, 2015, 25, 6050-6060.	7.8	79
300	Targeted Magnetic Nanoparticles for Remote Magnetothermal Disruption of Amyloidâ€Î² Aggregates. Advanced Healthcare Materials, 2015, 4, 2100-2109.	3.9	23
301	Dextran sulfate sodium inhibits amyloidâ $\hat{\epsilon}^2$ oligomer binding to cellular prion protein. Journal of Neurochemistry, 2015, 134, 611-617.	2.1	11
303	The elusive nature and diagnostics of misfolded $\hat{Al^2}$ oligomers. Frontiers in Chemistry, 2015, 3, 17.	1.8	24

#	Article	IF	Citations
304	Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases. Antibodies, 2015, 4, 170-196.	1.2	5
305	Alternative salt bridge formation in Aβ—a hallmark of early-onset Alzheimer's disease?. Frontiers in Molecular Biosciences, 2015, 2, 14.	1.6	17
306	Fragile X mental retardation protein: from autism to neurodegenerative disease. Frontiers in Cellular Neuroscience, 2015, 9, 43.	1.8	20
307	Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. Frontiers in Neurology, 2015, 6, 256.	1.1	16
308	Detection of ubiquitinated huntingtin species in intracellular aggregates. Frontiers in Molecular Neuroscience, $2015, 8, 1$.	1.4	63
309	Ubiquitin-dependent proteolysis in yeast cells expressing neurotoxic proteins. Frontiers in Molecular Neuroscience, 2015, 8, 8.	1.4	19
310	Evaluation of the amyloid beta-GFP fusion protein as a model of amyloid beta peptides-mediated aggregation: a study of DNAJB6 chaperone. Frontiers in Molecular Neuroscience, 2015, 8, 40.	1.4	20
311	Tailoring the Antibody Response to Aggregated Aß Using Novel Alzheimer-Vaccines. PLoS ONE, 2015, 10, e0115237.	1.1	28
312	Anti-Aβ Oligomer IgG and Surface Sialic Acid in Intravenous Immunoglobulin: Measurement and Correlation with Clinical Outcomes in Alzheimer's Disease Treatment. PLoS ONE, 2015, 10, e0120420.	1.1	12
313	Nanoscale Synaptic Membrane Mimetic Allows Unbiased High Throughput Screen That Targets Binding Sites for Alzheimer's-Associated Aβ Oligomers. PLoS ONE, 2015, 10, e0125263.	1.1	28
314	Intravenous Infusion of Monocytes Isolated from 2-Week-Old Mice Enhances Clearance of Beta-Amyloid Plaques in an Alzheimer Mouse Model. PLoS ONE, 2015, 10, e0121930.	1,1	17
315	Amyloid \hat{I}^2 Oligomeric Species Present in the Lag Phase of Amyloid Formation. PLoS ONE, 2015, 10, e0127865.	1.1	21
316	Self-Assembly of A \hat{I}^2 40, A \hat{I}^2 42 and A \hat{I}^2 43 Peptides in Aqueous Mixtures of Fluorinated Alcohols. PLoS ONE, 2015, 10, e0136567.	1.1	16
317	Deficient and Null Variants of SERPINA1 Are Proteotoxic in a Caenorhabditis elegans Model of $\hat{l}\pm 1$ -Antitrypsin Deficiency. PLoS ONE, 2015, 10, e0141542.	1.1	9
318	Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases. Mediators of Inflammation, 2015, 2015, 1-27.	1.4	154
319	Prion-Protein-interacting Amyloid- \hat{l}^2 Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models. Journal of Biological Chemistry, 2015, 290, 17415-17438.	1.6	104
320	Competition between Fibrillation and Induction of Vesicle Fusion for the Membrane-Associated 40-Residue \hat{l}^2 -Amyloid Peptides. Biochemistry, 2015, 54, 3416-3419.	1.2	20
321	Proteotoxicity and Cardiac Dysfunction. Circulation Research, 2015, 116, 1863-1882.	2.0	80

#	Article	IF	CITATIONS
322	Chitosan Oligosaccharides Inhibit/Disaggregate Fibrils and Attenuate Amyloid \hat{l}^2 -Mediated Neurotoxicity. International Journal of Molecular Sciences, 2015, 16, 10526-10536.	1.8	45
323	Molecular Design for Dual Modulation Effect of Amyloid Protein Aggregation. Journal of the American Chemical Society, 2015, 137, 8062-8068.	6.6	31
324	Synthesis of chemically-tethered amyloid- \hat{l}^2 segment trimer possessing amyloidogenic properties. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2976-2979.	1.0	16
325	Limited Proteolysis Reveals That Amyloids from the 3D Domain-Swapping Cystatin B Have a Non-Native Î ² -Sheet Topology. Journal of Molecular Biology, 2015, 427, 2418-2434.	2.0	10
326	Systematic analysis of time-dependent neural effects of soluble amyloid \hat{l}^2 oligomers in culture and in vivo: Prevention by scyllo-inositol. Neurobiology of Disease, 2015, 82, 152-163.	2.1	43
327	Yeast red pigment modifies Amyloid beta growth in Alzheimer disease models in both <i>Saccharomyces cerevisiae</i>) and <i>Drosophila melanogaster</i>) and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 100-111	1.4	8
328	Label-free imaging and quantitative chemical analysis of Alzheimer's disease brain samples with multimodal multiphoton nonlinear optical microspectroscopy. Journal of Biomedical Optics, 2015, 20, 056013.	1.4	28
329	Chemical Tools for the Study of Intramembrane Proteases. ACS Chemical Biology, 2015, 10, 2423-2434.	1.6	8
330	Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and \hat{Al}^2 pathology and modulates \hat{Al}^2 oligomerization. Neurobiology of Disease, 2015, 82, 552-560.	2.1	48
331	The roles of the conserved tyrosine in the $\hat{l}^22-\hat{l}\pm2$ loop of the prion protein. Prion, 2015, 9, 412-419.	0.9	10
332	Tau missorting and spastin-induced microtubule disruption in neurodegeneration: Alzheimer Disease and Hereditary Spastic Paraplegia. Molecular Neurodegeneration, 2015, 10, 68.	4.4	69
333	Isotope-edited FTIR reveals distinct aggregation and structural behaviors of unmodified and pyroglutamylated amyloid \hat{l}^2 peptides. Physical Chemistry Chemical Physics, 2015, 17, 32149-32160.	1.3	14
334	Quaternary Structure Defines a Large Class of Amyloid- \hat{l}^2 Oligomers Neutralized by Sequestration. Cell Reports, 2015, 11, 1760-1771.	2.9	141
335	Strong Inhibition of Betaâ€Amyloid Peptide Aggregation Realized by Twoâ€Steps Evolved Peptides. Chemical Biology and Drug Design, 2015, 85, 356-368.	1.5	6
336	Striatum and entorhinal cortex atrophy in AD mouse models: MRI comprehensive analysis. Neurobiology of Aging, 2015, 36, 776-788.	1.5	25
337	β-Amyloid peptides display protective activity against the human Alzheimer's disease-associated herpes simplex virus-1. Biogerontology, 2015, 16, 85-98.	2.0	170
338	Cortical hypermetabolism in MCI subjects: a compensatory mechanism?. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 447-458.	3.3	99
339	Ginkgolide B revamps neuroprotective role of apurinic/apyrimidinic endonuclease 1 and mitochondrial oxidative phosphorylation against Al² _{25–35} â€induced neurotoxicity in human neuroblastoma cells. Journal of Neuroscience Research, 2015, 93, 938-947.	1.3	60

#	Article	IF	CITATIONS
340	Neuronal death induced by misfolded prion protein is due to NAD+ depletion and can be relieved in vitro and in vivo by NAD+ replenishment. Brain, 2015, 138, 992-1008.	3.7	67
341	Anti-inflammatory Signaling in Microglia Exacerbates Alzheimer's Disease-Related Pathology. Neuron, 2015, 85, 450-452.	3.8	57
342	Reduction of p75 neurotrophin receptor ameliorates the cognitive deficits in a model of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 740-752.	1.5	25
343	Probing the Sources of the Apparent Irreproducibility of Amyloid Formation: Drastic Changes in Kinetics and a Switch in Mechanism Due to Micellelike Oligomer Formation at Critical Concentrations of IAPP. Journal of Physical Chemistry B, 2015, 119, 2886-2896.	1.2	85
344	Compromised MAPK signaling in human diseases: an update. Archives of Toxicology, 2015, 89, 867-882.	1.9	782
345	Phosphorylation as Conformational Switch from the Native to Amyloid State: Trp-Cage as a Protein Aggregation Model. Journal of Physical Chemistry B, 2015, 119, 2946-2955.	1.2	14
346	Epigallocatechin-3-Gallate, a Promising Molecule for Parkinson's Disease?. Rejuvenation Research, 2015, 18, 257-269.	0.9	48
347	Amyloid \hat{l}^2 oligomers in Alzheimer $\hat{a} \in \mathbb{N}$ s disease pathogenesis, treatment, and diagnosis. Acta Neuropathologica, 2015, 129, 183-206.	3.9	490
348	New Insights in Amyloid Beta Interactions with Human Telomerase. Journal of the American Chemical Society, 2015, 137, 1213-1219.	6.6	76
349	The pathophysiology of repetitive concussive traumatic brain injury in experimental models; new developments and open questions. Molecular and Cellular Neurosciences, 2015, 66, 91-98.	1.0	45
350	Stabilization of Nontoxic AÂ-Oligomers: Insights into the Mechanism of Action of Hydroxyquinolines in Alzheimer's Disease. Journal of Neuroscience, 2015, 35, 2871-2884.	1.7	67
351	Cyclinâ€Dependent kinase 5 targeting prevents βâ€Amyloid aggregation involving glycogen synthase kinase 3β and phosphatases. Journal of Neuroscience Research, 2015, 93, 1258-1266.	1.3	20
352	Cytoplasmic Fragment of Alcadein î± Generated by Regulated Intramembrane Proteolysis Enhances Amyloid î²-Protein Precursor (APP) Transport into the Late Secretory Pathway and Facilitates APP Cleavage. Journal of Biological Chemistry, 2015, 290, 987-995.	1.6	18
353	<i>Atlas stumbled</i> : Kinesin light chainâ€1 variant E triggers a vicious cycle of axonal transport disruption and amyloidâ€Î² generation in Alzheimer's disease. BioEssays, 2015, 37, 131-141.	1.2	14
354	Rapidly progressive Alzheimer's disease features distinct structures of amyloid-β. Brain, 2015, 138, 1009-1022.	3.7	166
355	Donepezil attenuates $\hat{Al^2}$ -associated mitochondrial dysfunction and $\hat{Al^2}$ -accumulation in $\hat{Al^2}$ -vivo and in Al^2	2.0	61
356	Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimerââ,¬â,,¢s disease. Frontiers in Cellular Neuroscience, 2015, 9, 191.	1.8	284
357	Na, K-ATPase $\hat{l}\pm 3$ is a death target of Alzheimer patient amyloid- \hat{l}^2 assembly. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4465-74.	3.3	112

#	Article	IF	CITATIONS
358	Real-Time Monitoring of Alzheimer's-Related Amyloid Aggregation via Probe Enhancement–Fluorescence Correlation Spectroscopy. ACS Chemical Neuroscience, 2015, 6, 1503-1508.	1.7	21
359	Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein Science, 2015, 349, 1255555.	·6.0	753
360	Regulation of protein homeostasis in neurodegenerative diseases: the role of coding and non-coding genes. Cellular and Molecular Life Sciences, 2015, 72, 4027-4047.	2.4	29
361	Conditioned medium from the stem cells of human dental pulp improves cognitive function in a mouse model of Alzheimer's disease. Behavioural Brain Research, 2015, 293, 189-197.	1.2	127
362	Analyzing dendritic spine pathology in Alzheimer's disease: problems and opportunities. Acta Neuropathologica, 2015, 130, 1-19.	3.9	154
363	Rapid nuclear transit and impaired degradation of amyloid \hat{l}^2 and glypican-1-derived heparan sulfate in Tg2576 mouse fibroblasts. Glycobiology, 2015, 25, 548-556.	1.3	11
364	Effect of amyloids on the vesicular machinery: implications for somatic neurotransmission. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140187.	1.8	12
365	Extracellular Vesicles in Alzheimer's Disease: Friends or Foes? Focus on Aβ-Vesicle Interaction. International Journal of Molecular Sciences, 2015, 16, 4800-4813.	1.8	73
366	Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials. CNS Drugs, 2015, 29, 487-502.	2.7	26
367	Structural, morphological, and functional diversity of amyloid oligomers. FEBS Letters, 2015, 589, 2640-2648.	1.3	150
368	High-resolution NMR characterization of low abundance oligomers of amyloid- \hat{l}^2 without purification. Scientific Reports, 2015, 5, 11811.	1.6	101
369	Modeling the complex pathology of Alzheimer's disease in Drosophila. Experimental Neurology, 2015, 274, 58-71.	2.0	54
370	Olive Oil Phenols as Promising Multi-targeting Agents Against Alzheimer's Disease. Advances in Experimental Medicine and Biology, 2015, 863, 1-20.	0.8	62
371	Dementia of the eye: the role of amyloid beta in retinal degeneration. Eye, 2015, 29, 1013-1026.	1.1	133
372	Fe65 Ser228 is phosphorylated by ATM/ATR and inhibits Fe65–APP-mediated gene transcription. Biochemical Journal, 2015, 465, 413-421.	1.7	11
373	Luteinizing hormone as a key player in the cognitive decline of Alzheimer's disease. Hormones and Behavior, 2015, 76, 48-56.	1.0	26
374	Modulation of bovine serum albumin fibrillation by ester bonded and conventional gemini surfactants. RSC Advances, 2015, 5, 58616-58624.	1.7	22
375	GPR84 deficiency reduces microgliosis, but accelerates dendritic degeneration and cognitive decline in a mouse model of Alzheimer's disease. Brain, Behavior, and Immunity, 2015, 46, 112-120.	2.0	50

#	Article	IF	CITATIONS
376	The aqueous phase of Alzheimer's disease brain contains assemblies built from $\hat{a}^{-1}/44$ and $\hat{a}^{-1}/47$ kDa Al $^{-1}/47$ kDa Al $^{-1}$	0.4	54
377	Dependence pH and proposed mechanism for aggregation of Alzheimer's disease-related amyloid-β(1–42) protein. Journal of Molecular Structure, 2015, 1094, 109-117.	1.8	28
378	Atorvastatin prevents $\hat{Al^2}$ oligomer-induced neurotoxicity in cultured rat hippocampal neurons by inhibiting Tau cleavage. Acta Pharmacologica Sinica, 2015, 36, 553-564.	2.8	12
379	The influence of cholesterol on membrane protein structure, function, and dynamics studied by molecular dynamics simulations. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 1783-1795.	1.4	144
380	Mechanisms of the self-assembly of EAK16-family peptides into fibrillar and globular structures: molecular dynamics simulations from nano- to micro-seconds. European Biophysics Journal, 2015, 44, 263-276.	1.2	19
381	Amyloid \hat{l}^2 oligomers induce interleukin- $1\hat{l}^2$ production in primary microglia in a cathepsin B- and reactive oxygen species-dependent manner. Biochemical and Biophysical Research Communications, 2015, 458, 561-567.	1.0	20
382	$\hat{Al^2}43$ is neurotoxic and primes aggregation of $\hat{Al^2}40$ in vivo. Acta Neuropathologica, 2015, 130, 35-47.	3.9	39
383	A mouse model of Alzheimer's disease displays increased susceptibility to kindling and seizureâ€associated death. Epilepsia, 2015, 56, e73-7.	2.6	35
384	APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons. Cell Reports, 2015, 11, 689-696.	2.9	158
385	Alzheimer Amyloid Peptide A \hat{l}^2 42 Regulates Gene Expression of Transcription and Growth Factors. Journal of Alzheimer's Disease, 2015, 44, 613-624.	1.2	47
386	Small angle X-ray scattering analysis of Cu2+-induced oligomers of the Alzheimer's amyloid \hat{l}^2 peptide. Metallomics, 2015, 7, 536-543.	1.0	25
387	Acute amnestic encephalopathy in amyloid-β oligomer–injected mice is due to their widespread diffusion inÂvivo. Neurobiology of Aging, 2015, 36, 2043-2052.	1.5	23
388	An Early Folding Contact between Phe19 and Leu34 is Critical for Amyloid- \hat{l}^2 Oligomer Toxicity. ACS Chemical Neuroscience, 2015, 6, 1290-1295.	1.7	52
389	Facile Micromolding-Based Fabrication of Biopolymeric–Synthetic Hydrogel Microspheres with Controlled Structures for Improved Protein Conjugation. Chemistry of Materials, 2015, 27, 3988-3998.	3.2	21
390	Neuroinflammatory Signals in Alzheimer Disease and APP/PS1 Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 2015, 74, 319-344.	0.9	105
391	Alzheimer's Disease and Mechanism-Based Attempts to Enhance Cognition. , 2015, , 193-231.		O
392	Amyloid \hat{l}^2 Protein and Alzheimer $\hat{a} \in \mathbb{N}$ Disease: When Computer Simulations Complement Experimental Studies. Chemical Reviews, 2015, 115, 3518-3563.	23.0	530
393	Beta Amyloid Hallmarks: From Intrinsically Disordered Proteins to Alzheimer's Disease. Advances in Experimental Medicine and Biology, 2015, 870, 401-421.	0.8	23

#	Article	IF	Citations
394	Identification of a Compound That Disrupts Binding of Amyloid- \hat{l}^2 to the Prion Protein Using a Novel Fluorescence-based Assay. Journal of Biological Chemistry, 2015, 290, 17020-17028.	1.6	36
395	Suppression of glypican-1 autodegradation by NO-deprivation correlates with nuclear accumulation of amyloid beta in normal fibroblasts. Glycoconjugate Journal, 2015, 32, 675-684.	1.4	5
396	Amyloid beta modulation of neuronal network activity in vitro. Brain Research, 2015, 1629, 1-9.	1.1	31
397	Review of Amyotrophic Lateral Sclerosis, Parkinson's and Alzheimer's diseases helps further define pathology of the novel paradigm for Alzheimer's with heavy metals as primary disease cause. Medical Hypotheses, 2015, 85, 779-790.	0.8	25
398	Protein structures in Alzheimer's disease: The basis for rationale therapeutic design. Archives of Biochemistry and Biophysics, 2015, 588, 1-14.	1.4	20
399	Two distinct \hat{l}^2 -sheet structures in Italian-mutant amyloid-beta fibrils: a potential link to different clinical phenotypes. Cellular and Molecular Life Sciences, 2015, 72, 4899-4913.	2.4	26
400	Anti-A \hat{l}^2 single-chain variable fragment antibodies exert synergistic neuroprotective activities in < i > Drosophila < /i > models of Alzheimer's disease. Human Molecular Genetics, 2015, 24, 6093-6105.	1.4	20
401	Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight. Biomedicine and Pharmacotherapy, 2015, 74, 101-110.	2.5	683
402	Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models. Acta Neuropathologica, 2015, 130, 713-729.	3.9	53
403	Brain-derived neurotrophic factor and TrkB expression in the "oldest-old,―the 90+ Study: correlation with cognitive status andÂlevels of soluble amyloid-beta. Neurobiology of Aging, 2015, 36, 3130-3139.	1.5	44
404	Soluble Prion Protein Binds Isolated Low Molecular Weight Amyloid-Î ² Oligomers Causing Cytotoxicity Inhibition. ACS Chemical Neuroscience, 2015, 6, 1972-1980.	1.7	19
405	High Membrane Curvature Enhances Binding, Conformational Changes, and Fibrillation of Amyloid- \hat{l}^2 on Lipid Bilayer Surfaces. Langmuir, 2015, 31, 11549-11557.	1.6	50
406	Structural differences of amyloid- \hat{l}^2 fibrils revealed by antibodies from phage display. BMC Biotechnology, 2015, 15, 57.	1.7	12
407	Neuronal Store-Operated Calcium Entry and Mushroom Spine Loss in Amyloid Precursor Protein Knock-In Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2015, 35, 13275-13286.	1.7	158
408	Amyloid- \hat{l}^2 Oligomers May Impair SNARE-Mediated Exocytosis by Direct Binding to Syntaxin 1a. Cell Reports, 2015, 12, 1244-1251.	2.9	54
409	Positively Charged Chitosan and <i>N</i> -Trimethyl Chitosan Inhibit AÎ 240 Fibrillogenesis. Biomacromolecules, 2015, 16, 2363-2373.	2.6	43
410	Proteopathies: Biological, Molecular and Clinical Perspectives., 2015,, 139-169.		1
411	Contrasting effects of nanoparticle–protein attraction on amyloid aggregation. RSC Advances, 2015, 5, 105489-105498.	1.7	56

#	Article	IF	CITATIONS
412	Anti-A \hat{l}^2 antibodies incapable of reducing cerebral A \hat{l}^2 oligomers fail to attenuate spatial reference memory deficits in J20 mice. Neurobiology of Disease, 2015, 82, 372-384.	2.1	37
413	Reduction of amyloid-beta levels in mouse eye tissues byÂintra-vitreally delivered neprilysin. Experimental Eye Research, 2015, 138, 134-144.	1.2	36
415	The structure of fibrils from â€~misfolded' proteins. Current Opinion in Structural Biology, 2015, 30, 43-49.	2.6	61
416	Introduction of a Fluorescent Probe to Amyloid $\hat{a} \in \hat{I}^2$ to Reveal Kinetic Insights into Its Interactions with Copper(II). Angewandte Chemie - International Edition, 2015, 54, 1227-1230.	7.2	47
417	Rapid, Cell-Free Assay for Membrane-Active Forms of Amyloid-Î ² . Langmuir, 2015, 31, 4049-4053.	1.6	26
418	Rescue of impaired late–phase long-term depression in a tau transgenic mouse model. Neurobiology of Aging, 2015, 36, 730-739.	1.5	37
419	Sildenafil Decreases BACE1 and Cathepsin B Levels and Reduces APP Amyloidogenic Processing in the SAMP8 Mouse. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 675-685.	1.7	30
420	The Role of Cholesterol Metabolism in Alzheimer's Disease. Molecular Neurobiology, 2015, 51, 947-965.	1.9	62
421	Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?. European Neuropsychopharmacology, 2015, 25, 713-724.	0.3	78
422	Aged monkey brains reveal the role of ubiquitin-conjugating enzyme UBE2N in the synaptosomal accumulation of mutant huntingtin. Human Molecular Genetics, 2015, 24, 1350-1362.	1.4	20
423	Curcumin derivative with the substitution at C-4 position, but not curcumin, is effective against amyloid pathology in APP/PS1 mice. Neurobiology of Aging, 2015, 36, 201-210.	1.5	65
424	Fibrillation of \hat{I}^2 amyloid peptides in the presence of phospholipid bilayers and the consequent membrane disruption. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 266-276.	1.4	52
425	Pan-PPAR Modulation Effectively Protects APP/PS1 Mice from Amyloid Deposition and Cognitive Deficits. Molecular Neurobiology, 2015, 51, 661-671.	1.9	35
426	3,4-Dihydroxyphenylethanol Attenuates Spatio-Cognitive Deficits in an Alzheimer's Disease Mouse Model: Modulation of the Molecular Signals in Neuronal Survival-Apoptotic Programs. Neurotoxicity Research, 2015, 27, 143-155.	1.3	48
427	The Anti-Prion Antibody 15B3 Detects Toxic Amyloid- \hat{l}^2 Oligomers. Journal of Alzheimer's Disease, 2016, 53, 1485-1497.	1.2	12
428	Killing Me Softly: Connotations to Unfolded Protein Response and Oxidative Stress in Alzheimer's Disease. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-17.	1.9	24
429	Amyloid-Beta Induced Changes in Vesicular Transport of BDNF in Hippocampal Neurons. Neural Plasticity, 2016, 2016, 1-15.	1.0	26
430	FcÎ 3 RIIb-SHIP2 axis links AÎ 2 to tau pathology by disrupting phosphoinositide metabolism in Alzheimer's disease model. ELife, 2016, 5, .	2.8	36

#	ARTICLE	IF	CITATIONS
431	The Protective Effect of Icariin on Mitochondrial Transport and Distribution in Primary Hippocampal Neurons from 3× Tg-AD Mice. International Journal of Molecular Sciences, 2016, 17, 163.	1.8	32
432	The Mineralocorticoid Agonist Fludrocortisone Promotes Survival and Proliferation of Adult Hippocampal Progenitors. Frontiers in Endocrinology, 2016, 7, 66.	1.5	17
433	Hippocampal Injections of Oligomeric Amyloid β-peptide (1–42) Induce Selective Working Memory Deficits and Long-lasting Alterations of ERK Signaling Pathway. Frontiers in Aging Neuroscience, 2015, 7, 245.	1.7	84
434	Glycines from the APP GXXXG/GXXXA Transmembrane Motifs Promote Formation of Pathogenic $\hat{Al^2}$ Oligomers in Cells. Frontiers in Aging Neuroscience, 2016, 8, 107.	1.7	28
435	Oridonin Attenuates Synaptic Loss and Cognitive Deficits in an Aβ1–42-Induced Mouse Model of Alzheimer's Disease. PLoS ONE, 2016, 11, e0151397.	1.1	42
436	Fe65 Is Phosphorylated on Ser289 after UV-Induced DNA Damage. PLoS ONE, 2016, 11, e0155056.	1.1	3
437	Metabolic Characterization of Intact Cells Reveals Intracellular Amyloid Beta but Not Its Precursor Protein to Reduce Mitochondrial Respiration. PLoS ONE, 2016, 11, e0168157.	1,1	26
438	The amyloid cascade hypothesis: are we poised for success or failure?. Journal of Neurochemistry, 2016, 139, 237-252.	2.1	308
439	Acâ€LPFFDâ€Th: A Trehaloseâ€Conjugated Peptidomimetic as a Strong Suppressor of Amyloidâ€Î² Oligomer Formation and Cytotoxicity. ChemBioChem, 2016, 17, 1541-1549.	1.3	28
440	Protein aggregation as an antibiotic design strategy. Molecular Microbiology, 2016, 99, 849-865.	1.2	44
441	Neuroprotective Effects of Icariin on Brain Metabolism, Mitochondrial Functions, and Cognition in Tripleâ€Transgenic Alzheimer's Disease Mice. CNS Neuroscience and Therapeutics, 2016, 22, 63-73.	1.9	54
442	Preferential interaction of the Alzheimer peptide Aβâ€(1–42) with Omegaâ€3â€containing lipid bilayers: structure and interaction studies. FEBS Letters, 2016, 590, 582-591.	1.3	10
443	Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases. Movement Disorders, 2016, 31, 771-781.	2.2	88
444	Introduction of <scp>d</scp> â€Glutamate at a Critical Residue of Aβ42 Stabilizes a Prefibrillary Aggregate with Enhanced Toxicity. Chemistry - A European Journal, 2016, 22, 11967-11970.	1.7	31
445	Sensitive imaging and effective capture of Cu2+: Towards highly efficient theranostics of Alzheimer's disease. Biomaterials, 2016, 104, 158-167.	5.7	64
446	Photoactive gâ€C ₃ N ₄ Nanosheets for Lightâ€Induced Suppression of Alzheimer's βâ€Amyloid Aggregation and Toxicity. Advanced Healthcare Materials, 2016, 5, 1560-1565.	3.9	72
447	Increased tauopathy drives microglia-mediated clearance of beta-amyloid. Acta Neuropathologica Communications, 2016, 4, 63.	2.4	35
448	Polymorphism of fibrillar structures depending on the size of assembled AÎ 2 17-42 peptides. Scientific Reports, 2016, 6, 38196.	1.6	19

#	Article	IF	Citations
449	7-(4-Hydroxyphenyl)-1-phenyl-4 <i>E</i> -hepten-3-one, a Diarylheptanoid from <i>Alpinia officinarum</i> , Protects Neurons against Amyloid-β Induced Toxicity. Biological and Pharmaceutical Bulletin, 2016, 39, 1961-1967.	0.6	19
450	Protective Effect of Amyloid- \hat{l}^2 Peptides Against Herpes Simplex Virus-1 Infection in a Neuronal Cell Culture Model. Journal of Alzheimer's Disease, 2016, 50, 1227-1241.	1.2	120
451	Amyloid structure exhibits polymorphism on multiple length scales in human brain tissue. Scientific Reports, 2016, 6, 33079.	1.6	48
452	Early Alterations of Hippocampal Neuronal Firing Induced by Abeta42. Cerebral Cortex, 2018, 28, 433-446.	1.6	30
453	The Alzheimer's-related amyloid beta peptide is internalised by R28 neuroretinal cells and disrupts the microtubule associated protein 2 (MAP-2). Experimental Eye Research, 2016, 153, 110-121.	1.2	18
454	Anti-Viral Properties of Amyloid- \hat{l}^2 Peptides. Journal of Alzheimer's Disease, 2016, 54, 859-878.	1.2	70
455	Soluble Amyloid-beta Aggregates from Human Alzheimer's Disease Brains. Scientific Reports, 2016, 6, 38187.	1.6	119
456	$A < i > \hat{l}^2 < i > -1$ Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment. Expert Reviews in Molecular Medicine, 2016, 18, e13.	1.6	34
457	3D culture models of Alzheimer's disease: a road map to a "cure-in-a-dish― Molecular Neurodegeneration, 2016, 11, 75.	4.4	109
458	Targets and Strategies Toward the Development of Alzheimer Therapeutics. Topics in Medicinal Chemistry, 2016, , 1-25.	0.4	0
459	Morphological observation of self-aggregation of \hat{l}^2 -amyloid $1\hat{a}^2$ 40. , 2016, , .		0
460	Structure of Crenezumab Complex with $A\hat{l}^2$ Shows Loss of \hat{l}^2 -Hairpin. Scientific Reports, 2016, 6, 39374.	1.6	84
461	A coarse grained protein model with internal degrees of freedom. Application to $\langle i \rangle \hat{l} \pm \langle i \rangle$ -synuclein aggregation. Journal of Chemical Physics, 2016, 144, 085103.	1.2	30
462	Development of new fusion proteins for visualizing amyloid- \hat{l}^2 oligomers in vivo. Scientific Reports, 2016, 6, 22712.	1.6	32
463	Specific Binding of Cu(II) Ions to Amyloid-Beta Peptides Bound to Aggregation-Inhibiting Molecules or SDS Micelles Creates Complexes that Generate Radical Oxygen Species. Journal of Alzheimer's Disease, 2016, 54, 971-982.	1.2	34
464	How Do the Size, Charge and Shape of Nanoparticles Affect Amyloid \hat{l}^2 Aggregation on Brain Lipid Bilayer?. Scientific Reports, 2016, 6, 19548.	1.6	88
465	A TgCRND8 Mouse Model of Alzheimer's Disease Exhibits Sexual Dimorphisms inÂBehavioral Indices of Cognitive Reserve. Journal of Alzheimer's Disease, 2016, 51, 757-773.	1.2	30
467	Study of Exosomes Shed New Light on Physiology of Amyloidogenesis. Cellular and Molecular Neurobiology, 2016, 36, 327-342.	1.7	13

#	Article	IF	CITATIONS
468	Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors. BioDrugs, 2016, 30, 173-194.	2.2	36
469	Traumatic Axonal Injury: Mechanisms and Translational Opportunities. Trends in Neurosciences, 2016, 39, 311-324.	4.2	241
470	Selective Persistence of Sensorimotor Mismatch Signals in Visual Cortex of Behaving Alzheimer's Disease Mice. Current Biology, 2016, 26, 956-964.	1.8	49
471	Alzheimer disease: modeling an Aβ-centered biological network. Molecular Psychiatry, 2016, 21, 861-871.	4.1	47
472	Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease. Neuroscience and Biobehavioral Reviews, 2016, 65, 326-340.	2.9	58
473	Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics. Annual Review of Neuroscience, 2016, 39, 57-79.	5.0	97
474	Phosphorylation of the amyloid \hat{l}^2 -peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. Acta Neuropathologica, 2016, 131, 525-537.	3.9	84
475	A \hat{l}^2 1-42-induced dysfunction in synchronized gamma oscillation during working memory. Behavioural Brain Research, 2016, 307, 112-119.	1.2	13
476	3D compartmented model to study the neurite-related toxicity of $\hat{Al^2}$ aggregates included in collagen gels of adaptable porosity. Acta Biomaterialia, 2016, 37, 38-49.	4.1	19
477	Improved \hat{l} -valerolactam templates for the assembly of $\hat{Al^2}$ -miniamyloids by boronic ester formation. Organic and Biomolecular Chemistry, 2016, 14, 5032-5048.	1.5	6
478	Distinct Membrane Disruption Pathways Are Induced by 40-Residue β-Amyloid Peptides. Journal of Biological Chemistry, 2016, 291, 12233-12244.	1.6	50
479	Alzheimer's disease: The use of contrast agents for magnetic resonance imaging to detect amyloid beta peptide inside the brain. Coordination Chemistry Reviews, 2016, 327-328, 27-34.	9.5	27
480	Droplet-based magnetic bead immunoassay using microchannel-connected multiwell plates (\hat{l} /4CHAMPs) for the detection of amyloid beta oligomers. Lab on A Chip, 2016, 16, 2245-2253.	3.1	34
481	Effects of Heart Bypass Surgery on Plasma A \hat{l}^2 40 and A \hat{l}^2 42 Levels in Infants and Young Children. Medicine (United States), 2016, 95, e2684.	0.4	7
482	Lymphatics in Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis and Alzheimer's Disease?. Neuron, 2016, 91, 957-973.	3.8	123
483	Inhibition of Insulin Amyloid Fibrillation by a Novel Amphipathic Heptapeptide. Journal of Biological Chemistry, 2016, 291, 23545-23556.	1.6	62
484	Dynamics of the conformational transitions during the dimerization of an intrinsically disordered peptide: a case study on the human islet amyloid polypeptide fragment. Physical Chemistry Chemical Physics, 2016, 18, 29892-29904.	1.3	15
485	Semisynthesis and Structure–Activity Studies of Uncarinic Acid C Isolated from <i>Uncaria rhynchophylla</i> as a Specific Inhibitor of the Nucleation Phase in Amyloid β42 Aggregation. Journal of Natural Products, 2016, 79, 2521-2529.	1.5	28

#	Article	IF	CITATIONS
486	Amyloid- \hat{l}^2 effects on synapses and memory require AMPA receptor subunit GluA3. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6526-E6534.	3.3	100
487	Assembly of Peptides Derived from \hat{l}^2 -Sheet Regions of \hat{l}^2 -Amyloid. Journal of the American Chemical Society, 2016, 138, 13882-13890.	6.6	34
488	Ultraviolet irradiation-mediated formation of A \hat{I}^2 42 oligomers and reactive oxygen species in Zn2+-bound A \hat{I}^2 42 aggregates irrespective of the removal of Zn2+. New Journal of Chemistry, 2016, 40, 9385-9394.	1.4	1
489	Characterization of Salt-Induced Oligomerization of Human \hat{l}^2 sub>2-Microglobulin at Low pH. Journal of Physical Chemistry B, 2016, 120, 7815-7823.	1.2	6
490	An infrared sensor analysing label-free the secondary structure of the Abeta peptide in presence of complex fluids. Journal of Biophotonics, 2016, 9, 224-234.	1.1	53
491	The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature, 2016, 537, 50-56.	13.7	2,179
492	Holdase activity of secreted Hsp70 masks amyloid- \hat{l}^2 42 neurotoxicity in <i>Drosophila</i> . Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5212-21.	3.3	60
493	Heat- and pH-induced BSA conformational changes, hydrogel formation and application as 3D cell scaffold. Archives of Biochemistry and Biophysics, 2016, 606, 134-142.	1.4	41
494	Fe–oxy adducts of heme–Aβ and heme–hIAPP complexes: intermediates in ROS generation. Metallomics, 2016, 8, 1266-1272.	1.0	12
495	Both pre- and post-synaptic alterations contribute to aberrant cholinergic transmission in superior cervical ganglia of APPâ^'/â^' mice. Neuropharmacology, 2016, 110, 493-502.	2.0	3
496	Soluble Conformers of $\hat{Al^2}$ and Tau Alter Selective Proteins Governing Axonal Transport. Journal of Neuroscience, 2016, 36, 9647-9658.	1.7	47
497	Kinetics of the Interactions between Copper and Amyloidâ€Î² with FAD Mutations and Phosphorylation at the N terminus. ChemBioChem, 2016, 17, 1732-1737.	1.3	15
498	Alzheimer's disease like pathology induced six weeks after aggregated amyloid-beta injection in rats: increased oxidative stress and impaired long-term memory with anxiety-like behavior. Neurological Research, 2016, 38, 838-850.	0.6	71
499	A Study of $A\hat{I}^2$ Oligomers in the Temporal Cortex and Cerebellum of Patients with Neuropathologically Confirmed Alzheimer's Disease Compared to Aged Controls. Neurodegenerative Diseases, 2016, 16, 398-406.	0.8	14
500	Structural Polymorphism of Alzheimer's β-Amyloid Fibrils as Controlled by an E22 Switch: A Solid-State NMR Study. Journal of the American Chemical Society, 2016, 138, 9840-9852.	6.6	79
501	Mammalian prions and their wider relevance in neurodegenerative diseases. Nature, 2016, 539, 217-226.	13.7	193
502	Network abnormalities and interneuron dysfunction in Alzheimer disease. Nature Reviews Neuroscience, 2016, 17, 777-792.	4.9	685

#	Article	IF	CITATIONS
504	An Atomistic View of Amyloidogenic Self-assembly: Structure and Dynamics of Heterogeneous Conformational States in the Pre-nucleation Phase. Scientific Reports, 2016, 6, 33156.	1.6	25
505	The Aggregation Paths and Products of AÎ ² 42 Dimers Are Distinct from Those of the AÎ ² 42 Monomer. Biochemistry, 2016, 55, 6150-6161.	1.2	22
506	Soluble amyloid beta oligomers block the learning-induced increase in hippocampal sharp wave-ripple rate and impair spatial memory formation. Scientific Reports, 2016, 6, 22728.	1.6	50
507	Imaging organelle transport in primary hippocampal neurons treated with amyloid- \hat{l}^2 oligomers. Methods in Cell Biology, 2016, 131, 425-451.	0.5	7
508	Presenilin 1 transgene addition to amyloid precursor protein overexpressing transgenic rats increases amyloid beta 42 levels and results in loss of memory retention. BMC Neuroscience, 2016, 17, 46.	0.8	14
509	Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease. Alzheimer's Research and Therapy, 2016, 8, 34.	3.0	15
510	Cholinergic Basal Forebrain Lesion Decreases Neurotrophin Signaling without Affecting Tau Hyperphosphorylation in Genetically Susceptible Mice. Journal of Alzheimer's Disease, 2016, 55, 1141-1154.	1.2	8
511	Amyloid Plaques Show Binding Capacity of Exogenous Injected Amyloid- \hat{l}^2 . Journal of Alzheimer's Disease, 2016, 55, 147-157.	1.2	5
512	An Account of Amyloid Oligomers: Facts and Figures Obtained from Experiments and Simulations. ChemBioChem, 2016, 17, 657-676.	1.3	95
513	Understanding Amyloidâ€Î² Oligomerization at the Molecular Level: The Role of the Fibril Surface. Chemistry - A European Journal, 2016, 22, 8768-8772.	1.7	34
514	Prospects and Challenges for Alzheimer Therapeutics. , 2016, , 605-637.		2
515	Biophysical insights into the membrane interaction of the core amyloid-forming $A\hat{l}^2$ (sub>40fragment K16â \in K28 and its role in the pathogenesis of Alzheimer's disease. Physical Chemistry Chemical Physics, 2016, 18, 16890-16901.	1.3	16
516	Insights on the pathophysiology of Alzheimer's disease: The crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system. Neuroscience and Biobehavioral Reviews, 2016, 68, 547-562.	2.9	114
517	Switchable photooxygenation catalysts that sense higher-order amyloid structures. Nature Chemistry, 2016, 8, 974-982.	6.6	104
518	Immunotherapy Against Amyloid-β in Alzheimer's Disease: An Overview. Methods in Pharmacology and Toxicology, 2016, , 3-17.	0.1	1
519	Quantitative multimodal multiparametric imaging in Alzheimer's disease. Brain Informatics, 2016, 3, 29-37.	1.8	13
520	Regulatory Forum Opinion Piece*. Toxicologic Pathology, 2016, 44, 137-146.	0.9	1
521	Non-alcoholic fatty liver disease induces signs of Alzheimer's disease (AD) in wild-type mice and accelerates pathological signs of AD in an AD model. Journal of Neuroinflammation, 2016, 13, 1.	3.1	254

#	Article	IF	CITATIONS
522	Alzheimer's Turning Point. , 2016, , .		8
523	Polyglutamine aggregates impair lipid membrane integrity and enhance lipid membrane rigidity. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 661-670.	1.4	20
524	The lipidome associated with the \hat{l}^3 -secretase complex is required for its integrity and activity. Biochemical Journal, 2016, 473, 321-334.	1.7	12
525	Distinct prion-like strains of amyloid beta implicated in phenotypic diversity of Alzheimer's disease. Prion, 2016, 10, 9-17.	0.9	57
526	Validation and Characterization of a Novel Peptide That Binds Monomeric and Aggregated \hat{l}^2 -Amyloid and Inhibits the Formation of Neurotoxic Oligomers. Journal of Biological Chemistry, 2016, 291, 547-559.	1.6	15
527	Single molecule experiments emphasize GM1 as a key player of the different cytotoxicity of structurally distinct Aβ1–42 oligomers. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 386-392.	1.4	22
528	Allosteric stabilization of the amyloid- \hat{l}^2 peptide hairpin by the fluctuating N-terminal. Chemical Communications, 2016, 52, 1733-1736.	2.2	25
529	Advances in the Simulation of Protein Aggregation at the Atomistic Scale. Journal of Physical Chemistry B, 2016, 120, 2991-2999.	1.2	102
530	Identification of proteins that are differentially expressed in brains with Alzheimer's disease using iTRAQ labeling and tandem mass spectrometry. Journal of Proteomics, 2016, 139, 103-121.	1.2	48
531	A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nature Reviews Neuroscience, 2016, 17, 251-260.	4.9	251
532	The effect of LCZ696 (sacubitril/valsartan) on amyloidâ $\hat{\mathbb{Q}}^2$ concentrations in cerebrospinal fluid in healthy subjects. British Journal of Clinical Pharmacology, 2016, 81, 878-890.	1.1	89
533	Peptides Composed of Alternating L- and D-Amino Acids Inhibit Amyloidogenesis in Three Distinct Amyloid Systems Independent of Sequence. Journal of Molecular Biology, 2016, 428, 2317-2328.	2.0	50
534	Gamma Secretase Modulators: New Alzheimer's Drugs on the Horizon?. Journal of Medicinal Chemistry, 2016, 59, 7389-7409.	2.9	118
535	The Cellular Phase of Alzheimer's Disease. Cell, 2016, 164, 603-615.	13.5	1,346
536	Monomeric Aβ ^{1â€"40} and Aβ ^{1â€"42} Peptides in Solution Adopt Very Similar Ramachandran Map Distributions That Closely Resemble Random Coil. Biochemistry, 2016, 55, 762-775.	1.2	168
537	APP Receptor? To Be or Not To Be. Trends in Pharmacological Sciences, 2016, 37, 390-411.	4.0	107
538	Systems Pharmacology Analysis of the Amyloid Cascade after Â-Secretase Inhibition Enables the Identification of an AÂ42 Oligomer Pool. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 205-216.	1.3	9
539	Dendritic Spine Pathology in Neurodegenerative Diseases. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 221-250.	9.6	161

#	Article	IF	CITATIONS
540	Amyloid Plaque in the Human Brain Can Decompose from $\hat{Al^2}(1-40/1-42)$ by Spontaneous Nonenzymatic Processes. Analytical Chemistry, 2016, 88, 2675-2684.	3.2	32
541	Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by $\hat{Al^2}$ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease. Neurobiology of Disease, 2016, 91, 124-131.	2.1	40
542	X-ray Crystallographic Structures of a Trimer, Dodecamer, and Annular Pore Formed by an AÎ ² _{17â€⁴36} Î ² -Hairpin. Journal of the American Chemical Society, 2016, 138, 4634-4642.	6.6	69
543	Amyloid- \hat{l}^2 Receptors: The Good, the Bad, and the Prion Protein. Journal of Biological Chemistry, 2016, 291, 3174-3183.	1.6	201
544	Peroxiredoxin 5 prevents amyloid-beta oligomer-induced neuronal cell death by inhibiting ERK–Drp1-mediated mitochondrial fragmentation. Free Radical Biology and Medicine, 2016, 90, 184-194.	1.3	69
545	Sex Dimorphism Profile of Alzheimer's Disease-Type Pathologies in an APP/PS1 Mouse Model. Neurotoxicity Research, 2016, 29, 256-266.	1.3	89
546	Propagation of Aß pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathologica, 2016, 131, 5-25.	3.9	68
547	Obestatin promotes proliferation and survival of adult hippocampal progenitors and reduces amyloid- \hat{l}^2 -induced toxicity. Molecular and Cellular Endocrinology, 2016, 422, 18-30.	1.6	20
548	Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective. Molecular Neurobiology, 2016, 53, 4833-4864.	1.9	52
549	Pharmacokinetic Properties of a Novel d-Peptide Developed to be Therapeutically Active Against Toxic Î ² -Amyloid Oligomers. Pharmaceutical Research, 2016, 33, 328-336.	1.7	35
550	An inÂvitro model for synaptic loss in neurodegenerative diseases suggests a neuroprotective role for valproic acid via inhibition of cPLA2 dependent signalling. Neuropharmacology, 2016, 101, 566-575.	2.0	22
551	The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease. Molecular Neurobiology, 2016, 53, 1905-1924.	1.9	73
552	Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. Progress in Neurobiology, 2017, 151, 4-34.	2.8	128
553	Facilitation of brain mitochondrial activity by 5-aminolevulinic acid in a mouse model of Alzheimer's disease. Nutritional Neuroscience, 2017, 20, 538-546.	1.5	12
554	Cerebrospinal Fluid Proteins as Regulators of Betaâ€amyloid Aggregation and Toxicity. Israel Journal of Chemistry, 2017, 57, 602-612.	1.0	17
555	Design of a Molecular Hybrid of Dual Peptide Inhibitors Coupled on AuNPs for Enhanced Inhibition of Amyloid βâ€Protein Aggregation and Cytotoxicity. Small, 2017, 13, 1601666.	5.2	82
556	Structural Studies of Amyloid Proteins at the Molecular Level. Annual Review of Biochemistry, 2017, 86, 69-95.	5.0	419
557	The Nucleation of Protein Aggregates - From Crystals to Amyloid Fibrils. International Review of Cell and Molecular Biology, 2017, 329, 187-226.	1.6	46

#	Article	IF	CITATIONS
558	Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by β-amyloid oligomers in an acute mouse model of Alzheimer's disease. Brain, Behavior, and Immunity, 2017, 60, 188-197.	2.0	123
559	Brain amyloid in preclinical Alzheimer's disease is associated withÂincreased driving risk. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 136-142.	1.2	21
560	Understanding curli amyloid-protein aggregation by hydrogen–deuterium exchange and mass spectrometry. International Journal of Mass Spectrometry, 2017, 420, 16-23.	0.7	12
561	Necâ \in 1 alleviates cognitive impairment with reduction of Aβ and tau abnormalities in <scp>APP $<$ /scp> $ <$ scp>PS $<$ /scp>1 mice. EMBO Molecular Medicine, 2017, 9, 61-77.	3.3	126
562	Real-Time Analysis of Binding Events between Different Aβ _{1–42} Species and Human Lilrb2 by Dual Polarization Interferometry. Analytical Chemistry, 2017, 89, 2606-2612.	3.2	21
563	Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy. Human Antibodies, 2017, 25, 131-146.	0.6	14
564	Concentrations of antibodies against \hat{l}^2 -amyloid 40/42 monomer and oligomers in Chinese intravenous immunoglobulins. Journal of Pharmaceutical and Biomedical Analysis, 2017, 138, 277-282.	1.4	5
565	The role of histidines in amyloid \hat{l}^2 fibril assembly. FEBS Letters, 2017, 591, 1167-1175.	1.3	36
566	Peroxiredoxin 5 Decreases Beta-Amyloid-Mediated Cyclin-Dependent Kinase 5 Activation Through Regulation of Ca ²⁺ -Mediated Calpain Activation. Antioxidants and Redox Signaling, 2017, 27, 715-726.	2.5	23
567	Reduced Lipid Bilayer Thickness Regulates the Aggregation and Cytotoxicity of Amyloid-Î ² . Journal of Biological Chemistry, 2017, 292, 4638-4650.	1.6	145
568	Insights into the Inhibitory Mechanism of Dicyanovinylâ€Substituted J147 Derivative against Aβ ₄₂ Aggregation and Protofibril Destabilization: A Molecular Dynamics Simulation Study. ChemistrySelect, 2017, 2, 1645-1657.	0.7	25
569	Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid- \hat{l}^2 and other amyloidogenic proteins. Journal of Lipid Research, 2017, 58, 824-836.	2.0	159
570	Inhibitory effect of hydrophobic fullerenes on the \hat{l}^2 -sheet-rich oligomers of a hydrophilic GNNQQNY peptide revealed by atomistic simulations. RSC Advances, 2017, 7, 13947-13956.	1.7	12
571	Amyloid-beta peptide decreases expression and function of glutamate transporters in nervous system cells. International Journal of Biochemistry and Cell Biology, 2017, 85, 75-84.	1.2	25
572	Understanding Alzheimer's disease by global quantification of protein phosphorylation and sialylated N-linked glycosylation profiles: A chance for new biomarkers in neuroproteomics?. Journal of Proteomics, 2017, 161, 11-25.	1.2	23
573	Role of Hydrophobic/Aromatic Residues on the Stability of Double-Wall \hat{l}^2 -Sheet Structures Formed by a Triblock Peptide. Journal of Physical Chemistry B, 2017, 121, 4115-4128.	1.2	5
574	Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. Annual Review of Biochemistry, 2017, 86, 27-68.	5.0	1,929
575	Alzheimer's Disease II. Topics in Medicinal Chemistry, 2017, , .	0.4	2

#	Article	IF	CITATIONS
577	Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice. Journal of Biological Inorganic Chemistry, 2017, 22, 851-865.	1.1	76
578	The amyloid- \hat{l}^2 oligomer A \hat{l}^2 *56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation. Science Signaling, 2017, 10, .	1.6	90
579	A novel pathway for amyloids self-assembly in aggregates at nanomolar concentration mediated by the interaction with surfaces. Scientific Reports, 2017, 7, 45592.	1.6	44
580	Curcumin Dictates Divergent Fates for the Central Salt Bridges in Amyloid- \hat{l}^2 40 and Amyloid- \hat{l}^2 42. Biophysical Journal, 2017, 112, 1597-1608.	0.2	16
581	Structural Rearrangement from Oligomer to Fibril Detected with FRET in a Designed Amphiphilic Peptide. ChemBioChem, 2017, 18, 195-205.	1.3	2
582	TRPC Channels and Alzheimer's Disease. Advances in Experimental Medicine and Biology, 2017, 976, 73-83.	0.8	12
583	Selective targeting of primary and secondary nucleation pathways in $A\hat{l}^242$ aggregation using a rational antibody scanning method. Science Advances, 2017, 3, e1700488.	4.7	116
584	γ-Secretase Modulators as Aβ42-Lowering Pharmacological Agents to Treat Alzheimer's Disease. Topics in Medicinal Chemistry, 2017, , 87-118.	0.4	6
585	A critical overview of therapeutic strategy and advancement for Alzheimer's disease treatment. Journal of the Taiwan Institute of Chemical Engineers, 2017, 77, 92-105.	2.7	11
586	High-resolution bioelectrical imaging of $\widehat{Al^2}$ -induced network dysfunction on CMOS-MEAs for neurotoxicity and rescue studies. Scientific Reports, 2017, 7, 2460.	1.6	34
587	Lipid membranes catalyse the fibril formation of the amyloid- \hat{l}^2 ($1\hat{a}$ \in "42) peptide through lipid-fibril interactions that reinforce secondary pathways. Biochimica Et Biophysica Acta - Biomembranes, 2017, 1859, 1921-1929.	1.4	90
588	NanoEHS beyond toxicity – focusing on biocorona. Environmental Science: Nano, 2017, 4, 1433-1454.	2.2	43
589	The double faced role of copper in $A\hat{l}^2$ homeostasis: A survey on the interrelationship between metal dyshomeostasis, UPS functioning and autophagy in neurodegeneration. Coordination Chemistry Reviews, 2017, 347, 1-22.	9.5	39
590	Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 58, 23-35.	1.2	23
591	Biochemically-defined pools of amyloid-l̂² in sporadic Alzheimer's disease: correlation with amyloid PET. Brain, 2017, 140, 1486-1498.	3.7	123
592	Preclinical to phase II amyloid beta (A _β) peptide modulators under investigation for Alzheimer's disease. Expert Opinion on Investigational Drugs, 2017, 26, 579-592.	1.9	23
593	Humanin Specifically Interacts with Amyloid- \hat{l}^2 Oligomers and Counteracts Their in vivo Toxicity. Journal of Alzheimer's Disease, 2017, 57, 857-871.	1.2	23
594	Unmodified and pyroglutamylated amyloid β peptides form hypertoxic heteroâ€oligomers of unique secondary structure. FEBS Journal, 2017, 284, 1355-1369.	2.2	15

#	Article	IF	CITATIONS
595	Surface Assay for Specific Detection of Soluble Amyloid Oligomers Utilizing Pronucleon Peptides Instead of Antibodies. ACS Chemical Neuroscience, 2017, 8, 1213-1221.	1.7	6
596	Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer's disease: An integrative review. Progress in Neurobiology, 2017, 156, 1-68.	2.8	112
597	A High-Cholesterol Diet Increases 27-Hydroxycholesterol and Modifies Estrogen Receptor Expression and Neurodegeneration in Rabbit Hippocampus. Journal of Alzheimer's Disease, 2017, 56, 185-196.	1.2	53
598	The Amyloidâ€Î² Peptide in Amyloid Formation Processes: Interactions with Blood Proteins and Naturally Occurring Metal Ions. Israel Journal of Chemistry, 2017, 57, 674-685.	1.0	21
599	Using chiral peptide substitutions to probe the structure function relationship of a key residue of A \hat{l}^2 42. Chirality, 2017, 29, 5-9.	1.3	6
600	Rationally Designed Peptides and Peptidomimetics as Inhibitors of Amyloid-β (Aβ) Aggregation: Potential Therapeutics of Alzheimer's Disease. ACS Combinatorial Science, 2017, 19, 55-80.	3.8	168
601	Familial Alzheimer's Disease Mutations within the Amyloid Precursor Protein Alter the Aggregation and Conformation of the Amyloid-β Peptide. Journal of Biological Chemistry, 2017, 292, 3172-3185.	1.6	123
602	Non human primate models for Alzheimer's disease-related research and drug discovery. Expert Opinion on Drug Discovery, 2017, 12, 187-200.	2.5	50
603	Stabilization, Assembly, and Toxicity of Trimers Derived from $\hat{Al^2}$. Journal of the American Chemical Society, 2017, 139, 966-975.	6.6	68
604	lon Channel Formation by Amyloid-Î ² 42 Oligomers but Not Amyloid-Î ² 40 in Cellular Membranes. Journal of Biological Chemistry, 2017, 292, 1404-1413.	1.6	159
605	Iron, Copper, and Zinc Concentration in Aβ Plaques in the APP/PS1 Mouse Model of Alzheimer's Disease Correlates with Metal Levels in the Surrounding Neuropil. ACS Chemical Neuroscience, 2017, 8, 629-637.	1.7	107
606	Pyroglutamate–amyloid-β peptide expression in Drosophila leads to caspase-dependent and endoplasmic reticulum stress–related progressive neurodegeneration. Human Molecular Genetics, 2017, 26, 4642-4656.	1.4	5
607	Animal models of cerebral amyloid angiopathy. Clinical Science, 2017, 131, 2469-2488.	1.8	43
608	Using chirality to probe the conformational dynamics and assembly of intrinsically disordered amyloid proteins. Scientific Reports, 2017, 7, 12433.	1.6	37
609	A mimotope of Aβ oligomers may also behave as a βâ€sheet inhibitor. FEBS Letters, 2017, 591, 3615-3624.	1.3	7
610	lmaging Aβ(1–42) fibril elongation reveals strongly polarised growth and growth incompetent states. Physical Chemistry Chemical Physics, 2017, 19, 27987-27996.	1.3	57
611	Propagation of Misfolded Proteins in Neurodegeneration: Insights and Cautions from the Study of Prion Disease Prototypes., 2017,, 203-223.		0
612	Kinetic Studies on Protein Aggregation With and Without the Presence of Crowders. World Scientific Lecture and Course Notes in Chemistry, 2017, , 187-220.	0.2	4

#	Article	IF	CITATIONS
613	Single-Molecule Fluorescence Resonance Energy Transfer Studies of \hat{l}^2 -Amyloid Clusters in Physiological Solutions. World Scientific Lecture and Course Notes in Chemistry, 2017, , 297-311.	0.2	0
614	Binding of protofibrillar $\hat{Al^2}$ trimers to lipid bilayer surface enhances $\hat{Al^2}$ structural stability and causes membrane thinning. Physical Chemistry Chemical Physics, 2017, 19, 27556-27569.	1.3	32
615	Self-Assembly Pathways of β-Sheet-Rich Amyloid-β(1–40) Dimers: Markov State Model Analysis on Millisecond Hybrid-Resolution Simulations. Journal of Chemical Theory and Computation, 2017, 13, 5731-5744.	2.3	45
616	Amyloid β-peptides 1–40 and 1–42 form oligomers with mixed β-sheets. Chemical Science, 2017, 8, 8247-8254.	3.7	32
617	A Hexamer of a Peptide Derived from Aβ _{16–36} . Biochemistry, 2017, 56, 6061-6071.	1.2	23
618	Soluble Oligomers Require a Ganglioside to Trigger Neuronal Calcium Overload. Journal of Alzheimer's Disease, 2017, 60, 923-938.	1.2	41
619	Membrane Binding and Pore Formation by a Cytotoxic Fragment of Amyloid \hat{l}^2 Peptide. Journal of Physical Chemistry B, 2017, 121, 10293-10305.	1.2	55
620	Morphological analysis of oligomeric vs. fibrillar forms of α-synuclein aggregates with super-resolution BALM imaging. Chemical Physics Letters, 2017, 690, 62-67.	1.2	5
621	Gold Nanoparticles as a Probe for Amyloid- \hat{l}^2 Oligomer and Amyloid Formation. Journal of Physical Chemistry C, 2017, 121, 20007-20015.	1.5	51
622	Molecular insights into $\hat{Al^2}$ sub>42 (l sub> protofibril destabilization with a fluorinated compound D744: A molecular dynamics simulation study. Journal of Molecular Recognition, 2017, 30, e2656.	1.1	24
623	Cytochrome b561, copper, \hat{l}^2 -cleaved amyloid precursor protein and niemann-pick C1 protein are involved in ascorbate-induced release and membrane penetration of heparan sulfate from endosomal S-nitrosylated glypican-1. Experimental Cell Research, 2017, 360, 171-179.	1.2	9
624	Resolving the Atomistic Modes of Anle138b Inhibitory Action on Peptide Oligomer Formation. ACS Chemical Neuroscience, 2017, 8, 2791-2808.	1.7	26
625	Anti-A \hat{l}^2 single-chain variable fragment antibodies restore memory acquisition in a Drosophila model of Alzheimer $\hat{a} \in \mathbb{R}^M$ s disease. Scientific Reports, 2017, 7, 11268.	1.6	13
626	A Toxic Conformer of Aβ42 with a Turn at 22–23 is a Novel Therapeutic Target for Alzheimer's Disease. Scientific Reports, 2017, 7, 11811.	1.6	23
627	Emerging Structural Understanding of Amyloid Fibrils by Solid-State NMR. Trends in Biochemical Sciences, 2017, 42, 777-787.	3.7	73
628	Shedding Light on Alzheimer's β-Amyloidosis: Photosensitized Methylene Blue Inhibits Self-Assembly of β-Amyloid Peptides and Disintegrates Their Aggregates. Scientific Reports, 2017, 7, 7523.	1.6	62
629	Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer's disease. Acta Biochimica Et Biophysica Sinica, 2017, 49, 853-866.	0.9	155
630	Structural studies of amyloid- \hat{l}^2 peptides: Unlocking the mechanism of aggregation and the associated toxicity. Biochimie, 2017, 140, 176-192.	1.3	59

#	Article	IF	CITATIONS
631	A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid $\hat{\epsilon}^2$ oligomers. Journal of Neurochemistry, 2017, 142, 934-947.	2.1	27
632	Surprisingly high stability of the $\hat{Al^2}$ oligomer eliminating all-d-enantiomeric peptide D3 in media simulating the route of orally administered drugs. European Journal of Pharmaceutical Sciences, 2017, 107, 203-207.	1.9	21
633	Synthesis and biological evaluation of benzothiazol-based 1,3,4-oxadiazole derivatives as amyloid β-targeted compounds against Alzheimer's disease. Monatshefte Für Chemie, 2017, 148, 1807-1815.	0.9	17
634	Alzheimer's-Causing Mutations Shift Aβ Length by Destabilizing γ-Secretase-Aβn Interactions. Cell, 2017, 170, 443-456.e14.	13.5	199
635	Modulating protein amyloid aggregation with nanomaterials. Environmental Science: Nano, 2017, 4, 1772-1783.	2.2	38
636	Dissecting the behaviour of βâ€amyloid peptide variants during oligomerization and fibrillation. Journal of Peptide Science, 2017, 23, 810-817.	0.8	5
637	Mannich base approach to 5-methoxyisatin 3-(4-isopropylphenyl)hydrazone: A water-soluble prodrug for a multitarget inhibition of cholinesterases, beta-amyloid fibrillization and oligomer-induced cytotoxicity. European Journal of Pharmaceutical Sciences, 2017, 109, 381-388.	1.9	33
638	miR-200a-3p promotes β-Amyloid-induced neuronal apoptosis through down-regulation of SIRT1 in Alzheimer's disease. Journal of Biosciences, 2017, 42, 397-404.	0.5	57
639	Differential spatial expression of peripheral olfactory neuron-derived BACE1 induces olfactory impairment by region-specific accumulation of \hat{l}^2 -amyloid oligomer. Cell Death and Disease, 2017, 8, e2977-e2977.	2.7	30
640	Inhibiting the Ca 2+ Influx Induced by Human CSF. Cell Reports, 2017, 21, 3310-3316.	2.9	20
641	Initial Structural Models of the A \hat{l}^2 42 Dimer from Replica Exchange Molecular Dynamics Simulations. ACS Omega, 2017, 2, 7621-7636.	1.6	10
642	Sensing of Alzheimer's Disease and Multiple Sclerosis Using Nano-Bio Interfaces. Journal of Alzheimer's Disease, 2017, 59, 1187-1202.	1.2	38
643	Low-dose \hat{l}^3 -secretase inhibition increases secretion of $A\hat{l}^2$ peptides and intracellular oligomeric $A\hat{l}^2$. Molecular and Cellular Neurosciences, 2017, 85, 211-219.	1.0	6
644	Spiropiperidine Sultam and Lactam Templates: Diastereoselective Overman Rearrangement and Metathesis followed by NH Arylation. Journal of Organic Chemistry, 2017, 82, 12246-12256.	1.7	10
645	Ultrasensitive Measurement of Ca ²⁺ Influx into Lipid Vesicles Induced by Protein Aggregates. Angewandte Chemie, 2017, 129, 7858-7862.	1.6	9
646	Ultrasensitive Measurement of Ca ²⁺ Influx into Lipid Vesicles Induced by Protein Aggregates. Angewandte Chemie - International Edition, 2017, 56, 7750-7754.	7.2	72
647	Monomeric and fibrillar $\hat{l}\pm$ -synuclein exert opposite effects on the catalytic cycle that promotes the proliferation of $A\hat{l}^242$ aggregates. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8005-8010.	3.3	45
648	Diverse functions of the prion protein – Does proteolytic processing hold the key?. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 2128-2137.	1.9	60

#	Article	IF	CITATIONS
649	Inhibition of Alzheimer's amyloid-beta aggregation in-vitro by carbenoxolone: Insight into mechanism of action. Neurochemistry International, 2017, 108, 481-493.	1.9	34
650	Advances in Alzheimer's Diagnosis and Therapy: The Implications of Nanotechnology. Trends in Biotechnology, 2017, 35, 937-953.	4.9	121
651	$\hat{A^{2}42}$ pentamers/hexamers are the smallest detectable oligomers in solution. Scientific Reports, 2017, 7, 2493.	1.6	49
652	A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 41.	3.0	9
653	Erythrocyte omega-3 fatty acids are inversely associated with incident dementia: Secondary analyses of longitudinal data from the Women's Health Initiative Memory Study (WHIMS). Prostaglandins Leukotrienes and Essential Fatty Acids, 2017, 121, 68-75.	1.0	37
654	Kinetic Analysis Reveals the Identity of A \hat{l}^2 -Metal Complex Responsible for the Initial Aggregation of A \hat{l}^2 in the Synapse. ACS Chemical Neuroscience, 2017, 8, 1970-1979.	1.7	22
655	Probing oligomerization of amyloid beta peptide in silico. Molecular BioSystems, 2017, 13, 165-182.	2.9	20
656	Cross- \hat{l}^2 Polymerization of Low Complexity Sequence Domains. Cold Spring Harbor Perspectives in Biology, 2017, 9, a023598.	2.3	51
657	Anthoxanthin Polyphenols Attenuate A <i>β</i> Oligomerâ€induced Neuronal Responses Associated with Alzheimer's Disease. CNS Neuroscience and Therapeutics, 2017, 23, 135-144.	1.9	31
658	Danger-associated molecular patterns in Alzheimer's disease. Journal of Leukocyte Biology, 2017, 101, 87-98.	1.5	158
659	Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders. Neurological Research, 2017, 39, 73-82.	0.6	688
660	Self-assembling peptide-based building blocks in medical applications. Advanced Drug Delivery Reviews, 2017, 110-111, 65-79.	6.6	169
661	Inhomogeneous distribution of <scp>A</scp> lzheimer pathology along the isocortical relief. Are cortical convolutions an <scp>A</scp> chilles heel of evolution?. Brain Pathology, 2017, 27, 603-611.	2.1	21
662	Protein-Induced Pluripotent Stem Cells Ameliorate Cognitive Dysfunction and Reduce $\hat{A^2}$ Deposition in a Mouse Model of Alzheimer's Disease. Stem Cells Translational Medicine, 2017, 6, 293-305.	1.6	58
663	Is there correlation between $A\hat{l}^2$ -heme peroxidase activity and the peptide aggregation state? A literature review combined with hypothesis. International Journal of Biological Macromolecules, 2017, 100, 18-36.	3.6	13
664	G-CSF-mobilized Bone Marrow Mesenchymal Stem Cells Replenish Neural Lineages in Alzheimer's Disease Mice via CXCR4/SDF-1 Chemotaxis. Molecular Neurobiology, 2017, 54, 6198-6212.	1.9	39
665	Aberrant Axonal Arborization of PDF Neurons Induced by Aβ42-Mediated JNK Activation Underlies Sleep Disturbance in an Alzheimer's Model. Molecular Neurobiology, 2017, 54, 6317-6328.	1.9	19
666	A Mitocentric View of Alzheimer's Disease. Molecular Neurobiology, 2017, 54, 6046-6060.	1.9	45

#	Article	IF	CITATIONS
667	l̂²-Hairpin mimics containing a piperidine–pyrrolidine scaffold modulate the l̂²-amyloid aggregation process preserving the monomer species. Chemical Science, 2017, 8, 1295-1302.	3.7	39
668	Tanshinone IIA attenuates Aβ25–35-induced spatial memory impairment via upregulating receptors for activated C kinase1 and inhibiting autophagy in hippocampus. Journal of Pharmacy and Pharmacology, 2017, 69, 191-201.	1.2	20
669	Cellular prion protein as a receptor for amyloid- \hat{l}^2 oligomers in Alzheimer's disease. Biochemical and Biophysical Research Communications, 2017, 483, 1143-1147.	1.0	72
670	Hyperforin attenuates aluminum-induced $\hat{Al^2}$ production and Tau phosphorylation via regulating Akt/GSK-3 $\hat{l^2}$ signaling pathway in PC12 cells. Biomedicine and Pharmacotherapy, 2017, 96, 1-6.	2.5	41
671	Identification and Characterization of Reconstituted α-Synuclein, Amyloid-β and Tau Fibrils by Immunogold Negative Staining Electron Microscopy. Microscopy and Microanalysis, 2017, 23, 1312-1313.	0.2	1
672	Autophagy-ERK1/2-Involved Disinhibition of Hippocampal Neurons Contributes to the Pre-Synaptic Toxicity Induced by Al²42 Exposure. Journal of Alzheimer's Disease, 2017, 59, 851-869.	1.2	11
673	Protein Gelation around Axons Inhibits Action Potential Propagation in Nerve Fibers., 2017, 07, .		0
674	Alzheimer's Disease Pathogenesis: The Denied Access Model. , 2017, 07, .		0
675	β-Amyloid and the Pathomechanisms of Alzheimer's Disease: A Comprehensive View. Molecules, 2017, 22, 1692.	1.7	82
676	Current Opportunities for Clinical Monitoring of Axonal Pathology in Traumatic Brain Injury. Frontiers in Neurology, 2017, 8, 599.	1.1	23
677	Exosomes and the Prion Protein: More than One Truth. Frontiers in Neuroscience, 2017, 11, 194.	1.4	60
678	The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. Frontiers in Neuroscience, 2017, 11, 254.	1.4	277
679	Aberrant Nitric Oxide Signaling Contributes to Protein Misfolding in Neurodegenerative Diseases via S-Nitrosylation and Tyrosine Nitration., 2017,, 373-384.		3
680	Isoflurane anesthesia promotes cognitive impairment by inducing expression of \hat{l}^2 -amyloid protein-related factors in the hippocampus of aged rats. PLoS ONE, 2017, 12, e0175654.	1.1	30
681	Presynaptic A $\hat{1}^2$ 40 prevents synapse addition in the adult Drosophila neuromuscular junction. PLoS ONE, 2017, 12, e0177541.	1.1	4
682	Study of structural stability and damaging effect on membrane for four $\hat{Al^2}42$ dimers. PLoS ONE, 2017, 12, e0179147.	1.1	4
683	In situ fibrillizing amyloid-beta 1-42 induces neurite degeneration and apoptosis of differentiated SH-SY5Y cells. PLoS ONE, 2017, 12, e0186636.	1.1	55
684	Effects of an $A\hat{l}^2$ -antibody fragment on $A\hat{l}^2$ aggregation and astrocytic uptake are modulated by apolipoprotein E and J mimetic peptides. PLoS ONE, 2017, 12, e0188191.	1.1	12

#	Article	IF	CITATIONS
685	Neurochemical Aspects of β-Amyloid Cascade Hypothesis for Alzheimer's Disease. , 2017, , 1-46.		0
686	Synthesized A \hat{l}^2 42 Caused Intracellular Oxidative Damage, Leading to Cell Death, via Lysosome Rupture. Cell Structure and Function, 2017, 42, 71-79.	0.5	23
687	Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 62.	3.0	62
688	Dynamic changes of oligomeric amyloid \hat{l}^2 levels in plasma induced by spiked synthetic A \hat{l}^2 42. Alzheimer's Research and Therapy, 2017, 9, 86.	3.0	57
689	Mutation-induced loss of APP function causes GABAergic depletion in recessive familial Alzheimer's disease: analysis of Osaka mutation-knockin mice. Acta Neuropathologica Communications, 2017, 5, 59.	2.4	23
690	Prion Proteins Without the Glycophosphatidylinositol Anchor: Potential Biomarkers in Neurodegenerative Diseases. Biomarker Insights, 2018, 13, 117727191875664.	1.0	5
691	Gelsolin pathogenic Gly167Arg mutation promotes domain-swap dimerization of the protein. Human Molecular Genetics, 2018, 27, 53-65.	1.4	16
692	Elucidating the Structures of Amyloid Oligomers with Macrocyclic β-Hairpin Peptides: Insights into Alzheimer's Disease and Other Amyloid Diseases. Accounts of Chemical Research, 2018, 51, 706-718.	7.6	93
693	Differential effect of amyloid beta peptides on mitochondrial axonal trafficking depends on their state of aggregation and binding to the plasma membrane. Neurobiology of Disease, 2018, 114, 1-16.	2.1	34
694	Inhibition of amyloid $\hat{A^2}$ aggregation by high pressures or specific < scp>d < /scp>-enantiomeric peptides. Chemical Communications, 2018, 54, 3294-3297.	2.2	13
695	The pro-apoptotic protein Bmf co-operates with Bim and Puma in neuron death induced by \hat{l}^2 -amyloid or NGF deprivation. Molecular and Cellular Neurosciences, 2018, 88, 249-257.	1.0	19
696	Biomolecular Corona Dictates A \hat{I}^2 Fibrillation Process. ACS Chemical Neuroscience, 2018, 9, 1725-1734.	1.7	23
698	Diffusible, highly bioactive oligomers represent a critical minority of soluble Aβ in Alzheimer's disease brain. Acta Neuropathologica, 2018, 136, 19-40.	3.9	100
699	Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid- \hat{l}^2 . Scientific Reports, 2018, 8, 6412.	1.6	182
700	Amyloid assembly and disassembly. Journal of Cell Science, 2018, 131, .	1.2	138
701	Determining the Potential of Mean Force for Amyloid-Î ² Dimerization: Combining Self-Consistent Field Theory with Molecular Dynamics Simulation. Journal of Chemical Theory and Computation, 2018, 14, 2696-2704.	2.3	16
702	Synaptotoxic Signaling by Amyloid Beta Oligomers in Alzheimer's Disease Through Prion Protein and mGluR5. Advances in Pharmacology, 2018, 82, 293-323.	1.2	67
703	A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-beta Oligomers. ACS Chemical Neuroscience, 2018, 9, 1591-1606.	1.7	21

#	Article	IF	Citations
704	${\rm A\hat{l}^2}$ -oligomer uptake and the resulting inflammatory response in adult human astrocytes are precluded by an anti- ${\rm A\hat{l}^2}$ single chain variable fragment in combination with an apoE mimetic peptide. Molecular and Cellular Neurosciences, 2018, 89, 49-59.	1.0	21
705	The Vascular Hypothesis of Alzheimer's Disease: A Key to Preclinical Prediction of Dementia Using Neuroimaging. Journal of Alzheimer's Disease, 2018, 63, 35-52.	1.2	90
706	Controlling the Oligomerization State of $\hat{Al^2}$ -Derived Peptides with Light. Journal of the American Chemical Society, 2018, 140, 5842-5852.	6.6	23
707	Sulforaphane Inhibits the Generation of Amyloid-β Oligomer and Promotes Spatial Learning and Memory in Alzheimer's Disease (PS1V97L) Transgenic Mice. Journal of Alzheimer's Disease, 2018, 62, 1803-1813.	1.2	48
708	Lipid nanocarriers loaded with natural compounds: Potential new therapies for age related neurodegenerative diseases?. Progress in Neurobiology, 2018, 168, 21-41.	2.8	27
709	High pressure NMR reveals conformational perturbations by disease-causing mutations in amyloid \hat{l}^2 -peptide. Chemical Communications, 2018, 54, 4609-4612.	2.2	6
710	Amyloid toxicity in Alzheimer's disease. Reviews in the Neurosciences, 2018, 29, 613-627.	1.4	312
711	Mechanistic analyses of the suppression of amyloid \hat{l}^2 42 aggregation by apomorphine. Bioorganic and Medicinal Chemistry, 2018, 26, 1538-1546.	1.4	18
712	Amyloidâ€beta 1â€40 is associated with alterations in NG2+ pericyte population exÂvivo and inÂvitro. Aging Cell, 2018, 17, e12728.	3.0	49
713	Aminopyrimidine Class Aggregation Inhibitor Effectively Blocks Aβ–Fibrinogen Interaction and Aβ-Induced Contact System Activation. Biochemistry, 2018, 57, 1399-1409.	1.2	12
714	Amyloid \hat{l}^2 -targeted metal complexes for potential applications in Alzheimer's disease. Future Medicinal Chemistry, 2018, 10, 679-701.	1.1	45
715	Alterations in spontaneous delta and gamma activity might provide clues to detect changes induced by amyloidâ $\in \hat{\mathbf{l}}^2$ administration. European Journal of Neuroscience, 2018, 47, 1013-1023.	1.2	12
716	Advancements of the <scp>sFIDA</scp> method for oligomerâ€based diagnostics of neurodegenerative diseases. FEBS Letters, 2018, 592, 516-534.	1.3	10
717	Real-time monitoring of the aggregation of Alzheimer's amyloid- \hat{l}^2 <i>via</i> ¹ H magic angle spinning NMR spectroscopy. Chemical Communications, 2018, 54, 2000-2003.	2.2	28
718	New Insights on the Role of Residue 673 of APP in Alzheimer's Disease. Journal of Neuroscience, 2018, 38, 515-517.	1.7	4
719	Allicin ameliorates cognitive impairment in APP/PS1 mice via Suppressing oxidative stress by Blocking JNK Signaling Pathways. Tissue and Cell, 2018, 50, 89-95.	1.0	21
720	Development and validation of an UHPLC-ESI-QTOF-MS method for quantification of the highly hydrophilic amyloid- \hat{l}^2 oligomer eliminating all- D -enantiomeric peptide RD2 in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1073, 123-129.	1.2	0
721	Wnt Signaling in the Central Nervous System: New Insights in Health and Disease. Progress in Molecular Biology and Translational Science, 2018, 153, 81-130.	0.9	68

#	Article	IF	Citations
722	Microglia-derived extracellular vesicles in Alzheimer's Disease: A double-edged sword. Biochemical Pharmacology, 2018, 148, 184-192.	2.0	85
723	Immunotherapy for neurodegenerative diseases: the Alzheimer's disease paradigm. Current Opinion in Chemical Engineering, 2018, 19, 59-67.	3.8	8
724	Discrete Pools of Oligomeric Amyloid- \hat{l}^2 Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis. American Journal of Pathology, 2018, 188, 739-756.	1.9	16
725	Intrinsic Conformational Preferences and Interactions in $\hat{l}\pm$ -Synuclein Fibrils: Insights from Molecular Dynamics Simulations. Journal of Chemical Theory and Computation, 2018, 14, 3298-3310.	2.3	24
726	Soluble Aβ1–42 increases the heterogeneity in synaptic vesicle pool size among synapses by suppressing intersynaptic vesicle sharing. Molecular Brain, 2018, 11, 10.	1.3	5
727	Prion-like propagation of \hat{l}^2 -amyloid aggregates in the absence of APP overexpression. Acta Neuropathologica Communications, 2018, 6, 26.	2.4	41
728	The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease. Progress in Neurobiology, 2018, 168, 104-127.	2.8	74
729	Alzheimer disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 325-337.	1.0	87
730	Surface Enhanced Raman Spectroscopy for Medical Diagnostics. , 2018, , 1-66.		6
731	Impact of late-onset Alzheimer's genetic risk factors on beta-amyloid endocytic production. Cellular and Molecular Life Sciences, 2018, 75, 2577-2589.	2.4	37
732	Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, S313-S327.	1.2	31
733	ABBY. Neurology, 2018, 90, e1889-e1897.	1.5	188
734	Recent computational studies of membrane interaction and disruption of human islet amyloid polypeptide: Monomers, oligomers and protofibrils. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1826-1839.	1.4	34
735	Targeting Amyloid- \hat{l}^2 Precursor Protein, APP, Splicing with Antisense Oligonucleotides Reduces Toxic Amyloid- \hat{l}^2 Production. Molecular Therapy, 2018, 26, 1539-1551.	3.7	27
736	Direct Evidence of the Presence of Cross-Linked Aβ Dimers in the Brains of Alzheimer's Disease Patients. Analytical Chemistry, 2018, 90, 4552-4560.	3.2	37
737	Time dependence of NMR observables reveals salient differences in the accumulation of early aggregated species between human islet amyloid polypeptide and amyloid-Î ² . Physical Chemistry Chemical Physics, 2018, 20, 9561-9573.	1.3	9
738	Complex role of chemokine mediators in animal models of Alzheimer's Disease. Biomedical Journal, 2018, 41, 34-40.	1.4	26
739	Interactions of amyloid- \hat{l}^2 peptides on lipid bilayer studied by single molecule imaging and tracking. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1616-1624.	1.4	26

#	ARTICLE	IF	CITATIONS
740	The Effects of N-terminal Mutations on \hat{I}^2 -amyloid Peptide Aggregation and Toxicity. Neuroscience, 2018, 379, 177-188.	1.1	20
741	Extending a Systems Model of the APP Pathway: Separation of \hat{I}^2 - and \hat{I}^3 -Secretase Sequential Cleavage Steps of APP. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 507-518.	1.3	10
742	Alzheimer's Disease, Oligomers, and Inflammation. Journal of Alzheimer's Disease, 2018, 62, 1261-1276.	1.2	141
743	Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway–PPAR Gamma, Energy Metabolism and Circadian Rhythms. NeuroMolecular Medicine, 2018, 20, 174-204.	1.8	39
744	Analysis of Physicochemical Interaction of A \hat{l}^2 (sub> 40 with a GM1 Ganglioside-Containing Lipid Membrane. Journal of Physical Chemistry B, 2018, 122, 3771-3781.	1.2	18
745	Metabolic Dysfunction in Alzheimer's Disease: From Basic Neurobiology to Clinical Approaches. Journal of Alzheimer's Disease, 2018, 64, S405-S426.	1.2	66
746	Metal-involved theranostics: An emerging strategy for fighting Alzheimer's disease. Coordination Chemistry Reviews, 2018, 362, 72-84.	9.5	53
747	Charge effects of self-assembled chitosan-hyaluronic acid nanoparticles on inhibiting amyloid \hat{l}^2 -protein aggregation. Carbohydrate Research, 2018, 461, 11-18.	1.1	37
748	Amyloid is essential but insufficient for Alzheimer causation: addition of subcellular cofactors is required for dementia. International Journal of Geriatric Psychiatry, 2018, 33, e14-e21.	1.3	17
749	β-Amyloid Prions and the Pathobiology of Alzheimer's Disease. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a023507.	2.9	64
750	Scrutiny of the mechanism of small molecule inhibitor preventing conformational transition of amyloid- \hat{l}^2 ₄₂ monomer: insights from molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics, 2018, 36, 663-678.	2.0	33
751	Untangling Genetic Risk for Alzheimer's Disease. Biological Psychiatry, 2018, 83, 300-310.	0.7	160
752	Rapid amyloidâ€Î² oligomer and protofibril accumulation in traumatic brain injury. Brain Pathology, 2018, 28, 451-462.	2.1	31
7 53	${\sf A}{\sf \hat{I}}^2$ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 208-225.	1.8	53
754	The contribution of biophysical and structural studies of protein self-assembly to the design of therapeutic strategies for amyloid diseases. Neurobiology of Disease, 2018, 109, 178-190.	2.1	62
755	Inhibition of Abeta Proteotoxicity by Paeoniflorin in <i>Caenorhabditis elegans</i> Through Regulation of Oxidative and Heat Shock Stress Responses. Rejuvenation Research, 2018, 21, 304-312.	0.9	22
756	Microglia-Mediated Neuroprotection, TREM2 , and Alzheimer's Disease: Evidence From OpticalÂlmaging. Biological Psychiatry, 2018, 83, 377-387.	0.7	84
757	Reprogramming energetic metabolism in Alzheimer's disease. Life Sciences, 2018, 193, 141-152.	2.0	28

#	ARTICLE	IF	CITATIONS
758	Valproic acid and its congener propylisopropylacetic acid reduced the amount of soluble amyloid- \hat{l}^2 oligomers released from 7PA2 cells. Neuropharmacology, 2018, 128, 54-62.	2.0	8
7 59	Modulation of Alzheimer's amyloid \hat{l}^2 peptide oligomerization and toxicity by extracellular Hsp70. Cell Stress and Chaperones, 2018, 23, 269-279.	1.2	33
760	Early Alzheimer-type lesions in cognitively normal subjects. Neurobiology of Aging, 2018, 62, 34-44.	1.5	36
761	Pharmacological activation of the Nrf2 pathway by 3H-1, 2-dithiole-3-thione is neuroprotective in a mouse model of Alzheimer disease. Behavioural Brain Research, 2018, 336, 219-226.	1.2	41
762	Cu ^{II} Binding to Various Forms of Amyloidâ€Î² Peptides: Are They Friends or Foes?. European Journal of Inorganic Chemistry, 2018, 2018, 7-15.	1.0	33
763	Distinct amyloid precursor protein processing machineries of the olfactory system. Biochemical and Biophysical Research Communications, 2018, 495, 533-538.	1.0	16
764	Neuroinflammation induced by amyloid β25–35 modifies mucin-type O -glycosylation in the rat's hippocampus. Neuropeptides, 2018, 67, 56-62.	0.9	15
765	Peptides isolated from animal venom as a platform for new therapeutics for the treatment of Alzheimer's disease. Neuropeptides, 2018, 67, 79-86.	0.9	12
766	Somatostatin in Alzheimer's disease: A new Role for an Old Player. Prion, 2018, 12, 1-8.	0.9	54
767	Prion Protein as a Toxic Acceptor of Amyloid- \hat{l}^2 Oligomers. Biological Psychiatry, 2018, 83, 358-368.	0.7	66
768	Organizing biochemistry in space and time using prion-like self-assembly. Current Opinion in Systems Biology, 2018, 8, 16-24.	1.3	16
769	Structural perturbation by arsenic triggers the aggregation of hen egg white lysozyme by promoting oligomers formation. International Journal of Biological Macromolecules, 2018, 109, 1108-1114.	3.6	10
770	The p38 mitogen activated protein kinase regulates \hat{l}^2 -amyloid protein internalization through the $\hat{l}\pm7$ nicotinic acetylcholine receptor in mouse brain. Brain Research Bulletin, 2018, 137, 41-52.	1.4	18
771	Topological Biomarker of Alzheimer's Disease. , 0, , .		1
772	Toxicity of Biologically Active Peptides and Future Safety Aspects: An Update. Current Drug Discovery Technologies, 2018, 15, 236-242.	0.6	14
773	Enhanced Effect of Combining Chlorogenic Acid on Selenium Nanoparticles in Inhibiting Amyloid \hat{l}^2 Aggregation and Reactive Oxygen Species Formation In Vitro. Nanoscale Research Letters, 2018, 13, 303.	3.1	38
774	3 .Neuropathologie und molekulare Mechanismen. , 2018, , 35-122.		1
775	The Impact of ESCRT on Al̂²1-42 Induced Membrane Lesions in a Yeast Model for Alzheimer's Disease. Frontiers in Molecular Neuroscience, 2018, 11, 406.	1.4	19

#	Article	IF	CITATIONS
776	Hippocampale synaptische Plastizit \tilde{A}^{Ξ} bei neurodegenerativen Erkrankungen: A \hat{I}^2 , Tau und dar \tilde{A}^1 /4ber hinaus. Neuroforum, 2018, 24, 203-212.	0.2	1
777	Cyclic undecapeptide Cyclosporin A mediated inhibition of amyloid synthesis: Implications in alleviation of amyloid induced neurotoxicity. Scientific Reports, 2018, 8, 17283.	1.6	5
778	Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy. Journal of Visualized Experiments, 2018, , .	0.2	2
779	Identification of a novel mutation in APP gene in a Thai subject with early-onset Alzheimer's disease. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 3015-3023.	1.0	15
780	Probing the Occurrence of Soluble Oligomers through Amyloid Aggregation Scaling Laws. Biomolecules, 2018, 8, 108.	1.8	10
781	Blocking Oligomeric Insulin Amyloid Fibrillation via Perylenebisimides Containing Dipeptide Tentacles. ACS Biomaterials Science and Engineering, 2018, 4, 4076-4083.	2.6	11
782	Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. Bioconjugate Chemistry, 2018, 29, 3937-3966.	1.8	23
783	d-Amino Acid Pseudopeptides as Potential Amyloid-Beta Aggregation Inhibitors. Molecules, 2018, 23, 2387.	1.7	9
784	A bispecific immunotweezer prevents soluble PrP oligomers and abolishes prion toxicity. PLoS Pathogens, 2018, 14, e1007335.	2.1	21
785	Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nature Neuroscience, 2018, 21, 1332-1340.	7.1	728
786	Hippocampal synaptic plasticity in neurodegenerative diseases: Aß, tau and beyond. Neuroforum, 2018, 24, A133-A141.	0.2	1
787	A Free Radical-Generating System Regulates Amyloid Oligomers: Involvement of Cathepsin B. Journal of Alzheimer's Disease, 2018, 66, 1397-1408.	1.2	9
788	The Early Events That Initiate β-Amyloid Aggregation in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 359.	1.7	85
789	Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease. Acta Neuropathologica, 2018, 136, 663-689.	3.9	151
790	Porphyrinic Metal–Organic Framework PCN-224 Nanoparticles for Near-Infrared-Induced Attenuation of Aggregation and Neurotoxicity of Alzheimer's Amyloid-β Peptide. ACS Applied Materials & Diterfaces, 2018, 10, 36615-36621.	4.0	107
791	Amyloidosis by Bacterial Infection in Critically III Patients?. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1475-1476.	2.5	0
792	Surveying the Energy Landscapes of $\hat{Al^2}$ Fibril Polymorphism. Journal of Physical Chemistry B, 2018, 122, 11414-11430.	1.2	18
793	Cell surface proteoglycan-mediated uptake and accumulation of the Alzheimer's disease peptide Aβ(1–42). Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 2204-2214.	1.4	13

#	Article	IF	CITATIONS
794	Bidirectional Microglia–Neuron Communication in Health and Disease. Frontiers in Cellular Neuroscience, 2018, 12, 323.	1.8	329
795	Antioxidant Activity and Neuroprotective Activity of Stilbenoids in Rat Primary Cortex Neurons via the PI3K/Akt Signalling Pathway. Molecules, 2018, 23, 2328.	1.7	23
796	Magnetic Nanoparticles Applications for Amyloidosis Study and Detection: A Review. Nanomaterials, 2018, 8, 740.	1.9	39
797	Lipid bilayer position and orientation of novel carprofens, modulators of \hat{l}^3 -secretase in Alzheimer's disease. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 2224-2233.	1.4	1
798	Selective disruption of TLR2-MyD88 interaction inhibits inflammation and attenuates Alzheimer's pathology. Journal of Clinical Investigation, 2018, 128, 4297-4312.	3.9	97
799	An integrated strategy to correlate aggregation state, structure and toxicity of Aß 1–42 oligomers. Talanta, 2018, 188, 17-26.	2.9	28
800	Dihydrochalcone molecules destabilize Alzheimer's amyloid- \hat{l}^2 protofibrils through binding to the protofibril cavity. Physical Chemistry Chemical Physics, 2018, 20, 17208-17217.	1.3	32
801	Geniposide attenuates Aβ _{25–35} -induced neurotoxicity <i>via</i> the TLR4/NF-κB pathway in HT22 cells. RSC Advances, 2018, 8, 18926-18937.	1.7	13
802	Extracellular Forms of Al̂² and Tau from iPSC Models of Alzheimer's Disease Disrupt Synaptic Plasticity. Cell Reports, 2018, 23, 1932-1938.	2.9	60
803	A guide to using functional magnetic resonance imaging to study Alzheimer's disease in animal models. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	20
804	Structure-activity relationships of \hat{l}^2 -hairpin mimics as modulators of amyloid \hat{l}^2 -peptide aggregation. European Journal of Medicinal Chemistry, 2018, 154, 280-293.	2.6	15
805	Lengthâ€Dependent Manifestation of Vibration Modes Regulates a Specific Intermediate Morphology of Aβ17â€42 in Different Environments. ChemPhysChem, 2018, 19, 1643-1654.	1.0	1
806	Fluorescence quenching by lipid encased nanoparticles shows that amyloid- \hat{l}^2 has a preferred orientation in the membrane. Chemical Communications, 2018, 54, 7750-7753.	2.2	10
807	Hetero-assembly of a dual \hat{l}^2 -amyloid variant peptide system. Chemical Communications, 2018, 54, 6380-6383.	2.2	10
808	Evidence from ITIR-FCS Diffusion Studies that the Amyloid-Beta ($A\hat{l}^2$) Peptide Does Not Perturb Plasma Membrane Fluidity in Neuronal Cells. Journal of Molecular Biology, 2018, 430, 3439-3453.	2.0	5
809	Free-floating adult human brain-derived slice cultures as a model to study the neuronal impact of Alzheimer's disease-associated Al̂² oligomers. Journal of Neuroscience Methods, 2018, 307, 203-209.	1.3	27
810	An Efficient Method for the Expression and Purification of Aβ(M1–42). Biochemistry, 2018, 57, 3861-3866.	1.2	19
811	Mechanisms of DHA-enriched phospholipids in improving cognitive deficits in aged SAMP8 mice with high-fat diet. Journal of Nutritional Biochemistry, 2018, 59, 64-75.	1.9	41

#	Article	IF	CITATIONS
812	A Friend or Foe: Calcineurin across the Gamut of Neurological Disorders. ACS Central Science, 2018, 4, 805-819.	5.3	35
813	An in-silico method for identifying aggregation rate enhancer and mitigator mutations in proteins. International Journal of Biological Macromolecules, 2018, 118, 1157-1167.	3.6	20
814	Alzheimer's Disease Model System Using Drosophila. Advances in Experimental Medicine and Biology, 2018, 1076, 25-40.	0.8	33
815	Engineered Hsp70 chaperones prevent Aβ42-induced memory impairments in a Drosophila model of Alzheimer's disease. Scientific Reports, 2018, 8, 9915.	1.6	26
816	Chiral modulation of amyloid beta fibrillation and cytotoxicity by enantiomeric carbon dots. Chemical Communications, 2018, 54, 7762-7765.	2.2	95
817	Nanoscopic Characterisation of Individual Endogenous Protein Aggregates in Human Neuronal Cells. ChemBioChem, 2018, 19, 2033-2038.	1.3	52
818	Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model. Alzheimer's Research and Therapy, 2018, 10, 54.	3.0	24
819	Remarkably Efficient Blood–Brain Barrier Crossing Polyfluorene–Chitosan Nanoparticle Selectively Tweaks Amyloid Oligomer in Cerebrospinal Fluid and Aβ1–40. ACS Omega, 2018, 3, 8059-8066.	1.6	19
820	Functional aspects of meningeal lymphatics in ageing and Alzheimer's disease. Nature, 2018, 560, 185-191.	13.7	839
821	Intravenously Injected Amyloid-β Peptide With Isomerized Asp7 and Phosphorylated Ser8 Residues Inhibits Cerebral β-Amyloidosis in AβPP/PS1 Transgenic Mice Model of Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 518.	1.4	15
822	Stabilization of a Membrane-Associated Amyloid- \hat{l}^2 Oligomer for Its Validation in Alzheimer's Disease. Frontiers in Molecular Biosciences, 2018, 5, 38.	1.6	11
823	Dihydropyridines Allosterically Modulate Hsp90 Providing a Novel Mechanism for Heat Shock Protein Co-induction and Neuroprotection. Frontiers in Molecular Biosciences, 2018, 5, 51.	1.6	27
824	Commentary: APP as a Mediator of the Synapse Pathology in Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2018, 12, 150.	1.8	3
825	Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 254.	1.4	17
826	Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology. International Journal of Molecular Sciences, 2018, 19, 336.	1.8	51
827	Aptamers Selected for Recognizing Amyloid β-Protein—A Case for Cautious Optimism. International Journal of Molecular Sciences, 2018, 19, 668.	1.8	14
828	Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer's Disease. International Journal of Molecular Sciences, 2018, 19, 1884.	1.8	66
829	Synaptic Alterations in Mouse Models for Alzheimer Disease—A Special Focus on N-Truncated Abeta 4-42. Molecules, 2018, 23, 718.	1.7	20

#	Article	IF	CITATIONS
830	Insights into Structure-Activity Relationships of 3-Arylhydrazonoindolin-2-One Derivatives for Their Multitarget Activity on \hat{l}^2 -Amyloid Aggregation and Neurotoxicity. Molecules, 2018, 23, 1544.	1.7	22
831	Intranasal rifampicin for Alzheimer's disease prevention. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 304-313.	1.8	20
832	An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer's disease. Nature Communications, 2018, 9, 2676.	5.8	50
833	Modulating Early Stage Amyloid Aggregates by Dipeptide-Linked Perylenebisimides: Structure–Activity Relationship, Inhibition of Fibril Formation in Human CSF and Aβ1–40. ACS Applied Bio Materials, 2018, 1, 403-413.	2.3	3
834	Amyloid- \hat{l}^2 Peptide Triggers Membrane Remodeling in Supported Lipid Bilayers Depending on Their Hydrophobic Thickness. Langmuir, 2018, 34, 9548-9560.	1.6	18
835	The Properties of Amyloid- \hat{l}^2 Fibrils Are Determined by their Path of Formation. Journal of Molecular Biology, 2018, 430, 1940-1949.	2.0	17
836	TREM2 regulates innate immunity in Alzheimer's disease. Journal of Neuroinflammation, 2018, 15, 107.	3.1	63
837	Memory Loss and the Onset of Alzheimer's Disease Could Be Under the Control of Extracellular Heat Shock Proteins. Journal of Alzheimer's Disease, 2018, 63, 927-934.	1.2	9
838	An inorganic overview of natural \hat{A}^2 fragments: Copper(II) and zinc(II)-mediated pathways. Coordination Chemistry Reviews, 2018, 369, 1-14.	9.5	14
839	Preparation of Stable Amyloid-β Oligomers Without Perturbative Methods. Methods in Molecular Biology, 2018, 1777, 331-338.	0.4	6
840	ApoE isoforms and carboxyl-terminal-truncated apoE4 forms affect neuronal BACE1 levels and ${\rm A}\hat{\rm I}^2$ production independently of their cholesterol efflux capacity. Biochemical Journal, 2018, 475, 1839-1859.	1.7	19
841	Recent Advances by In Silico and In Vitro Studies of Amyloid- \hat{l}^2 1-42 Fibril Depicted a S-Shape Conformation. International Journal of Molecular Sciences, 2018, 19, 2415.	1.8	21
842	Side-chain moieties from the N-terminal region of ${\rm A}^{\hat{1}^2}$ are Involved in an oligomer-stabilizing network of interactions. PLoS ONE, 2018, 13, e0201761.	1.1	14
843	Nanoscale Discrimination between Toxic and Nontoxic Protein Misfolded Oligomers with Tipâ€Enhanced Raman Spectroscopy. Small, 2018, 14, e1800890.	5 . 2	35
844	Riluzole reduces amyloid beta pathology, improves memory, and restores gene expression changes in a transgenic mouse model of early-onset Alzheimer's disease. Translational Psychiatry, 2018, 8, 153.	2.4	64
845	Repurposing Triphenylmethane Dyes to Bind to Trimers Derived from $\hat{Al^2}$. Journal of the American Chemical Society, 2018, 140, 11745-11754.	6.6	27
846	The Amyloid- \hat{l}^2 Oligomer Hypothesis: Beginning of the Third Decade. Journal of Alzheimer's Disease, 2018, 64, S567-S610.	1.2	572
847	Contribution of early Alzheimer's diseaseâ€related pathophysiology to the development of acquired epilepsy. European Journal of Neuroscience, 2018, 47, 1534-1562.	1.2	14

#	Article	IF	CITATIONS
848	PTK2B/Pyk2 overexpression improves a mouse model of Alzheimer's disease. Experimental Neurology, 2018, 307, 62-73.	2.0	36
849	Protective Effects of Fibroblast Growth Factor 21 Against Amyloid-Beta1–42-Induced Toxicity in SH-SY5Y Cells. Neurotoxicity Research, 2018, 34, 574-583.	1.3	29
850	Chronic cerebral hypoperfusion accelerates Alzheimer's disease pathology with the change of mitochondrial fission and fusion proteins expression in a novel mouse model. Brain Research, 2018, 1696, 63-70.	1.1	18
851	Neurodegenerative Diseases as Protein Folding Disorders. , 2018, , 243-267.		O
852	Preparation of Pure Populations of Amyloid \hat{l}^2 -Protein Oligomers of Defined Size. Methods in Molecular Biology, 2018, 1779, 3-12.	0.4	6
853	Transthyretin Interferes with ${\hat {\sf Al}}^2$ Amyloid Formation by Redirecting Oligomeric Nuclei into Non-Amyloid Aggregates. Journal of Molecular Biology, 2018, 430, 2722-2733.	2.0	23
854	Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models. Neurobiology of Aging, 2018, 70, 128-139.	1.5	52
855	Origin of metastable oligomers and their effects on amyloid fibril self-assembly. Chemical Science, 2018, 9, 5937-5948.	3.7	76
856	Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade. Chemical Reviews, 2019, 119, 1221-1322.	23.0	360
857	Diverse Structural Conversion and Aggregation Pathways of AlzheimerÊ⅓s Amyloid-β (1–40). ACS Nano, 2019, 13, 8766-8783.	7.3	33
858	Structure and Function of Alzheimer's Amyloid βeta Proteins from Monomer to Fibrils: A Mini Review. Protein Journal, 2019, 38, 425-434.	0.7	21
859	Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis. Nature Neuroscience, 2019, 22, 1258-1268.	7.1	48
860	Aβ(M1–40) and Wild-Type Aβ40 Self-Assemble into Oligomers with Distinct Quaternary Structures. Molecules, 2019, 24, 2242.	1.7	2
861	Cellular Prion Protein as a Receptor of Toxic Amyloid-β42 Oligomers Is Important for Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2019, 13, 339.	1.8	46
862	Doxycycline for Alzheimer's Disease: Fighting β-Amyloid Oligomers and Neuroinflammation. Frontiers in Pharmacology, 2019, 10, 738.	1.6	58
863	Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression. Acta Neuropathologica Communications, 2019, 7, 120.	2.4	64
864	Optimal control strategies for inhibition of protein aggregation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 14593-14598.	3.3	21
865	Mechanistic Insights into the Early Events in the Aggregation of Immunoglobulin Light Chains. Biochemistry, 2019, 58, 3155-3168.	1.2	20

#	Article	IF	CITATIONS
866	Guiding the Morphology of Amyloid Assemblies by Electrostatic Capping: from Polymorphic Twisted Fibrils to Uniform Nanorods. Small, 2019, 15, e1901806.	5.2	23
867	His6, His13, and His14 residues in Aβ 1–40 peptide significantly and specifically affect oligomeric equilibria. Scientific Reports, 2019, 9, 9449.	1.6	10
868	Organoplatinumâ€Substituted Polyoxometalate Inhibits βâ€amyloid Aggregation for Alzheimer's Therapy. Angewandte Chemie - International Edition, 2019, 58, 18032-18039.	7.2	40
869	Differential Roles of Plasma Protein Corona on Immune Cell Association and Cytokine Secretion of Oligomeric and Fibrillar Beta-Amyloid. Biomacromolecules, 2019, 20, 4208-4217.	2.6	16
870	Unraveling the structure and dynamics of the human DNAJB6b chaperone by NMR reveals insights into Hsp40-mediated proteostasis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21529-21538.	3.3	62
871	Molecular basis for chirality-regulated $\hat{Al^2}$ self-assembly and receptor recognition revealed by ion mobility-mass spectrometry. Nature Communications, 2019, 10, 5038.	5.8	35
872	Identification of Novel 1,3,5-Triphenylbenzene Derivative Compounds as Inhibitors of Hen Lysozyme Amyloid Fibril Formation. International Journal of Molecular Sciences, 2019, 20, 5558.	1.8	6
873	Amyloid-Î ² -Dependent Inactivation of the Mitochondrial Electron Transport Chain at Low Transmembrane Potential: An Ameliorating Process in Hypoxia-Associated Neurodegenerative Disease?. Journal of Alzheimer's Disease, 2019, 72, 663-675.	1.2	3
874	Oligomers imaging of amyloid- $\langle i \rangle \hat{l}^2 \langle i \rangle \langle sub \rangle 1-42 \langle sub \rangle$ by scanning tunneling microscopy. Japanese Journal of Applied Physics, 2019, 58, SIIB30.	0.8	5
875	Organoplatinumâ€Substituted Polyoxometalate Inhibits βâ€amyloid Aggregation for Alzheimer's Therapy. Angewandte Chemie, 2019, 131, 18200-18207.	1.6	12
876	A Human Embryonic Stem Cell Model of $\hat{A^{12}}$ -Dependent Chronic Progressive Neurodegeneration. Frontiers in Neuroscience, 2019, 13, 1007.	1.4	6
877	Drugs for Targeted Therapies of Alzheimer's Disease. Current Medicinal Chemistry, 2019, 26, 335-359.	1.2	12
878	Intrinsically disordered proteins in the formation of functional amyloids from bacteria to humans. Progress in Molecular Biology and Translational Science, 2019, 166, 109-143.	0.9	19
879	Inhibition of amyloid beta toxicity in zebrafish with a chaperone-gold nanoparticle dual strategy. Nature Communications, 2019, 10, 3780.	5.8	132
880	Homomeric and Heteromeric Aβ Species Exist in Human Brain and CSF Regardless of Alzheimer's Disease Status and Risk Genotype. Frontiers in Molecular Neuroscience, 2019, 12, 176.	1.4	6
881	Emerging Alternative Proteinases in APP Metabolism and Alzheimer's Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP. Frontiers in Aging Neuroscience, 2019, 11, 244.	1.7	46
882	Exosomal miRNAs in central nervous system diseases: biomarkers, pathological mediators, protective factors and therapeutic agents. Progress in Neurobiology, 2019, 183, 101694.	2.8	127
883	An amplification label of core–shell CdSe@CdS QD sensitized GO for a signal-on photoelectrochemical immunosensor for amyloid β-protein. Journal of Materials Chemistry B, 2019, 7, 1142-1148.	2.9	34

#	Article	IF	CITATIONS
884	Dual Size-Dependent Effect of Fe3O4 Magnetic Nanoparticles Upon Interaction with Lysozyme Amyloid Fibrils: Disintegration and Adsorption. Nanomaterials, 2019, 9, 37.	1.9	13
885	Influence of fullerenol on hIAPP aggregation: amyloid inhibition and mechanistic aspects. Physical Chemistry Chemical Physics, 2019, 21, 4022-4031.	1.3	33
886	Electric Field Disruption of Amyloid Aggregation: Potential Noninvasive Therapy for Alzheimer's Disease. ACS Chemical Neuroscience, 2019, 10, 2250-2262.	1.7	30
887	The APMAP interactome reveals new modulators of APP processing and beta-amyloid production that are altered in Alzheimer's disease. Acta Neuropathologica Communications, 2019, 7, 13.	2.4	22
888	Ubiquitin binds the amyloid \hat{l}^2 peptide and interferes with its clearance pathways. Chemical Science, 2019, 10, 2732-2742.	3.7	46
889	Insights into the molecular mechanism behind solubilization of amyloidogenic polyglutamineâ€containing peptides. Peptide Science, 2019, 111, e24094.	1.0	6
890	Glycopeptide Nanofiber Platform for A \hat{l}^2 -Sialic Acid Interaction Analysis and Highly Sensitive Detection of A \hat{l}^2 . Analytical Chemistry, 2019, 91, 8129-8136.	3.2	26
891	Effects of MDMA on neuroplasticity, amyloid burden and phospho-tau expression in APPswe/PS1dE9 mice. Journal of Psychopharmacology, 2019, 33, 1170-1182.	2.0	7
892	Intertwined Pathologies of Amyloid-β and Metal Ions in Alzheimer's Disease: Metal–Amyloid-β. Chemistry Letters, 2019, 48, 951-960.	0.7	14
893	Salivary biological biomarkers for Alzheimer's disease. Archives of Oral Biology, 2019, 105, 5-12.	0.8	26
894	Specific keratinase derived designer peptides potently inhibit $\hat{Al^2}$ aggregation resulting in reduced neuronal toxicity and apoptosis. Biochemical Journal, 2019, 476, 1817-1841.	1.7	5
895	Binary Structure of Amyloid Beta Oligomers Revealed by Dual Recognition Mapping. Analytical Chemistry, 2019, 91, 8422-8428.	3.2	9
896	Interactions between BIM Protein and Beta-Amyloid May Reveal a Crucial Missing Link between Alzheimer's Disease and Neuronal Cell Death. ACS Chemical Neuroscience, 2019, 10, 3555-3564.	1.7	21
897	ABAD/ $17\hat{l}^2$ -HSD10 reduction contributes to the protective mechanism of huperzine a on the cerebral mitochondrial function in APP/PS1 mice. Neurobiology of Aging, 2019, 81, 77-87.	1.5	19
898	Three Structural Features of Functional Food Components and Herbal Medicine with Amyloid \hat{l}^2 42 Anti-Aggregation Properties. Molecules, 2019, 24, 2125.	1.7	24
899	Atomic resolution map of the soluble amyloid beta assembly toxic surfaces. Chemical Science, 2019, 10, 6072-6082.	3.7	48
900	Endophilin 1 knockdown prevents synaptic dysfunction induced by oligomeric amyloid \hat{l}^2 . Molecular Medicine Reports, 2019, 19, 4897-4905.	1.1	4
901	Hsp60 Protects against Amyloid \hat{I}^2 Oligomer Synaptic Toxicity via Modification of Toxic Oligomer Conformation. ACS Chemical Neuroscience, 2019, 10, 2858-2867.	1.7	19

#	Article	IF	Citations
902	The Toxicity of Misfolded Protein Oligomers Is Independent of Their Secondary Structure. ACS Chemical Biology, 2019, 14, 1593-1600.	1.6	34
903	COMBINATION THERAPY FOR ALZHEIMER'S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-5.	1.5	29
904	Exploring Amyloid- \hat{l}^2 Dimer Structure Using Molecular Dynamics Simulations. Journal of Physical Chemistry A, 2019, 123, 4658-4670.	1.1	13
905	Secondary nucleation and elongation occur at different sites on Alzheimer's amyloid-β aggregates. Science Advances, 2019, 5, eaau3112.	4.7	127
906	Exendin-4 attenuates brain mitochondrial toxicity through PI3K/Akt-dependent pathway in amyloid beta (1–42)-induced cognitive deficit rats. Neurochemistry International, 2019, 128, 39-49.	1.9	46
907	Why AÎ ² 42 Is Much More Toxic than AÎ ² 40. ACS Chemical Neuroscience, 2019, 10, 2843-2847.	1.7	22
908	The structure of amyloid-β dimers in Alzheimer's disease brain: a step forward for oligomers. Brain, 2019, 142, 1168-1169.	3.7	3
909	Beneficial Role of Curcumin in Preventing the Aggregation of the Amyloid-β Peptide in Alzheimer's Disease. , 2019, , 345-363.		3
910	Insight into the internal structure of amyloid- \hat{l}^2 oligomers by isotope-edited Fourier transform infrared spectroscopy. Physical Chemistry Chemical Physics, 2019, 21, 8587-8597.	1.3	22
911	The vexing complexity of the amyloidogenic pathway. Protein Science, 2019, 28, 1177-1193.	3.1	25
912	Systemic LPS-induced $\hat{Al^2}$ -solubilization and clearance in $\hat{Al^2}$ PP-transgenic mice is diminished by heparanase overexpression. Scientific Reports, 2019, 9, 4600.	1.6	10
913	Alzheimer A \hat{l}^2 Assemblies Accumulate in Excitatory Neurons upon Proteasome Inhibition and Kill Nearby NAK $\hat{l}\pm3$ Neurons by Secretion. IScience, 2019, 13, 452-477.	1.9	13
914	ApoE-fragment/Aβ heteromers in the brain of patients with Alzheimer's disease. Scientific Reports, 2019, 9, 3989.	1.6	24
915	Emergence of synaptic and cognitive impairment in a mature-onset APP mouse model of Alzheimer's disease. Acta Neuropathologica Communications, 2019, 7, 25.	2.4	28
916	Direct observation of prion protein oligomer formation reveals an aggregation mechanism with multiple conformationally distinct species. Chemical Science, 2019, 10, 4588-4597.	3.7	22
917	Chronic cerebral hypoperfusion shifts the equilibrium of amyloid \hat{l}^2 oligomers to aggregation-prone species with higher molecular weight. Scientific Reports, 2019, 9, 2827.	1.6	27
918	Subtyping of circulating exosome-bound amyloid \hat{l}^2 reflects brain plaque deposition. Nature Communications, 2019, 10, 1144.	5.8	136
919	Multifunctional carbon dots as a therapeutic nanoagent for modulating Cu($<$ scp $>$ ii $<$ /scp $>$)-mediated \hat{l}^2 -amyloid aggregation. Nanoscale, 2019, 11, 6297-6306.	2.8	59

#	Article	IF	CITATIONS
920	A Novel PEGylated Block Copolymer in New Age Therapeutics for Alzheimer's Disease. Molecular Neurobiology, 2019, 56, 6551-6565.	1.9	16
921	Amyloid \hat{l}^2 oligomers suppress excitatory transmitter release via presynaptic depletion of phosphatidylinositol-4,5-bisphosphate. Nature Communications, 2019, 10, 1193.	5.8	92
922	Protein Solubility Predictions Using the CamSol Method in the Study of Protein Homeostasis. Cold Spring Harbor Perspectives in Biology, 2019, 11, a033845.	2.3	42
923	Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer's disease. Journal of Neuroinflammation, 2019, 16, 74.	3.1	125
924	Ratiometric Nanoparticle Array-Based Near-Infrared Fluorescent Probes for Quantitative Protein Sensing. Langmuir, 2019, 35, 5599-5607.	1.6	15
925	Amyloid- \hat{l}^2 oligomers have a profound detergent-like effect on lipid membrane bilayers, imaged by atomic force and electron microscopy. Journal of Biological Chemistry, 2019, 294, 7566-7572.	1.6	112
926	Toxic amyloid- \hat{l}^2 oligomers induced self-replication in astrocytes triggering neuronal injury. EBioMedicine, 2019, 42, 174-187.	2.7	32
927	Transition Metal Ion Interactions with Disordered Amyloid-β Peptides in the Pathogenesis of Alzheimer's Disease: Insights from Computational Chemistry Studies. Journal of Chemical Information and Modeling, 2019, 59, 1782-1805.	2.5	46
928	Calcitonin native prefibrillar oligomers but not monomers induce membrane damage that triggers NMDA-mediated Ca2+-influx, LTP impairment and neurotoxicity. Scientific Reports, 2019, 9, 5144.	1.6	9
929	Different soluble aggregates of \hat{A}^2 42 can give rise to cellular toxicity through different mechanisms. Nature Communications, 2019, 10, 1541.	5.8	140
930	The cyanobacterial neurotoxin \hat{l}^2 -N-methylamino-l-alanine prevents addition of heparan sulfate to glypican-1 and increases processing of amyloid precursor protein in dividing neuronal cells. Experimental Cell Research, 2019, 379, 172-181.	1.2	6
931	Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid- \hat{l}^2 oligomers. Scientific Reports, 2019, 9, 5715.	1.6	25
932	Alzheimer's Amyloidopathy: An Alternative Aspect. Journal of Alzheimer's Disease, 2019, 68, 483-488.	1.2	5
933	Increased Secondary Nucleation Underlies Accelerated Aggregation of the Four-Residue N-Terminally Truncated Aβ42 Species Aβ5–42. ACS Chemical Neuroscience, 2019, 10, 2374-2384.	1.7	16
934	Vitamin D-binding protein-loaded PLGA nanoparticles suppress Alzheimer's disease-related pathology in 5XFAD mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 17, 297-307.	1.7	76
935	Imaging beta amyloid aggregation and iron accumulation in Alzheimer's disease using quantitative susceptibility mapping MRI. Neurolmage, 2019, 191, 176-185.	2.1	122
936	Amyloid \hat{I}^2 Induces Early Changes in the Ribosomal Machinery, Cytoskeletal Organization and Oxidative Phosphorylation in Retinal Photoreceptor Cells. Frontiers in Molecular Neuroscience, 2019, 12, 24.	1.4	28
937	Ordering Transitions in Liquid Crystals Triggered by Bioactive Cyclic Amphiphiles: Potential Application in Label-Free Detection of Amyloidogenic Peptides. Journal of Physical Chemistry C, 2019, 123, 6526-6536.	1.5	10

#	Article	IF	CITATIONS
938	Structure of amyloid $\hat{l}^225\hat{a}$ \in "35 in lipid environment and cholesterol-dependent membrane pore formation. Scientific Reports, 2019, 9, 2689.	1.6	43
939	Solvent Composition Effects on the Structural Properties of the AÎ ² 42 Monomer from the 3D-RISM-KH Molecular Theory of Solvation. Journal of Physical Chemistry B, 2019, 123, 2491-2506.	1.2	6
941	Automated detection of age-related macular degeneration in color fundus photography: a systematic review. Survey of Ophthalmology, 2019, 64, 498-511.	1.7	48
942	Ordered and Disordered Segments of Amyloid- \hat{l}^2 Drive Sequential Steps of the Toxic Pathway. ACS Chemical Neuroscience, 2019, 10, 2498-2509.	1.7	21
943	The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. Laboratory Investigation, 2019, 99, 958-970.	1.7	82
944	Meningeal Lymphatics: A Review and Future Directions From a Clinical Perspective. Neuroscience Insights, 2019, 14, 117906951988902.	0.9	23
945	Decrease in p3â€Alcβ37 and p3â€Alcβ40, products of Alcadein β generated by γâ€secretase cleavages, in aged monkeys and patients with Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 740-750.	1.8	6
946	Exposure of a cryptic Hsp70 binding site determines the cytotoxicity of the ALS-associated SOD1-mutant A4V. Protein Engineering, Design and Selection, 2019, 32, 443-457.	1.0	6
947	Alcohol drinking exacerbates neural and behavioral pathology in the 3xTg-AD mouse model of Alzheimer's disease. International Review of Neurobiology, 2019, 148, 169-230.	0.9	56
948	Increased soluble amyloid-beta causes early aberrant brain network hypersynchronisation in a mature-onset mouse model of amyloidosis. Acta Neuropathologica Communications, 2019, 7, 180.	2.4	19
949	Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease. Frontiers in Neurology, 2019, 10, 1140.	1.1	46
950	In search of pathogenic amyloid \hat{l}^2 -peptide in familial Alzheimer's disease. Progress in Molecular Biology and Translational Science, 2019, 168, 71-78.	0.9	14
951	11. Cobalt-Schiff Base Complexes: Preclinical Research and Potential Therapeutic Uses., 2019, 19, 267-302.		5
952	Gene delivery of a modified antibody to Aβ reduces progression of murine Alzheimer's disease. PLoS ONE, 2019, 14, e0226245.	1.1	16
953	Tracking down a missing trigger for Alzheimer's disease by mass spectrometric imaging based on brain network analysis. Progress in Molecular Biology and Translational Science, 2019, 168, 25-55.	0.9	1
954	Amyloidâ€Î² oligomers suppress subunitâ€specific glutamate receptor increase during LTP. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 797-808.	1.8	14
955	Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric ${\sf A}\hat{\sf I}^2$. Alzheimer's Research and Therapy, 2019, 11, 97.	3.0	22
956	Tau- but not Aß -pathology enhances NMDAR-dependent depotentiation in AD-mouse models. Acta Neuropathologica Communications, 2019, 7, 202.	2.4	O

#	Article	IF	CITATIONS
957	Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis. Alzheimer's Research and Therapy, 2019, 11, 101.	3.0	131
958	Prenylated Curcumin Analogues as Multipotent Tools To Tackle Alzheimer's Disease. ACS Chemical Neuroscience, 2019, 10, 1420-1433.	1.7	21
959	Cellular prion protein neither binds to alpha-synuclein oligomers nor mediates their detrimental effects. Brain, 2019, 142, 249-254.	3.7	38
960	A novel crosslinking protocol stabilizes amyloid β oligomers capable of inducing Alzheimer'sâ€associated pathologies. Journal of Neurochemistry, 2019, 148, 822-836.	2.1	20
961	Age-related diseases as vicious cycles. Ageing Research Reviews, 2019, 49, 11-26.	5.0	58
962	Multi-targeting aurones with monoamine oxidase and amyloid-beta inhibitory activities: Structure-activity relationship and translating multi-potency to neuroprotection. Biomedicine and Pharmacotherapy, 2019, 110, 118-128.	2.5	10
963	The Anti-amyloid Compound DO1 Decreases Plaque Pathology and Neuroinflammation-Related Expression Changes in 5xFAD Transgenic Mice. Cell Chemical Biology, 2019, 26, 109-120.e7.	2.5	8
964	Review: PrP 106â€126 – 25 years after. Neuropathology and Applied Neurobiology, 2019, 45, 430-440.	1.8	19
965	A Fluorogenic <i>AggTag</i> Method Based on Halo―and SNAPâ€Tags to Simultaneously Detect Aggregation of Two Proteins in Live Cells. ChemBioChem, 2019, 20, 1078-1087.	1.3	45
966	Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease. Brain Research Bulletin, 2019, 146, 171-184.	1.4	70
967	Oxidation of methionine residues in human apolipoprotein A-I generates a potent pro-inflammatory molecule. Journal of Biological Chemistry, 2019, 294, 3634-3646.	1.6	12
968	Obstacles to translating the promise of nanoparticles into viable amyloid disease therapeutics. Physical Biology, 2019, 16, 021002.	0.8	2
969	Trodusquemine enhances $\hat{Al^2}$ 42 aggregation but suppresses its toxicity by displacing oligomers from cell membranes. Nature Communications, 2019, 10, 225.	5.8	111
970	Restoring microglial and astroglial homeostasis using DNA immunization in a Down Syndrome mouse model. Brain, Behavior, and Immunity, 2019, 75, 163-180.	2.0	19
971	Amyloid-β and Parkinson's disease. Journal of Neurology, 2019, 266, 2605-2619.	1.8	79
972	Repulsive interaction induces fibril formation and their growth. International Journal of Biological Macromolecules, 2019, 123, 20-25.	3.6	10
973	Microenvironment Remodeling Micelles for Alzheimer's Disease Therapy by Early Modulation of Activated Microglia. Advanced Science, 2019, 6, 1801586.	5.6	88
974	Coagulation factor XIIIa cross-links amyloid \hat{l}^2 into dimers and oligomers and to blood proteins. Journal of Biological Chemistry, 2019, 294, 390-396.	1.6	20

#	Article	IF	CITATIONS
975	Curcumin and a hemi-analogue with improved blood–brain barrier permeability protect against amyloid-beta toxicity in <i>Caenorhabditis elegans</i> via SKN-1/Nrf activation. Journal of Pharmacy and Pharmacology, 2019, 71, 860-868.	1.2	16
976	Dysfunctional γ-Secretase in Familial Alzheimer's Disease. Neurochemical Research, 2019, 44, 5-11.	1.6	26
977	Analyzing aggregation propensities of clinically relevant PTEN mutants: a new culprit in pathogenesis of cancer and other PTENopathies. Journal of Biomolecular Structure and Dynamics, 2020, 38, 2253-2266.	2.0	6
978	The Amyloid Phenomenon and Its Significance in Biology and Medicine. Cold Spring Harbor Perspectives in Biology, 2020, 12, a033878.	2.3	111
979	New diagnostic method for Alzheimer $\hat{a} \in \mathbb{N}$ s disease based on the toxic conformation theory of amyloid \hat{l}^2 . Bioscience, Biotechnology and Biochemistry, 2020, 84, 1-16.	0.6	32
980	Plasma amyloid beta level changes in aged mice with cognitive dysfunction following sevoflurane exposure. Experimental Gerontology, 2020, 129, 110737.	1.2	7
981	Open questions on the nature of Parkinson's disease: from triggers to spreading pathology. Journal of Medical Genetics, 2020, 57, 73-81.	1.5	17
982	Realâ€Time BODIPYâ€Binding Assay To Screen Inhibitors of the Early Oligomerization Process of Aβ1–42 Peptide. ChemBioChem, 2020, 21, 1129-1135.	1.3	17
983	Structural Interaction of Apolipoprotein A-I Mimetic Peptide with Amyloid-Î ² Generates Toxic Hetero-oligomers. Journal of Molecular Biology, 2020, 432, 1020-1034.	2.0	25
984	PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. Acta Neuropathologica, 2020, 139, 503-526.	3.9	110
985	Neural stem cell therapy for neurovascular injury in Alzheimer's disease. Experimental Neurology, 2020, 324, 113112.	2.0	60
986	Stabilization Mechanism for a Nonfibrillar Amyloid \hat{l}^2 Oligomer Based on Formation of a Hydrophobic Core Determined by Dissipative Particle Dynamics. ACS Chemical Neuroscience, 2020, 11, 385-394.	1.7	15
987	Au23(CR)14 nanocluster restores fibril Aβ's unfolded state with abolished cytotoxicity and dissolves endogenous Aβ plaques. National Science Review, 2020, 7, 763-774.	4.6	21
988	Epigenetic mechanisms of neurodegenerative diseases and acute brain injury. Neurochemistry International, 2020, 133, 104642.	1.9	37
989	Design, Synthesis, and Properties of a Chemically Tethered Amyloid- \hat{l}^2 Segment Trimer Resistant to Intertrimer Mis-aggregation. Journal of Organic Chemistry, 2020, 85, 1635-1643.	1.7	5
990	The Structural Basis of Amyloid Strains in Alzheimer's Disease. ACS Biomaterials Science and Engineering, 2020, 6, 2498-2505.	2.6	9
991	Increased Microglial Exosomal miR-124-3p Alleviates Neurodegeneration and Improves Cognitive Outcome after rmTBI. Molecular Therapy, 2020, 28, 503-522.	3.7	121
992	Usnic acid derivatives as tau-aggregation and neuroinflammation inhibitors. European Journal of Medicinal Chemistry, 2020, 187, 111961.	2.6	21

#	Article	IF	Citations
993	NMR-based site-resolved profiling of \hat{l}^2 -amyloid misfolding reveals structural transitions from pathologically relevant spherical oligomer to fibril. Journal of Biological Chemistry, 2020, 295, 458-467.	1.6	21
994	Colorimetric sensor array based on gold nanoparticles: Design principles and recent advances. TrAC - Trends in Analytical Chemistry, 2020, 122, 115754.	5.8	147
995	Destabilization of $\hat{l}^2 \hat{a} \in amyloid$ aggregates by thrombin derived peptide: plausible role of thrombin in neuroprotection. FEBS Journal, 2020, 287, 2386-2413.	2.2	1
996	Multifunctional imaging of amyloid-beta peptides with a new gadolinium-based contrast agent in Alzheimer's disease. Journal of Industrial and Engineering Chemistry, 2020, 83, 214-223.	2.9	12
997	The Diverse Roles of TIMP-3: Insights into Degenerative Diseases of the Senescent Retina and Brain. Cells, 2020, 9, 39.	1.8	25
998	Inhibitory Activity of Insulin on Aβ Aggregation Is Restricted Due to Binding Selectivity and Specificity to Polymorphic Aβ States. ACS Chemical Neuroscience, 2020, 11, 445-452.	1.7	14
999	Synthesis of functionalized derivatives of the gamma-secretase modulator BMS-932481 and identification of its major metabolite. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127530.	1.0	3
1000	Endocytosis Is a Key Mode of Interaction between Extracellular \hat{I}^2 -Amyloid and the Cell Membrane. Biophysical Journal, 2020, 119, 1078-1090.	0.2	7
1001	Kinetic fingerprints differentiate the mechanisms of action of anti-A \hat{l}^2 antibodies. Nature Structural and Molecular Biology, 2020, 27, 1125-1133.	3.6	123
1002	Rapid Structural, Kinetic, and Immunochemical Analysis of Alpha-Synuclein Oligomers in Solution. Nano Letters, 2020, 20, 8163-8169.	4.5	24
1003	Parallels between retinal and brain pathology and response to immunotherapy in old, lateâ€stage Alzheimer's disease mouse models. Aging Cell, 2020, 19, e13246.	3.0	32
1004	Bicine promotes rapid formation of Î ² -sheet-rich amyloid-Î ² fibrils. PLoS ONE, 2020, 15, e0240608.	1.1	2
1005	Soluble Prion Peptide 107–120 Protects Neuroblastoma SH-SY5Y Cells against Oligomers Associated with Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 7273.	1.8	2
1006	Bridging the Gap Between Fluid Biomarkers for Alzheimer's Disease, Model Systems, and Patients. Frontiers in Aging Neuroscience, 2020, 12, 272.	1.7	17
1007	The Effects of Resveratrol, Caffeine, βâ€Carotene, and Epigallocatechin Gallate (EGCG) on Amyloidâ€Î²25–35 Aggregation in Synthetic Brain Membranes. Molecular Nutrition and Food Research, 2020, 64, e2000632.	1.5	8
1008	Amyloid fibril inhibition, acceleration, or fragmentation; Are nano-based approaches advance in the right direction?. Nano Today, 2020, 35, 100983.	6.2	5
1009	Assessments of the Effect of Neurokinin B on Toxic Aβ Aggregates in Alzheimer's Disease with the Molecular Mechanisms' Action. ACS Chemical Neuroscience, 2020, 11, 3418-3429.	1.7	5
1010	Photostimulation of Extravasation of Beta-Amyloid through the Model of Blood-Brain Barrier. Electronics (Switzerland), 2020, 9, 1056.	1.8	15

#	Article	IF	CITATIONS
1011	Metal-chelating benzothiazole multifunctional compounds for the modulation and $\langle sup \rangle 64 \langle sup \rangle Cu$ PET imaging of AÎ ² aggregation. Chemical Science, 2020, 11, 7789-7799.	3.7	40
1012	Highlighting the effect of amyloid beta assemblies on the mechanical properties and conformational stability of cell membrane. Journal of Molecular Graphics and Modelling, 2020, 100, 107670.	1.3	7
1013	Structural characteristics of oligomers formed by pyroglutamate-modified amyloid \hat{l}^2 peptides studied by solid-state NMR. Physical Chemistry Chemical Physics, 2020, 22, 16887-16895.	1.3	11
1014	Capturing Amyloid- \hat{l}^2 Oligomers by Stirring with Microscaled Iron Oxide Stir Bars into Magnetic Plaques to Reduce Cytotoxicity toward Neuronal Cells. Nanomaterials, 2020, 10, 1284.	1.9	0
1015	Longitudinal profiling of oligomeric $A\hat{l}^2$ in human nasal discharge reflecting cognitive decline in probable Alzheimer $\hat{a} \in \mathbb{R}^{M}$ s disease. Scientific Reports, 2020, 10, 11234.	1.6	25
1016	Molecular simulations of amyloid beta assemblies. Advances in Physics: X, 2020, 5, 1770627.	1.5	16
1017	Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers. International Journal of Molecular Sciences, 2020, 21, 8651.	1.8	23
1018	Design of a multivalent bifunctional chelator for diagnostic ⁶⁴ Cu PET imaging in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30928-30933.	3.3	25
1019	Inhibition of 37/67kDa Laminin-1 Receptor Restores APP Maturation and Reduces Amyloid-β in Human Skin Fibroblasts from Familial Alzheimer's Disease. Journal of Personalized Medicine, 2020, 10, 232.	1.1	6
1020	p47phox deficiency improves cognitive impairment and attenuates tau hyperphosphorylation in mouse models of AD. Alzheimer's Research and Therapy, 2020, 12, 146.	3.0	10
1021	Emergence of Barrel Motif in Amyloid- \hat{l}^2 Trimer: A Computational Study. Journal of Physical Chemistry B, 2020, 124, 10617-10631.	1.2	12
1022	Amyloid β-Peptide Increases Mitochondria-Endoplasmic Reticulum Contact Altering Mitochondrial Function and Autophagosome Formation in Alzheimer's Disease-Related Models. Cells, 2020, 9, 2552.	1.8	39
1023	Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers. International Journal of Molecular Sciences, 2020, 21, 8920.	1.8	8
1024	Neuron Loss in Alzheimer's Disease: Translation in Transgenic Mouse Models. International Journal of Molecular Sciences, 2020, 21, 8144.	1.8	39
1025	Distinct responses of neurons and astrocytes to TDP-43 proteinopathy in amyotrophic lateral sclerosis. Brain, 2020, 143, 430-440.	3.7	68
1026	The existence of Aβ strains and their potential for driving phenotypic heterogeneity in Alzheimer's disease. Acta Neuropathologica, 2021, 142, 17-39.	3.9	35
1027	Nanoscale rearrangement of APP organization as a therapeutic target for Alzheimer's disease. Medical Hypotheses, 2020, 143, 110143.	0.8	4
1028	Catechins as Tools to Understand the Molecular Basis of Neurodegeneration. Molecules, 2020, 25, 3571.	1.7	27

#	Article	IF	CITATIONS
1029	Amentoflavone: A Bifunctional Metal Chelator that Controls the Formation of Neurotoxic Soluble $\hat{Al^2}$ sub>42 Oligomers. ACS Chemical Neuroscience, 2020, 11, 2741-2752.	1.7	25
1030	Multiplicity of α-Synuclein Aggregated Species and Their Possible Roles in Disease. International Journal of Molecular Sciences, 2020, 21, 8043.	1.8	33
1031	Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 7443.	1.8	33
1032	Serum amyloid A inhibits astrocyte migration via activating p38 MAPK. Journal of Neuroinflammation, 2020, 17, 254.	3.1	12
1033	The two faces of synaptic failure in AppNL-G-F knock-in mice. Alzheimer's Research and Therapy, 2020, 12, 100.	3.0	25
1034	A two-step biopolymer nucleation model shows a nonequilibrium critical point. Journal of Chemical Physics, 2020, 153, 025102.	1.2	2
1035	Internalisation and toxicity of amyloidâ \in Î ² 1â \in 42 are influenced by its conformation and assembly state rather than size. FEBS Letters, 2020, 594, 3490-3503.	1.3	27
1036	A rationally designed bicyclic peptide remodels Aβ42 aggregation in vitro and reduces its toxicity in a worm model of Alzheimer's disease. Scientific Reports, 2020, 10, 15280.	1.6	15
1037	A preview of selected articles. Stem Cells Translational Medicine, 2020, 9, 955-958.	1.6	0
1038	The role of the cellular prion protein in the uptake and toxic signaling of pathological neurodegenerative aggregates. Progress in Molecular Biology and Translational Science, 2020, 175, 297-323.	0.9	5
1039	Tetrapeptide Ac-HAEE-NH2 Protects $\hat{l}\pm4\hat{l}^22$ nAChR from Inhibition by A \hat{l}^2 . International Journal of Molecular Sciences, 2020, 21, 6272.	1.8	9
1040	Frondoside A Attenuates Amyloid- \hat{l}^2 Proteotoxicity in Transgenic Caenorhabditis elegans by Suppressing Its Formation. Frontiers in Pharmacology, 2020, 11, 553579.	1.6	17
1041	Impact of Mutations on the Conformational Transition from \hat{I}_{\pm} -Helix to \hat{I}_{\pm} -Sheet Structures in Arctic-Type A \hat{I}_{\pm} -Sub>40: Insights from Molecular Dynamics Simulations. ACS Omega, 2020, 5, 23219-23228.	1.6	6
1042	Thermodynamic and kinetic design principles for amyloid-aggregation inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24251-24257.	3.3	49
1043	Pyk2 overexpression in postsynaptic neurons blocks amyloid $\hat{l}^21\hat{a}\in$ 42-induced synaptotoxicity in microfluidic co-cultures. Brain Communications, 2020, 2, fcaa139.	1.5	13
1044	Estradiol Replacement at the Critical Period Protects Hippocampal Neural Stem Cells to Improve Cognition in APP/PS1 Mice. Frontiers in Aging Neuroscience, 2020, 12, 240.	1.7	14
1045	Distinguishing the Effect on the Rate and Yield of A \hat{I}^2 42 Aggregation by Green Tea Polyphenol EGCG. ACS Omega, 2020, 5, 21497-21505.	1.6	10
1046	Synthetic and Biophysical Studies on the Toxic Conformer in Amyloid \hat{l}^2 with the E22 \hat{l} " Mutation in Alzheimer Pathology. ACS Chemical Neuroscience, 2020, 11, 3017-3024.	1.7	2

#	ARTICLE	IF	CITATIONS
1047	Hyperspectral Imaging and the Retina: Worth the Wave?. Translational Vision Science and Technology, 2020, 9, 9.	1.1	12
1048	Trodusquemine displaces protein misfolded oligomers from cell membranes and abrogates their cytotoxicity through a generic mechanism. Communications Biology, 2020, 3, 435.	2.0	44
1049	Saliva Biomarkers in Diagnostics of Early Stages of Alzheimer's Disease. Neurochemical Journal, 2020, 14, 429-438.	0.2	5
1050	Natural Compounds as Inhibitors of $\hat{Al^2}$ Peptide Aggregation: Chemical Requirements and Molecular Mechanisms. Frontiers in Neuroscience, 2020, 14, 619667.	1.4	59
1051	Interaction of Aβ1â^'42 chains and fibrillary seeds studied by allâ€atom molecular dynamics simulations. Computational and Mathematical Methods, 2020, , e1138.	0.3	0
1052	Telescoping the Synthesis of the [18 F]CABS13 Alzheimer's Disease Radiopharmaceutical via Flow Microfluidic Rhenium(I) Complexations. European Journal of Inorganic Chemistry, 2020, 2020, 3554-3564.	1.0	2
1053	An insight into the in vivo imaging potential of curcumin analogues as fluorescence probes. Asian Journal of Pharmaceutical Sciences, 2021, 16, 419-431.	4.3	16
1054	Alzheimer's amyloid β heterogeneous species differentially affect brain endothelial cell viability, bloodâ€brain barrier integrity, and angiogenesis. Aging Cell, 2020, 19, e13258.	3.0	39
1055	Metal- and UV- Catalyzed Oxidation Results in Trapped Amyloid-β Intermediates Revealing that Self-Assembly Is Required for Aβ-Induced Cytotoxicity. IScience, 2020, 23, 101537.	1.9	18
1056	Single-molecule studies of amyloid proteins: from biophysical properties to diagnostic perspectives. Quarterly Reviews of Biophysics, 2020, 53, e12.	2.4	12
1057	APOE2: protective mechanism and therapeutic implications for Alzheimer's disease. Molecular Neurodegeneration, 2020, 15, 63.	4.4	110
1058	Interaction of amyloid beta with humanin and acetylcholinesterase is modulated by ATP. FEBS Open Bio, 2020, 10, 2805-2823.	1.0	12
1059	Small-molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer's disease. Science Advances, 2020, 6, .	4.7	95
1060	Network pharmacology used to decode potential active ingredients in Ferula assafoetida and mechanisms for the application to Alzheimer's disease. Journal of Traditional Chinese Medical Sciences, 2020, 7, 199-209.	0.1	1
1061	Mechanisms of neurodegeneration — Insights from familial Alzheimer's disease. Seminars in Cell and Developmental Biology, 2020, 105, 75-85.	2.3	35
1062	Self-Coiling of Single-Stranded Protofibrils into Rings: A Pathway of Alzheimer's β-Peptide Amyloidosis on Lipid Membranes. ACS Macro Letters, 2020, 9, 813-818.	2.3	7
1063	Humanin Blocks the Aggregation of Amyloid- \hat{l}^2 Induced by Acetylcholinesterase, an Effect Abolished in the Presence of IGFBP-3. Biochemistry, 2020, 59, 1981-2002.	1.2	19
1064	Thermodynamic and Evolutionary Coupling between the Native and Amyloid State of Globular Proteins. Cell Reports, 2020, 31, 107512.	2.9	34

#	Article	IF	Citations
1065	High-Throughput Screening at the Membrane Interface Reveals Inhibitors of Amyloid- \hat{l}^2 . Biochemistry, 2020, 59, 2249-2258.	1.2	40
1066	Xingnaojing ameliorates synaptic plasticity and memory deficits in an Aβ1–42 induced mouse model of Alzheimer's disease. Journal of Pharmacological Sciences, 2020, 143, 245-254.	1.1	8
1067	Endo/Lysosomeâ€Escapable Delivery Depot for Improving BBB Transcytosis and Neuron Targeted Therapy of Alzheimer's Disease. Advanced Functional Materials, 2020, 30, 1909999.	7.8	71
1068	Optimization of Solid-Phase Synthesis of the 1-40 Beta-Amyloid and Preparation of Antibodies Revealing It under Immunoblotting Conditions. Russian Journal of Bioorganic Chemistry, 2020, 46, 217-222.	0.3	1
1069	Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation. Brain, 2020, 143, 1811-1825.	3.7	20
1070	Determining the effects of LLD and MCI on brain decline according to machine learning and a structural covariance network analysis. Journal of Psychiatric Research, 2020, 126, 43-54.	1.5	4
1071	Alzheimer's Disease: What Can We Learn From the Peripheral Olfactory System?. Frontiers in Neuroscience, 2020, 14, 440.	1.4	30
1072	The Brain AT2R—a Potential Target for Therapy in Alzheimer's Disease and Vascular Cognitive Impairment: a Comprehensive Review of Clinical and Experimental Therapeutics. Molecular Neurobiology, 2020, 57, 3458-3484.	1.9	17
1073	Helical γâ€Peptide Foldamers as Dual Inhibitors of Amyloidâ€Î² Peptide and Islet Amyloid Polypeptide Oligomerization and Fibrillization. Chemistry - A European Journal, 2020, 26, 14612-14622.	1.7	17
1074	Efficient suppression of amyloid- \hat{l}^2 peptide aggregation and cytotoxicity with photosensitive polymer nanodots. Journal of Materials Chemistry B, 2020, 8, 5776-5782.	2.9	11
1075	Biophysical studies of protein misfolding and aggregation inin vivomodels of Alzheimer's and Parkinson's diseases. Quarterly Reviews of Biophysics, 2020, 53, e22.	2.4	13
1076	Effects of N-Terminal Residues on the Assembly of Constrained \hat{l}^2 -Hairpin Peptides Derived from A \hat{l}^2 . Journal of the American Chemical Society, 2020, 142, 11593-11601.	6.6	12
1077	Rational design of a conformation-specific antibody for the quantification of $\hat{Al^2}$ oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13509-13518.	3.3	61
1078	Unraveling VEALYL Amyloid Formation Using Advanced Vibrational Spectroscopy and Microscopy. Biophysical Journal, 2020, 119, 87-98.	0.2	7
1079	Icariin improves cognitive deficits by reducing the deposition of \hat{l}^2 -amyloid peptide and inhibition of neurons apoptosis in SAMP8 mice. NeuroReport, 2020, 31, 663-671.	0.6	16
1080	$\hat{Al^2}(1-42)$ tetramer and octamer structures reveal edge conductivity pores as a mechanism for membrane damage. Nature Communications, 2020, 11, 3014.	5.8	162
1081	Environment-Sensitive Probes for Illuminating Amyloid Aggregation <i>In Vitro</i> and in Zebrafish. ACS Sensors, 2020, 5, 2792-2799.	4.0	21
1082	Nanoscale Interplay of Membrane Composition and Amyloid Self-Assembly. Journal of Physical Chemistry B, 2020, 124, 5837-5846.	1.2	8

#	ARTICLE	IF	CITATIONS
1083	Fluorogenic detection of protein aggregates in live cells using the AggTag method. Methods in Enzymology, 2020, 639, 1-22.	0.4	9
1084	Cerebral amyloid angiopathy-linked \hat{l}^2 -amyloid mutations promote cerebral fibrin deposits via increased binding affinity for fibrinogen. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 14482-14492.	3.3	24
1085	CIRBP Ameliorates Neuronal Amyloid Toxicity via Antioxidative and Antiapoptotic Pathways in Primary Cortical Neurons. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-9.	1.9	14
1086	Kai-Xin-San, a Chinese Herbal Decoction, Accelerates the Degradation of $\langle i \rangle \hat{l}^2 \langle i \rangle$ -Amyloid by Enhancing the Expression of Neprilysin in Rats. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-8.	0.5	6
1087	Analysing the nanoparticle-protein corona for potential molecular target identification. Journal of Controlled Release, 2020, 322, 122-136.	4.8	33
1088	Neurodegeneration in Alzheimer's disease and glaucoma: overlaps and missing links. Eye, 2020, 34, 1546-1553.	1.1	39
1089	Characterization and Neuroprotection Potential of Seleno-Polymannuronate. Frontiers in Pharmacology, 2020, 11, 21.	1.6	11
1090	Computational studies of protein aggregation mediated by amyloid: Fibril elongation and secondary nucleation. Progress in Molecular Biology and Translational Science, 2020, 170, 461-504.	0.9	12
1091	Molecular dynamics simulations of amyloid-l²(16–22) peptide aggregation at air–water interfaces. Journal of Chemical Physics, 2020, 152, 095101.	1.2	25
1092	Ameliorating amyloid aggregation through osmolytes as a probable therapeutic molecule against Alzheimer's disease and type 2 diabetes. RSC Advances, 2020, 10, 12166-12182.	1.7	8
1093	Acetylation of AÎ 2 42 at Lysine 16 Disrupts Amyloid Formation. ACS Chemical Neuroscience, 2020, 11, 1178-1191.	1.7	18
1094	Microfluidic Shrinking Droplet Concentrator for Analyte Detection and Phase Separation of Protein Solutions. Analytical Chemistry, 2020, 92, 5803-5812.	3.2	38
1095	Structure and Aggregation Mechanisms in Amyloids. Molecules, 2020, 25, 1195.	1.7	108
1096	Molecular mechanisms of amyloid aggregation in human proteinopathies. , 2020, , 153-179.		1
1097	Alzheimerâ∈™s disease: microglia targets and their modulation to promote amyloid phagocytosis and mitigate neuroinflammation. Expert Opinion on Therapeutic Targets, 2020, 24, 331-344.	1.5	43
1098	Parkinson's Disease and the Gut: Future Perspectives for Early Diagnosis. Frontiers in Neuroscience, 2020, 14, 626.	1.4	18
1099	Principal component analysis of data from NMR titration experiment of uniformly 15N labeled amyloid beta (1–42) peptide with osmolytes and phenolic compounds. Archives of Biochemistry and Biophysics, 2020, 690, 108446.	1.4	5
1100	Heptameric Peptide Interferes with Amyloid- \hat{l}^2 Aggregation by Structural Reorganization of the Toxic Oligomers. ACS Omega, 2020, 5, 16128-16138.	1.6	4

#	Article	IF	CITATIONS
1101	Rationally Designed Antibodies as Research Tools to Study the Structure–Toxicity Relationship of Amyloid-l² Oligomers. International Journal of Molecular Sciences, 2020, 21, 4542.	1.8	12
1102	X-ray Crystallography Reveals Parallel and Antiparallel β-Sheet Dimers of a β-Hairpin Derived from Aβ _{16–36} that Assemble to Form Different Tetramers. ACS Chemical Neuroscience, 2020, 11, 2340-2347.	1.7	18
1103	Age-Specific Retinal and Cerebral Immunodetection of Amyloid-β Plaques and Oligomers in a Rodent Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 76, 1135-1150.	1.2	26
1104	Small molecule-mediated co-assembly of amyloid- \hat{l}^2 oligomers reduces neurotoxicity through promoting non-fibrillar aggregation. Chemical Science, 2020, 11, 7158-7169.	3.7	27
1105	Synthetic and biochemical studies on the effect of persulfidation on disulfide dimer models of amyloid \hat{l}^2 42 at position 35 in Alzheimer's etiology. RSC Advances, 2020, 10, 19506-19512.	1.7	3
1106	Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers. Chemical Society Reviews, 2020, 49, 5446-5472.	18.7	56
1107	Conjugation of RTHLVFFARK to human lysozyme creates a potent multifunctional modulator for $Cu < sup > 2 + < /sup > -mediated amyloid \hat{I}^2-protein aggregation and cytotoxicity. Journal of Materials Chemistry B, 2020, 8, 2256-2268.$	2.9	12
1108	Evaluation of Toxic Amyloid \hat{I}^2 42 Oligomers in Rat Primary Cerebral Cortex Cells and Human iPS-derived Neurons Treated with 10-Me-Aplog-1, a New PKC Activator. International Journal of Molecular Sciences, 2020, 21, 1179.	1.8	6
1109	Effects of Boron Nitride Nanotube on the Secondary Structure of Aβ(1–42) Trimer: Possible Inhibitory Effect on Amyloid Formation. Journal of Physical Chemistry B, 2020, 124, 1928-1940.	1.2	16
1110	Melatonin affects the release of exosomes and tau-content in in vitro amyloid-beta toxicity model. Journal of Clinical Neuroscience, 2020, 73, 237-244.	0.8	18
1111	Sclerotiorin Stabilizes the Assembly of Nonfibrillar Abeta42 Oligomers with Low Toxicity, Seeding Activity, and Beta-sheet Content. Journal of Molecular Biology, 2020, 432, 2080-2098.	2.0	12
1112	Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How. Neurobiology of Disease, 2020, 139, 104811.	2.1	44
1114	Bis(ethylmaltolato)oxidovanadium(<scp>iv</scp>) inhibited the pathogenesis of Alzheimer's disease in triple transgenic model mice. Metallomics, 2020, 12, 474-490.	1.0	22
1115	Serotonin and 5-HT2B receptors in microglia control of behavior. Handbook of Behavioral Neuroscience, 2020, 31, 589-599.	0.7	4
1116	Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 16.	3.0	31
1117	Molecular Tools to Detect Alloforms of Aβ and Tau: Implications for Multiplexing and Multimodal Diagnosis of Alzheimer's Disease. Bulletin of the Chemical Society of Japan, 2020, 93, 507-546.	2.0	39
1118	Augmentation of Bri2 molecular chaperone activity against amyloid- \hat{l}^2 reduces neurotoxicity in mouse hippocampus in vitro. Communications Biology, 2020, 3, 32.	2.0	42
1119	The Interaction between Amyloid Prefibrillar Oligomers of Salmon Calcitonin and a Lipid-Raft Model: Molecular Mechanisms Leading to Membrane Damage, Ca2+-Influx and Neurotoxicity. Biomolecules, 2020, 10, 58.	1.8	3

#	Article	IF	Citations
1120	PI3K activation prevents A $\hat{1}^2$ 42-induced synapse loss and favors insoluble amyloid deposit formation. Molecular Biology of the Cell, 2020, 31, 244-260.	0.9	8
1121	Meningeal Immunity and Its Function in Maintenance of the Central Nervous System in Health and Disease. Annual Review of Immunology, 2020, 38, 597-620.	9.5	199
1122	Structural Characterization of Individual α-Synuclein Oligomers Formed at Different Stages of Protein Aggregation by Atomic Force Microscopy-Infrared Spectroscopy. Analytical Chemistry, 2020, 92, 6806-6810.	3.2	77
1123	Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?. Biochemical Pharmacology, 2020, 177, 113945.	2.0	62
1124	Aging Fits the Disease Criteria of the International Classification of Diseases. Mechanisms of Ageing and Development, 2020, 189, 111230.	2.2	26
1125	Dynamics of oligomer populations formed during the aggregation of Alzheimer's Aβ42 peptide. Nature Chemistry, 2020, 12, 445-451.	6.6	223
1126	High-resolution probing of early events in amyloid- \hat{l}^2 aggregation related to Alzheimer's disease. Chemical Communications, 2020, 56, 4627-4639.	2.2	71
1127	Neuroprotective Properties of Resveratrol and Its Derivatives—Influence on Potential Mechanisms Leading to the Development of Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 2749.	1.8	21
1128	Small heat shock proteins in neurodegenerative diseases. Cell Stress and Chaperones, 2020, 25, 679-699.	1.2	57
1129	New Insights into the Molecular Bases of Familial Alzheimer's Disease. Journal of Personalized Medicine, 2020, 10, 26.	1.1	19
1130	AFM Probing of Amyloid-Beta 42 Dimers and Trimers. Frontiers in Molecular Biosciences, 2020, 7, 69.	1.6	17
1131	Regulation of microglia by glutamate and its signal pathway in neurodegenerative diseases. Drug Discovery Today, 2020, 25, 1074-1085.	3.2	18
1132	A Multifunctional Chemical Agent as an Attenuator of Amyloid Burden and Neuroinflammation in Alzheimer's Disease. ACS Chemical Neuroscience, 2020, 11, 1471-1481.	1.7	25
1133	Human serum albumin-mediated recognition of soluble amyloid- \hat{l}^2 peptides using a time-resolved luminescent probe in plasma. Chemical Communications, 2020, 56, 5945-5948.	2.2	13
1134	Multiâ€angle development of therapeutic methods for Alzheimer's disease. British Journal of Pharmacology, 2021, 178, 770-783.	2.7	7
1135	Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer's mice. Cell Death and Differentiation, 2021, 28, 203-218.	5.0	63
1136	Retinal changes in Alzheimer's diseaseâ€" integrated prospects of imaging, functional and molecular advances. Progress in Retinal and Eye Research, 2021, 82, 100899.	7.3	71
1137	Mechanisms and therapeutic potential of interactions between human amyloids and viruses. Cellular and Molecular Life Sciences, 2021, 78, 2485-2501.	2.4	20

#	Article	IF	CITATIONS
1138	Alzheimer's AÎ ² 42 and AÎ ² 40 form mixed oligomers with direct molecular interactions. Biochemical and Biophysical Research Communications, 2021, 534, 292-296.	1.0	17
1139	Anti-AÎ ² Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 79, 249-265.	1.2	27
1140	Green tea extract EGCG plays a dual role in \hat{A}^{12} 42 protofibril disruption and membrane protection: A molecular dynamic study. Chemistry and Physics of Lipids, 2021, 234, 105024.	1.5	19
1141	Oral absorption enhancement of the amyloid- \hat{l}^2 oligomer eliminating compound RD2 by conjugation with folic acid. European Journal of Pharmaceutical Sciences, 2021, 156, 105581.	1.9	2
1142	β-amyloid: The known unknowns. Ageing Research Reviews, 2021, 65, 101212.	5.0	27
1143	Reviewing nanoplastic toxicology: It's an interface problem. Advances in Colloid and Interface Science, 2021, 288, 102337.	7.0	52
1144	Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight. Progress in Molecular Biology and Translational Science, 2021, 177, 175-202.	0.9	21
1145	A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer's disease. Acta Neuropathologica, 2021, 141, 217-233.	3.9	33
1146	Systems-based proteomics to resolve the biology of Alzheimer's disease beyond amyloid and tau. Neuropsychopharmacology, 2021, 46, 98-115.	2.8	70
1147	Class I HDAC Inhibitor Improves Synaptic Proteins and Repairs Cytoskeleton Through Regulating Synapse-Related Genes In vitro and In vivo. Frontiers in Aging Neuroscience, 2020, 12, 619866.	1.7	9
1148	The Hunt for Ancient Prions: Archaeal Prion-Like Domains Form Amyloid-Based Epigenetic Elements. Molecular Biology and Evolution, 2021, 38, 2088-2103.	3 . 5	15
1149	Conformation-specific perturbation of membrane dynamics by structurally distinct oligomers of Alzheimer's amyloid-Î ² peptide. Physical Chemistry Chemical Physics, 2021, 23, 9686-9694.	1.3	9
1150	Novel Phosphorylation-State Specific Antibodies Reveal Differential Deposition of Ser26 Phosphorylated AÎ ² Species in a Mouse Model of Alzheimer's Disease. Frontiers in Molecular Neuroscience, 2020, 13, 619639.	1.4	7
1151	The 5-HT2B Receptor, the Immune System and Neuroinflammation. Receptors, 2021, , 87-97.	0.2	1
1152	Plasmonic nanoparticle amyloid corona for screening $\hat{Al^2}$ oligomeric aggregate-degrading drugs. Nature Communications, 2021, 12, 639.	5.8	17
1153	Alpinia officinarum., 2021,, 453-461.		1
1154	3D Alzheimer's disease in a dish: Implications for drug discovery. , 2021, , 311-331.		1
1155	Soluble amyloid beta-containing aggregates are present throughout the brain at early stages of Alzheimer's disease. Brain Communications, 2021, 3, fcab147.	1.5	32

#	ARTICLE	IF	CITATIONS
1156	Kinetics of amyloid \hat{l}^2 from deep learning. Nature Computational Science, 2021, 1, 20-21.	3.8	2
1157	The Pathogenesis Mechanism, Structure Properties, Potential Drugs and Therapeutic Nanoparticles against the Small Oligomers of Amyloid- \hat{l}^2 . Current Topics in Medicinal Chemistry, 2021, 21, 151-167.	1.0	5
1158	α-CGRP disrupts amylin fibrillization and regulates insulin secretion: implications on diabetes and migraine. Chemical Science, 2021, 12, 5853-5864.	3.7	6
1159	Parkinson's Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway. Cells, 2021, 10, 230.	1.8	37
1160	Isomeric Effect of Nano-Inhibitors on A $\hat{1}^2$ ₄₀ Fibrillation at The Nano-Bio Interface. ACS Applied Materials & Samp; Interfaces, 2021, 13, 4894-4904.	4.0	10
1161	Synthesis and study of macrocyclic \hat{l}^2 -hairpin peptides for investigating amyloid oligomers. Methods in Enzymology, 2021, 656, 123-168.	0.4	2
1162	Microenvironment-tailored nanoassemblies for the diagnosis and therapy of neurodegenerative diseases. Nanoscale, 2021, 13, 10197-10238.	2.8	6
1163	Advances in fluorescent probes for detection and imaging of amyloid- \hat{l}^2 peptides in Alzheimer's disease. Advances in Clinical Chemistry, 2021, 103, 135-190.	1.8	13
1164	3D-visualization of amyloid- \hat{l}^2 oligomer interactions with lipid membranes by cryo-electron tomography. Chemical Science, 2021, 12, 6896-6907.	3.7	31
1165	Impairment of Spike-Timing-Dependent Plasticity at Schaffer Collateral-CA1 Synapses in Adult APP/PS1 Mice Depends on Proximity of Aβ Plaques. International Journal of Molecular Sciences, 2021, 22, 1378.	1.8	10
1166	Rationally Designed Bicyclic Peptides Prevent the Conversion of Al 2 42 Assemblies Into Fibrillar Structures. Frontiers in Neuroscience, 2021, 15, 623097.	1.4	6
1167	Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases. Nature Reviews Chemistry, 2021, 5, 277-294.	13.8	56
1168	${\sf A\hat{l}^2}$ Oligomers Dysregulate Calcium Homeostasis by Mechanosensitive Activation of AMPA and NMDA Receptors. ACS Chemical Neuroscience, 2021, 12, 766-781.	1.7	35
1169	Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. Chemical Reviews, 2021, 121, 2545-2647.	23.0	406
1170	Peptidomimetic-Based Vesicles Inhibit Amyloid- \hat{l}^2 Fibrillation and Attenuate Cytotoxicity. Journal of the American Chemical Society, 2021, 143, 3086-3093.	6.6	32
1172	Promotion and Inhibition of Amyloid- \hat{l}^2 Peptide Aggregation: Molecular Dynamics Studies. International Journal of Molecular Sciences, 2021, 22, 1859.	1.8	12
1173	Mutual structural effects of unmodified and pyroglutamylated amyloid \hat{l}^2 peptides during aggregation. Journal of Peptide Science, 2021, 27, e3312.	0.8	3
1174	Monitoring amyloid- \hat{l}^2 42 conformational change using a spray-printed graphene electrode. Electrochemistry Communications, 2021, 123, 106927.	2.3	10

#	Article	IF	CITATIONS
1175	Dengzhan shengmai capsule combined with donepezil hydrochloride in the treatment of Alzheimer's disease: preliminary findings, randomized and controlled clinical trial. Revista Da Associação Médica Brasileira, 2021, 67, 190-194.	0.3	7
1176	Naringin Exhibits Mas Receptor–Mediated Neuroprotection Against Amyloid Beta–Induced Cognitive Deficits and Mitochondrial Toxicity in Rat Brain. Neurotoxicity Research, 2021, 39, 1023-1043.	1.3	19
1177	Atomic Resolution Map of Hierarchical Self-Assembly for an Amyloidogenic Protein Probed through Thermal ¹⁵ N–R ₂ Correlation Matrices. Journal of the American Chemical Society, 2021, 143, 4668-4679.	6.6	11
1178	Hybrid resolution molecular dynamics simulations of amyloid proteins interacting with membranes. Methods, 2022, 197, 89-96.	1.9	4
1179	Linalool Alleviates Aβ42-Induced Neurodegeneration via Suppressing ROS Production and Inflammation in Fly and Rat Models of Alzheimer's Disease. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-10.	1.9	27
1180	Acitretin reverses early functional network degradation in a mouse model of familial Alzheimer's disease. Scientific Reports, 2021, 11, 6649.	1.6	15
1182	Polymorphic SERPINA3 prolongs oligomeric state of amyloid beta. PLoS ONE, 2021, 16, e0248027.	1.1	7
1183	GDE2-RECK controls ADAM10 α-secretase–mediated cleavage of amyloid precursor protein. Science Translational Medicine, 2021, 13, .	5 . 8	12
1184	Keto form of curcumin derivatives strongly binds to $\hat{Al^2}$ oligomers but not fibrils. Biomaterials, 2021, 270, 120686.	5.7	21
1185	Segmental structural dynamics in A \hat{l}^2 42 globulomers. Biochemical and Biophysical Research Communications, 2021, 545, 119-124.	1.0	6
1186	Role of Hypoxia Inducible Factor-1α in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 80, 949-961.	1.2	22
1187	PolyQ-expanded proteins impair cellular proteostasis of ataxin-3 through sequestering the co-chaperone HSJ1 into aggregates. Scientific Reports, 2021, 11, 7815.	1.6	11
1188	Beneficial Effects of Cyclic Ether 2-Butoxytetrahydrofuran from Sea Cucumber Holothuria scabra against $\hat{Al^2}$ Aggregate Toxicity in Transgenic Caenorhabditis elegans and Potential Chemical Interaction. Molecules, 2021, 26, 2195.	1.7	9
1189	Mixed pathologies in pancreatic \hat{l}^2 cells from subjects with neurodegenerative diseases and their interaction with prion protein. Acta Neuropathologica Communications, 2021, 9, 64.	2.4	20
1190	Potential role of cannabidiol in Parkinsonâ∈™s disease by targeting the WNT/β-catenin pathway, oxidative stress and inflammation. Aging, 2021, 13, 10796-10813.	1.4	20
1191	Rapid size-exclusion high performance liquid chromatography method for the quality control of amyloid- \hat{l}^2 oligomers. Journal of Chromatography A, 2021, 1643, 462024.	1.8	2
1192	The role of alpha-helix on the structure-targeting drug design of amyloidogenic proteins. Chemistry and Physics of Lipids, 2021, 236, 105061.	1.5	7
1193	Ang(1–7) exerts Nrf2-mediated neuroprotection against amyloid beta-induced cognitive deficits in rodents. Molecular Biology Reports, 2021, 48, 4319-4331.	1.0	11

#	Article	IF	CITATIONS
1194	Amyloids: The History of Toxicity and Functionality. Biology, 2021, 10, 394.	1.3	12
1195	$A\hat{l}^243$ aggregates exhibit enhanced prion-like seeding activity in mice. Acta Neuropathologica Communications, 2021, 9, 83.	2.4	14
1196	Heightened Hippocampal \hat{l}^2 -Adrenergic Receptor Function Drives Synaptic Potentiation and Supports Learning and Memory in the TgF344-AD Rat Model during Prodromal Alzheimer's Disease. Journal of Neuroscience, 2021, 41, 5747-5761.	1.7	35
1197	Potential roles of natural products in the targeting of proteinopathic neurodegenerative diseases. Neurochemistry International, 2021, 145, 105011.	1.9	20
1198	Calcium Dyshomeostasis in Alzheimer's Disease Pathogenesis. International Journal of Molecular Sciences, 2021, 22, 4914.	1.8	76
1199	Binding Mechanisms of Amyloid-like Peptides to Lipid Bilayers and Effects of Divalent Cations. ACS Chemical Neuroscience, 2021, 12, 2027-2035.	1.7	19
1200	Brain Targeting and A \hat{I}^2 Binding Bifunctional Nanoparticles Inhibit Amyloid Protein Aggregation in APP/PS1 Transgenic Mice. ACS Chemical Neuroscience, 2021, 12, 2110-2121.	1.7	15
1201	Phenanthroline impairs \hat{l}^2 APP processing and expression, increases p53 protein levels and induces cell cycle arrest in human neuroblastoma cells. Brain Research Bulletin, 2021, 170, 29-38.	1.4	5
1202	Regulation of amyloid- \hat{l}^2 levels by matrix metalloproteinase-2/9 (MMP2/9) in the media of lung cancer cells. Scientific Reports, 2021, 11, 9708.	1.6	14
1203	Re-emphasizing early Alzheimer's disease pathology starting in select entorhinal neurons, with a special focus on mitophagy. Ageing Research Reviews, 2021, 67, 101307.	5.0	62
1204	Quality control of mislocalized and orphan proteins. Experimental Cell Research, 2021, 403, 112617.	1.2	11
1205	Exosomes and Melatonin: Where Their Destinies Intersect. Frontiers in Immunology, 2021, 12, 692022.	2.2	23
1206	Rapid Conversion of Amyloid-Beta 1-40 Oligomers to Mature Fibrils through a Self-Catalytic Bimolecular Process. International Journal of Molecular Sciences, 2021, 22, 6370.	1.8	8
1207	Single molecule imaging of protein aggregation in Dementia: Methods, insights and prospects. Neurobiology of Disease, 2021, 153, 105327.	2.1	2
1208	An evaluation of the self-assembly enhancing properties of cell-derived hexameric amyloid- \hat{l}^2 . Scientific Reports, 2021, 11, 11570.	1.6	9
1209	Amyloid Prefibrillar Oligomers: The Surprising Commonalities in Their Structure and Activity. International Journal of Molecular Sciences, 2021, 22, 6435.	1.8	15
1210	Multipronged Regulatory Functions of Serum Albumin in Early Stages of Amyloid-Î ² Aggregation. ACS Chemical Neuroscience, 2021, 12, 2409-2420.	1.7	10
1211	Spontaneous formation of β-sheet nano-barrels during the early aggregation of Alzheimer's amyloid beta. Nano Today, 2021, 38, 101125.	6.2	44

#	Article	IF	CITATIONS
1212	Critical Appraisal of Amyloid Lowering Agents in AD. Current Neurology and Neuroscience Reports, 2021, 21, 39.	2.0	57
1213	Refining the amyloid β peptide and oligomer fingerprint ambiguities in Alzheimer's disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. Journal of Neurochemistry, 2021, 159, 234-257.	2.1	8
1214	Correlation between Alzheimer's disease and type 2 diabetes using non-negative matrix factorization. Scientific Reports, 2021, 11, 15265.	1.6	13
1216	Reassembling protein complexes after controlled disassembly by top-down mass spectrometry in native mode. International Journal of Mass Spectrometry, 2021, 465, 116591.	0.7	8
1217	Two human metabolites rescue a C. elegans model of Alzheimer's disease via a cytosolic unfolded protein response. Communications Biology, 2021, 4, 843.	2.0	6
1218	Epileptic Mechanisms Shared by Alzheimer's Disease: Viewed via the Unique Lens of Genetic Epilepsy. International Journal of Molecular Sciences, 2021, 22, 7133.	1.8	11
1219	Exogenous misfolded protein oligomers can cross the intestinal barrier and cause a disease phenotype in C. elegans. Scientific Reports, 2021, 11, 14391.	1.6	6
1220	Inhibition of aggregation of amyloid- \hat{l}^2 through covalent modification with benzylpenicillin; potential relevance to Alzheimer's disease. Biochemistry and Biophysics Reports, 2021, 26, 100943.	0.7	3
1221	Sequence Determinants of the Aggregation of Proteins Within Condensates Generated by Liquid-liquid Phase Separation. Journal of Molecular Biology, 2022, 434, 167201.	2.0	62
1222	Suppression of amyloidâ€Î² secretion from neurons by <i>cis</i> à€9, <i>trans</i> â€11â€octadecadienoic acid, ar isomer of conjugated linoleic acid. Journal of Neurochemistry, 2021, 159, 603-617.	2.1	3
1223	Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment. Molecules, 2021, 26, 5091.	1.7	23
1224	Identification of key stabilizing interactions of amyloidâ€ <i>β</i> oligomers based on fragment molecular orbital calculations on macrocyclic <scp><i>β</i>â€hairpin</scp> peptides. Proteins: Structure, Function and Bioinformatics, 2022, 90, 229-238.	1.5	6
1225	Casein Kinase 2 dependent phosphorylation of eIF4B regulates BACE1 expression in Alzheimer's disease. Cell Death and Disease, 2021, 12, 769.	2.7	8
1226	Challenges in sample preparation and structure determination of amyloids by cryo-EM. Journal of Biological Chemistry, 2021, 297, 100938.	1.6	20
1227	Inhibition of miR-96-5p May Reduce A $\hat{1}^2$ 42/A $\hat{1}^2$ 40 Ratio via Regulating ATP-binding cassette transporter A1. Journal of Alzheimer's Disease, 2021, 83, 367-377.	1.2	3
1228	Protein S-nitrosylation and oxidation contribute to protein misfolding in neurodegeneration. Free Radical Biology and Medicine, 2021, 172, 562-577.	1.3	44
1229	Searching for Natural Products That Delay Nucleation Phase and Promote Elongation Phase of Amyloid l²42 toward Alzheimer's Disease Therapeutics. ACS Chemical Neuroscience, 2021, 12, 3467-3476.	1.7	3
1230	Soluble Amyloid-β Consumption in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 82, 1403-1415.	1.2	31

#	Article	IF	CITATIONS
1231	Dynamic Changes in the Levels of Amyloid-β42 Species in the Brain and Periphery of APP/PS1 Mice and Their Significance for Alzheimer's Disease. Frontiers in Molecular Neuroscience, 2021, 14, 723317.	1.4	14
1232	Identification of transmissible proteotoxic oligomer-like fibrils that expand conformational diversity of amyloid assemblies. Communications Biology, 2021, 4, 939.	2.0	15
1233	Transferrin-Pep63-liposomes accelerate the clearance of $A\hat{l}^2$ and rescue impaired synaptic plasticity in early Alzheimerâ \in TM s disease models. Cell Death Discovery, 2021, 7, 256.	2.0	13
1234	Thiopheneâ€Based Dual Modulators of Aβ and Tau Aggregation. ChemBioChem, 2021, 22, 3348-3357.	1.3	8
1235	Oligomeric and Fibrillar Species of \hat{A}^2 42 Diversely Affect Human Neural Stem Cells. International Journal of Molecular Sciences, 2021, 22, 9537.	1.8	4
1236	On the Common Journey of Neural Cells through Ischemic Brain Injury and Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 9689.	1.8	19
1237	Effects of AÎ ² -derived peptide fragments on fibrillogenesis of AÎ ² . Scientific Reports, 2021, 11, 19262.	1.6	10
1238	Mechanisms of amyloid proteins aggregation and their inhibition by antibodies, small molecule inhibitors, nano-particles and nano-bodies. International Journal of Biological Macromolecules, 2021, 186, 580-590.	3.6	25
1239	The Absence of Myelin Basic Protein Reduces Non-Amyloidogenic Processing of Amyloid Precursor Protein. Current Alzheimer Research, 2021, 18, 326-334.	0.7	3
1240	Î ² -Amyloid fibrils catalyze neurotransmitter degradation. Chem Catalysis, 2021, 1, 908-922.	2.9	24
1241	AbsoluRATE: An in-silico method to predict the aggregation kinetics of native proteins. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2021, 1869, 140682.	1.1	8
1242	NLRP3 Inflammasome: A Starring Role in Amyloid-β- and Tau-Driven Pathological Events in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 83, 939-961.	1.2	55
1243	Exploring amyloid oligomers with peptide model systems. Current Opinion in Chemical Biology, 2021, 64, 106-115.	2.8	23
1245	Understanding and controlling amyloid aggregation with chirality. Current Opinion in Chemical Biology, 2021, 64, 1-9.	2.8	18
1246	Cytoplasmic TDP-43 impairs the activity of the ubiquitin-proteasome system. Experimental Neurology, 2021, 345, 113833.	2.0	11
1247	A label-free fluorescent probe for dynamic in situ visualization of amyloid- \hat{l}^2 peptides aggregation. Sensors and Actuators B: Chemical, 2021, 347, 130607.	4.0	7
1248	The role of amyloids in Alzheimer's and Parkinson's diseases. International Journal of Biological Macromolecules, 2021, 190, 44-55.	3.6	33
1249	The role of the half-turn in determining structures of Alzheimer's Aβ wild-type and mutants. Journal of Structural Biology, 2021, 213, 107792.	1.3	1

#	Article	IF	CITATIONS
1250	Reversal of apolipoprotein E4-dependent or chemical-induced accumulation of APP degradation products by vitamin C-induced release of heparan sulfate from glypican-1. Glycobiology, 2021, 31, 800-811.	1.3	4
1251	"Fishing―nano–bio interactions at the key biological barriers. Nanoscale, 2021, 13, 5954-5964.	2.8	6
1252	Region-specific amyloid- \hat{l}^2 accumulation in the olfactory system influences olfactory sensory neuronal dysfunction in 5xFAD mice. Alzheimer's Research and Therapy, 2021, 13, 4.	3.0	11
1253	Exercise-Mediated Autophagy and Alzheimer's Disease. , 2021, , 127-154.		0
1254	Non-Oncologic Applications of Nanomedicine-Based Phototherapy. Biomedicines, 2021, 9, 113.	1.4	26
1255	Degradation Products of Amyloid Protein: Are They The Culprits?. Current Alzheimer Research, 2021, 17, 869-880.	0.7	9
1256	A conformation-specific antibody against oligomeric \hat{l}^2 -amyloid restores neuronal integrity in a mouse model of Alzheimer's disease. Journal of Biological Chemistry, 2021, 296, 100241.	1.6	4
1257	Dysfunction of axonal transport in normal-tension glaucoma: a biomarker of disease progression and a potential therapeutic target. Neural Regeneration Research, 2021, 16, 506.	1.6	5
1258	The APP Proteolytic System and Its Interactions with Dynamic Networks in Alzheimer's Disease. Methods in Molecular Biology, 2016, 1303, 71-99.	0.4	7
1260	Gel Phase Membrane Retards Amyloid β-Peptide (1–42) Fibrillation by Restricting Slaved Diffusion of Peptides on Lipid Bilayers. Langmuir, 2018, 34, 8408-8414.	1.6	20
1261	Screening of small molecules using the inhibition of oligomer formation in \hat{l}_{\pm} -synuclein aggregation as a selection parameter. Communications Chemistry, 2020, 3, .	2.0	27
1262	CHAPTER 7. Amyloid-Like Peptide Aggregates. RSC Soft Matter, 2020, , 217-268.	0.2	2
1263	Multi-target-directed phenol–triazole ligands as therapeutic agents for Alzheimer's disease. Chemical Science, 2017, 8, 5636-5643.	3.7	79
1264	Membrane affinity of individual toxic protein oligomers determined at the single-molecule level. Physical Chemistry Chemical Physics, 2020, 22, 14613-14620.	1.3	8
1265	On the role of the cellular prion protein in the uptake and signaling of pathological aggregates in neurodegenerative diseases. Prion, 2020, 14, 257-270.	0.9	15
1276	Thinking laterally about neurodegenerative proteinopathies. Journal of Clinical Investigation, 2013, 123, 1847-1855.	3.9	98
1277	Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. Alzheimer's Research and Therapy, 2020, 12, 169.	3.0	31
1278	Model Hirano Bodies Protect against Tau-Independent and Tau-Dependent Cell Death Initiated by the Amyloid Precursor Protein Intracellular Domain. PLoS ONE, 2012, 7, e44996.	1.1	18

#	Article	IF	CITATIONS
1279	Cyclophilin D Deficiency Rescues Axonal Mitochondrial Transport in Alzheimer's Neurons. PLoS ONE, 2013, 8, e54914.	1.1	97
1280	The Amyloid- \hat{l}^2 -SDR5C1(ABAD) Interaction Does Not Mediate a Specific Inhibition of Mitochondrial RNase P. PLoS ONE, 2013, 8, e65609.	1.1	9
1281	Ablation of CaV2.1 Voltage-Gated Ca2+ Channels in Mouse Forebrain Generates Multiple Cognitive Impairments. PLoS ONE, 2013, 8, e78598.	1.1	28
1282	S100A9 Knockout Decreases the Memory Impairment and Neuropathology in Crossbreed Mice of Tg2576 and S100A9 Knockout Mice Model. PLoS ONE, 2014, 9, e88924.	1.1	47
1283	A Generic Method for Design of Oligomer-Specific Antibodies. PLoS ONE, 2014, 9, e90857.	1.1	38
1284	Effects of Huanglian-Jie-Du-Tang and Its Modified Formula on the Modulation of Amyloid-Î ² Precursor Protein Processing in Alzheimer's Disease Models. PLoS ONE, 2014, 9, e92954.	1.1	32
1285	IGF2 Ameliorates Amyloidosis, Increases Cholinergic Marker Expression and Raises BMP9 and Neurotrophin Levels in the Hippocampus of the APPswePS1dE9 Alzheimer's Disease Model Mice. PLoS ONE, 2014, 9, e94287.	1,1	77
1286	Di-Tyrosine Cross-Link Decreases the Collisional Cross-Section of $\hat{Al^2}$ Peptide Dimers and Trimers in the Gas Phase: An Ion Mobility Study. PLoS ONE, 2014, 9, e100200.	1.1	23
1287	Disruption of Amyloid Plaques Integrity Affects the Soluble Oligomers Content from Alzheimer Disease Brains. PLoS ONE, 2014, 9, e114041.	1.1	20
1288	Involvement of Intracellular and Mitochondrial $\hat{Al^2}$ in the Ameliorative Effects of Huperzine A against Oligomeric $\hat{Al^2}$ 42-Induced Injury in Primary Rat Neurons. PLoS ONE, 2015, 10, e0128366.	1.1	23
1289	IgG Conformer's Binding to Amyloidogenic Aggregates. PLoS ONE, 2015, 10, e0137344.	1.1	5
1290	Light Chain Amyloid Fibrils Cause Metabolic Dysfunction in Human Cardiomyocytes. PLoS ONE, 2015, 10, e0137716.	1.1	58
1291	Bis(sulfosuccinimidyl) suberate (BS3) crosslinking analysis of the behavior of amyloid- \hat{l}^2 peptide in solution and in phospholipid membranes. PLoS ONE, 2017, 12, e0173871.	1.1	15
1292	Functional Amyloids and their Possible Influence on Alzheimer Disease. Discoveries, 2017, 5, e79.	1.5	9
1293	Alzheimer's Disease and the Immune System. SOJ Neurology, 2015, 2, 1-11.	0.1	7
1294	Inhibition of Al 2 42 oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs. Microbial Cell, 2016, 3, 53-64.	1.4	18
1295	$\hat{Al^2}$ Plaques. Free Neuropathology, 2020, 1, .	2.4	21
1296	Recapitulating Amyloid ß and Tau Pathology in Human Neural Cell Culture Models—Clinical Implications. US Neurology, 2015, 11, 102.	0.2	19

#	Article	IF	Citations
1297	Detection of mis-folded protein aggregates from a clinical perspective. Journal of Clinical and Translational Research, $2016, 2, \ldots$	0.3	2
1298	Expression of amyloid- \hat{l}^2 in mouse cochlear hair cells causes an early-onset auditory defect in high-frequency sound perception. Aging, 2016, 8, 427-439.	1.4	21
1299	Early and progressive deficit of neuronal activity patterns in a model of local amyloid pathology in mouse prefrontal cortex. Aging, 2016, 8, 3430-3449.	1.4	10
1300	Riluzole: a therapeutic strategy in Alzheimer's disease by targeting the WNT/β-catenin pathway. Aging, 2020, 12, 3095-3113.	1.4	29
1301	High fat diet exacerbates Alzheimer's disease-related pathology in APPswe/PS1 mice. Oncotarget, 2016, 7, 67808-67827.	0.8	94
1302	Amyloid-β Aggregation Inhibitory and Neuroprotective Effects of Xanthohumol and its Derivatives for Alzheimer's Diseases. Current Alzheimer Research, 2019, 16, 836-842.	0.7	11
1303	Mechanistic Modeling of Soluble Aβ Dynamics and Target Engagement in the Brain by Anti-Aβ mAbs in Alzheimer's Disease. Current Alzheimer Research, 2020, 17, 393-406.	0.7	6
1304	Targeting Pathological Amyloid Aggregates with Conformation-Sensitive Antibodies. Current Alzheimer Research, 2020, 17, 722-734.	0.7	12
1305	AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer's Disease. Current Neuropharmacology, 2016, 14, 364-375.	1.4	66
1306	Recent Updates in the Alzheimer's Disease Etiopathology and Possible Treatment Approaches: A Narrative Review of Current Clinical Trials. Current Molecular Pharmacology, 2020, 13, 273-294.	0.7	16
1307	Methods for Studying and Structure–Function Relationships of Non-Fibrillar Protein Assemblies in Alzheimer's Disease and Related Disorders. , 2014, , 291-374.		1
1308	The epigenetic dimension of Alzheimer's disease: causal, consequence, or curiosity?. Dialogues in Clinical Neuroscience, 2014, 16, 373-393.	1.8	55
1309	Smart Nanotheranostics Responsive to Pathological Stimuli. Frontiers in Bioengineering and Biotechnology, 2020, 8, 503.	2.0	22
1310	Circadian rhythms, Neuroinflammation and Oxidative Stress in the Story of Parkinson's Disease. Cells, 2020, 9, 314.	1.8	29
1311	Challenges in understanding the structure/activity relationship of $\hat{Al^2}$ oligomers. AIMS Biophysics, 2019, 6, 1-22.	0.3	3
1312	Towards defining the Mechanisms of Alzheimer's disease based on a contextual analysis of molecular pathways. AIMS Genetics, 2016, 03, 025-048.	1.9	3
1313	Vincamine alleviates amyloid- \hat{l}^2 25-35 peptides-induced cytotoxicity in PC12 cells. Pharmacognosy Magazine, 2017, 13, 123.	0.3	13
1314	Dab2 attenuates brain injury in APP/PS1 mice via targeting transforming growth factor-beta/SMAD signaling. Neural Regeneration Research, 2014, 9, 41.	1.6	20

#	Article	IF	CITATIONS
1315	The complexities underlying age-related macular degeneration: could amyloid beta play an important role?. Neural Regeneration Research, 2017, 12, 538.	1.6	34
1316	Physiological and pathological effects of amyloid- \hat{l}^2 species in neural stem cell biology. Neural Regeneration Research, 2019, 14, 2035.	1.6	22
1317	CMV Driven Immunosenescence and Alzheimer's Disease. Journal of Neuroinfectious Diseases, 2015, 06,	0.2	3
1318	Tyrosine kinase receptor B isoforms alter APP and BACE1 endogenous levels independently of BDNF. Advances in Alzheimer's Disease, 2012, 01, 93-101.	0.3	1
1319	Stem cell therapy for Alzheimer's disease. World Journal of Stem Cells, 2020, 12, 787-802.	1.3	77
1320	Toxic oligomer species of amyloid- \hat{l}^2 in Alzheimer's disease, a timing issue. Swiss Medical Weekly, 2014, 144, w14021.	0.8	27
1321	Pin1 Protects Against Alzheimer's Disease: One Goal, Multiple Mechanisms., 0,,.		2
1322	A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1. ELife, 2015, 4, .	2.8	29
1323	Spatial control of irreversible protein aggregation. ELife, 2019, 8, .	2.8	37
1324	Structural mapping of oligomeric intermediates in an amyloid assembly pathway. ELife, 2019, 8, .	2.8	44
1325	Structure-based inhibitors of amyloid beta core suggest a common interface with tau. ELife, 2019, 8, .	2.8	81
1326	Sleep is bi-directionally modified by amyloid beta oligomers. ELife, 2020, 9, .	2.8	24
1327	Ammonium hydroxide treatment of $\hat{Al^2}$ produces an aggregate free solution suitable for biophysical and cell culture characterization. PeerJ, 2013, 1, e73.	0.9	93
1328	Mechanism of Cellular Formation and In Vivo Seeding Effects of Hexameric β-Amyloid Assemblies. Molecular Neurobiology, 2021, 58, 6647-6669.	1.9	8
1329	NMR Studies of the Ion Channel-Forming Human Amyloid- \hat{l}^2 with Zinc Ion Concentrations. Membranes, 2021, 11, 799.	1.4	3
1330	Investigating Pathogenetic Mechanisms of Alzheimer's Disease by Systems Biology Approaches for Drug Discovery. International Journal of Molecular Sciences, 2021, 22, 11280.	1.8	3
1331	The Role of Microglia in the Development of Neurodegenerative Diseases. Biomedicines, 2021, 9, 1449.	1.4	18
1332	TREM2 modulates differential deposition of modified and non-modified $\hat{Al^2}$ species in extracellular plaques and intraneuronal deposits. Acta Neuropathologica Communications, 2021, 9, 168.	2.4	12

#	Article	IF	CITATIONS
1333	Direct Delivery of ANA-TA9, a Peptide Capable of $\hat{A^2}$ Hydrolysis, to the Brain by Intranasal Administration. Pharmaceutics, 2021, 13, 1673.	2.0	2
1335	Interactions of the Aβ(1–42) Peptide with Boron Nitride Nanoparticles of Varying Curvature in an Aqueous Medium: Different Pathways to Inhibit β-Sheet Formation. Journal of Physical Chemistry B, 2021, 125, 11159-11178.	1.2	8
1336	Transglutaminase 2 as a therapeutic target for neurological conditions. Expert Opinion on Therapeutic Targets, 2021, 25, 721-731.	1.5	10
1337	NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load. ELife, 2021, 10, .	2.8	12
1338	Cerebral ageing-the role of insulin and insulin-like growth factor signalling: A review. World Journal of Neurology, 2014, 4, 12.	0.6	0
1340	Thermodynamics and Kinetics of Amyloid Aggregation from Atomistic Simulations. , 2015, , 29-45.		0
1342	Unproven Hypotheses on the Cause of Alzheimer's. , 2016, , 39-48.		0
1344	Solving the Puzzle of Neurodegeneration. , 2018, , 1-22.		2
1356	Synthesis and Structure-Function Analyses of the Toxic Dimer and Trimer Models of Amyloid \hat{l}^2 . Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 2019, 77, 1201-1208.	0.0	0
1357	Effect of Different A \hat{I}^2 Aggregates as Antigen on the Measure of Naturally Occurring Autoantibodies against Amyloid- \hat{I}^2 40/42 in IVIG. Current Alzheimer Research, 2020, 16, 1290-1299.	0.7	1
1358	Analysis of Electrostatic Interaction between Dimer Complexes. Part II: Criteria and Conditions on Inhibitors of APP Protein Derivatives. Technical Physics, 2020, 65, 1313-1320.	0.2	0
1359	Inflamma-MicroRNAs in Alzheimer's Disease: From Disease Pathogenesis to Therapeutic Potentials. Frontiers in Cellular Neuroscience, 2021, 15, 785433.	1.8	23
1360	Role of brain extracellular vesicles in air pollution-related cognitive impairment and neurodegeneration. Environmental Research, 2022, 204, 112316.	3.7	13
1361	Severe histomorphological alterations in postâ€mortem olfactory glomeruli in Alzheimer's disease. Brain Pathology, 2021, , e13033.	2.1	4
1362	Real-Time Analysis of Specific Binding between Apolipoprotein E Isoforms and Amyloid \hat{l}^2 -Peptide by Dual Polarization Interferometry. Analytical Chemistry, 2021, 93, 1472-1479.	3.2	6
1366	Immunotherapy Targeting Amyloid-ĀŸ Peptides in Alzheimer's Disease. , 0, , 23-49.		3
1369	Dissecting the complexities of Alzheimer disease with in vitro models of the human brain. Nature Reviews Neurology, 2022, 18, 25-39.	4.9	30
1370	Astrocyteâ€neuronal network interplay is disrupted in Alzheimer's disease mice. Glia, 2022, 70, 368-378.	2.5	33

#	Article	IF	CITATIONS
1371	A Novel Method to Stimulate Lymphatic Clearance of Beta-Amyloid from Mouse Brain Using Noninvasive Music-Induced Opening of the Blood–Brain Barrier with EEG Markers. Applied Sciences (Switzerland), 2021, 11, 10287.	1.3	3
1376	Regulation of protein conformation by Pin1 offers novel disease mechanisms and therapeutic approaches in Alzheimer's disease. Discovery Medicine, 2014, 17, 93-9.	0.5	43
1377	Brain Na(+), K(+)-ATPase Activity In Aging and Disease. International Journal of Biomedical Science, 2014, 10, 85-102.	0.5	71
1378	Probing of Amyloid A \hat{l}^2 (14-23) Trimers by Single-Molecule Force Spectroscopy. , 2016, 1, .		7
1379	Hypoxia increases amyloid- \hat{l}^2 level in exosomes by enhancing the interaction between CD147 and Hook1. American Journal of Translational Research (discontinued), 2018, 10, 150-163.	0.0	5
1380	Detection of misfolded protein aggregates from a clinical perspective. Journal of Clinical and Translational Research, 2016, 2, 11-26.	0.3	3
1382	Cell competition from development to neurodegeneration. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	3
1383	Mechanosensitivity of N-methyl-D-aspartate receptors (NMDAR) is the key through which amyloid beta oligomers activate them. Neural Regeneration Research, 2022, 17, 1263.	1.6	1
1384	Cytotoxic $\hat{Al^2}$ Protofilaments Are Generated in the Process of $\hat{Al^2}$ Fibril Disaggregation. International Journal of Molecular Sciences, 2021, 22, 12780.	1.8	2
1385	Night Photostimulation of Clearance of Beta-Amyloid from Mouse Brain: New Strategies in Preventing Alzheimer's Disease. Cells, 2021, 10, 3289.	1.8	29
1386	Biological and methodological complexities of betaâ€amyloid peptide: Implications for Alzheimer's disease research. Journal of Neurochemistry, 2022, 160, 434-453.	2.1	12
1387	Amyloid-beta peptide and tau protein crosstalk in Alzheimer's disease. Neural Regeneration Research, 2022, 17, 1666.	1.6	87
1388	Effects of α-Lipoic Acid on Phagocytosis of Oligomeric Beta-Amyloid1–42 in BV-2 Mouse Microglial Cells. Frontiers in Aging Neuroscience, 2021, 13, 788723.	1.7	2
1389	Impairment of the autophagy–lysosomal pathway in Alzheimer's diseases: Pathogenic mechanisms and therapeutic potential. Acta Pharmaceutica Sinica B, 2022, 12, 1019-1040.	5.7	56
1390	Can SARS-CoV-2 Infection Exacerbate Alzheimer's Disease? An Overview of Shared Risk Factors and Pathogenetic Mechanisms. Journal of Personalized Medicine, 2022, 12, 29.	1.1	17
1391	The role of membranes in function and dysfunction of intrinsically disordered amyloidogenic proteins. Advances in Protein Chemistry and Structural Biology, 2022, 128, 397-434.	1.0	1
1392	Kinetic Modulation of Amyloid-β (1–42) Aggregation and Toxicity by Structure-Based Rational Design. Journal of the American Chemical Society, 2022, 144, 1603-1611.	6.6	10
1394	A calcium-sensitive antibody isolates soluble amyloid-β aggregates and fibrils from Alzheimer's disease brain. Brain, 2022, , .	3.7	7

#	Article	IF	CITATIONS
1395	A Disulfide-Stabilized AÎ ² that Forms Dimers but Does Not Form Fibrils. Biochemistry, 2022, 61, 252-264.	1.2	4
1396	A Fluorescent Sensor for Quantitative Superâ€Resolution Imaging of Amyloid Fibril Assembly**. Angewandte Chemie - International Edition, 2022, 61, .	7.2	9
1397	Kinetic profiling of therapeutic strategies for inhibiting the formation of amyloid oligomers. Journal of Chemical Physics, 2022, 156, 164904.	1.2	13
1398	A Fluorescent Sensor for Quantitative Superâ€Resolution Imaging of Amyloid Fibril Assembly**. Angewandte Chemie, 0, , .	1.6	2
1399	Aptamers targeting amyloidogenic proteins and their emerging role in neurodegenerative diseases. Journal of Biological Chemistry, 2022, 298, 101478.	1.6	12
1400	Molecular packing of lipid membranes and action mechanisms of membrane-active peptides. Colloids and Surfaces B: Biointerfaces, 2022, 213, 112384.	2.5	2
1401	Passion fruit seed extract protects betaâ€amyloidâ€induced neuronal cell death in a differentiated human neuroblastoma SHâ€SY5Y cell model. Food Science and Nutrition, 2022, 10, 1461-1468.	1.5	8
1402	The amyloid state of proteins: A boon or bane?. International Journal of Biological Macromolecules, 2022, 200, 593-617.	3.6	12
1403	Amyloid fishing: \hat{l}^2 -Amyloid adsorption using tailor-made coated titania nanoparticles. Colloids and Surfaces B: Biointerfaces, 2022, 212, 112374.	2.5	1
1404	Anatomy and formation mechanisms of early amyloid-β oligomers with lateral branching: graph network analysis on large-scale simulations. Chemical Science, 2022, 13, 2649-2660.	3.7	3
1405	MiR-155: An Important Regulator of Neuroinflammation. International Journal of Molecular Sciences, 2022, 23, 90.	1.8	52
1406	The Role of NLRP3 Inflammasome in Alzheimer's Disease and Potential Therapeutic Targets. Frontiers in Pharmacology, 2022, 13, 845185.	1.6	42
1407	Effects of Familial Alzheimer's Disease Mutations on the Assembly of a β-Hairpin Peptide Derived from Aβ _{16–36} . Biochemistry, 2022, 61, 446-454.	1.2	7
1408	Macrocyclic Peptides Derived from Familial Alzheimer's Disease Mutants Show Charge-Dependent Oligomeric Assembly and Toxicity. ACS Chemical Neuroscience, 2022, 13, 714-720.	1.7	1
1409	Alzheimer's disease amyloid- \hat{l}^2 pathology in the lens of the eye. Experimental Eye Research, 2022, 221, 108974.	1.2	5
1410	Characterizing Heparin Tetrasaccharides Binding to Amyloid-Beta Peptide. Frontiers in Molecular Biosciences, 2022, 9, 824146.	1.6	4
1411	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nature Reviews Drug Discovery, 2022, 21, 306-318.	21.5	273
1412	Structure Optimization of the Toxic Conformation Model of Amyloid \hat{l}^2 42 by Intramolecular Disulfide Bond Formation. ChemBioChem, 2022, 23, .	1.3	7

#	Article	IF	Citations
1413	Amyloid Cross-Seeding: Mechanism, Implication, and Inhibition. Molecules, 2022, 27, 1776.	1.7	34
1414	Single-molecule fluorescence imaging and deep learning reveal highly heterogeneous aggregation of amyloid- \hat{l}^2 42. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2116736119.	3.3	12
1415	Mechanistic Kinetic Model Reveals How Amyloidogenic Hydrophobic Patches Facilitate the Amyloid- \hat{l}^2 Fibril Elongation. ACS Chemical Neuroscience, 2022, 13, 987-1001.	1.7	4
1416	Yeast red pigment, protein aggregates, and amyloidoses: a review. Cell and Tissue Research, 2022, , 1.	1.5	1
1417	Amyloid- \hat{l}^2 42 oligomeric forms: AFM nanoscale structural characterization and impact on long-term memory of young and aged zebrafish. Neuroscience, 2022, , .	1.1	2
1418	Cross-Seeding Controls $\hat{Al^2}$ Fibril Populations and Resulting Functions. Journal of Physical Chemistry B, 2022, 126, 2217-2229.	1.2	4
1419	Amelioration of Experimental Autoimmune Encephalomyelitis in Alzheimer's Disease Mouse Models: A Potential Role for Aβ. Cells, 2022, 11, 1004.	1.8	1
1420	Immunotherapy for Alzheimerâ \in ^M s disease: targeting \hat{l}^2 -amyloid and beyond. Translational Neurodegeneration, 2022, 11, 18.	3.6	75
1421	Dendrimers as Antiamyloid Agents. Pharmaceutics, 2022, 14, 760.	2.0	11
1422	Activity-differential search for amyloid- \hat{l}^2 aggregation inhibitors using LC-MS combined with principal component analysis. Bioorganic and Medicinal Chemistry Letters, 2022, 61, 128613.	1.0	4
1423	Supramolecular Nanostructures Based on Perylene Diimide Bioconjugates: From Self-Assembly to Applications. Nanomaterials, 2022, 12, 1223.	1.9	16
1424	Elevated amyloid beta disrupts the nanoscale organization and function of synaptic vesicle pools in hippocampal neurons. Cerebral Cortex, 2023, 33, 1263-1276.	1.6	5
1425	Formulation and optimization of silymarin-encapsulated binary micelles for enhanced amyloid disaggregation activity. Drug Development and Industrial Pharmacy, 2021, 47, 1775-1785.	0.9	4
1426	Copper oxide nanoparticles promote amyloid- \hat{l}^2 -triggered neurotoxicity through formation of oligomeric species as a prelude to Alzheimer's diseases. International Journal of Biological Macromolecules, 2022, 207, 121-129.	3.6	7
1427	A guide to studying protein aggregation. FEBS Journal, 2023, 290, 554-583.	2.2	55
1428	Complex modulation of cytokine-induced î±-synuclein aggregation by glypican-1-derived heparan sulfate in neural cells. Glycobiology, 2022, 32, 333-342.	1.3	4
1429	Alzheimer's disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis. Nature Aging, 2022, 2, 60-73.	5. 3	12
1430	Tieguanyin Oolong Tea Extracts Alleviate Behavioral Abnormalities by Modulating Neuroinflammation in APP/PS1 Mouse Model of Alzheimer's Disease. Foods, 2022, 11, 81.	1.9	7

#	Article	IF	CITATIONS
1432	Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2022, 14, 858429.	1.7	9
1433	Modulation of Amyloid \hat{l}^2 -Induced Microglia Activation and Neuronal Cell Death by Curcumin and Analogues. International Journal of Molecular Sciences, 2022, 23, 4381.	1.8	7
1434	Deep Learning Assisted Stratification of Amyloid Beta Mutants Using Drying Droplet Patterns. Advanced Materials, 2022, , 2110404.	11,1	3
1435	Brain pathological changes during neurodegenerative diseases and their identification methods: How does QSM perform in detecting this process?. Insights Into Imaging, 2022, 13, 74.	1.6	9
1436	Clinical and Molecular Findings in a Turkish Family Who Had a (c.869-1G>A) Splicing Variant in PSEN1 Gene with A Rare Condition: The Variant Alzheimer's Disease with Spastic Paraparesis. Current Alzheimer Research, 2022, 19, 223-235.	0.7	3
1453	Biophysical characterization as a tool to predict amyloidogenic and toxic properties of amyloidâ€Î²42 peptides. FEBS Letters, 2022, 596, 1401-1411.	1.3	2
1454	Cell competition from development to neurodegeneration. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	8
1455	Physical Mechanism of Amyloid-Î ² Peptide Chain Aggregation on Fluidic Lipid Nanotubules. Langmuir, 2022, 38, 5752-5758.	1.6	2
1456	Exosomes Derived From M2 Microglia Cells Attenuates Neuronal Impairment and Mitochondrial Dysfunction in Alzheimer's Disease Through the PINK1/Parkin Pathway. Frontiers in Cellular Neuroscience, 2022, 16, 874102.	1.8	15
1457	Neurogenesis in aging and age-related neurodegenerative diseases. Ageing Research Reviews, 2022, 78, 101636.	5.0	41
1458	Constructing conformational library for amyloid- \hat{l}^2 42 dimers as the smallest toxic oligomers using two CHARMM force fields. Journal of Molecular Graphics and Modelling, 2022, 115, 108207.	1.3	5
1459	Molecular Insights into Cell Type-specific Roles in Alzheimer's Disease: Human Induced Pluripotent Stem Cell-based Disease Modelling. Neuroscience, 2023, 518, 10-26.	1.1	5
1460	$\hat{Al^2}$ oligomer concentration in mouse and human brain and its drug-induced reduction ex \hat{A} vivo. Cell Reports Medicine, 2022, 3, 100630.	3.3	12
1462	The effect of mechanical shocks on the initial aggregation behavior of yeast prion protein Sup35NM. International Journal of Biological Macromolecules, 2022, 212, 465-473.	3.6	1
1465	Site specific NMR characterization of abeta-40 oligomers cross seeded by abeta-42 oligomers. Chemical Science, 2022, 13, 8526-8535.	3.7	8
1466	Amyloids on Membrane Interfaces: Implications for Neurodegeneration. Journal of Membrane Biology, 2022, 255, 705-722.	1.0	2
1467	Targeting the alternative oxidase (AOX) for human health and food security, a pharmaceutical and agrochemical target or a rescue mechanism?. Biochemical Journal, 2022, 479, 1337-1359.	1.7	6
1469	Pore Formation Mechanism of A-Beta Peptide on the Fluid Membrane: A Combined Coarse-Grained and All-Atomic Model. Molecules, 2022, 27, 3924.	1.7	1

#	Article	IF	CITATIONS
1470	Tissue Engineering and Photodynamic Therapy: A New Frontier of Science for Clinical Application -An Up-To-Date Review. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	5
1471	Toxicity Mechanism of AÎ ² 42 Oligomer in the Binding between the GABA _B R1a sushi1 Domain and Amyloid Precursor Protein 9mer: A Mechanism like Substitution Reaction. ACS Chemical Neuroscience, 2022, 13, 2048-2059.	1.7	1
1472	Rationally designed amyloid inhibitors based on amyloid-related structural studies. Chinese Chemical Letters, 2023, 34, 107623.	4.8	2
1473	Brain Amyloid- ß Accumulation in AD Mouse Models Modified by Their Altered Gene Expression in the Presence of Human apoE Isoforms Through Aging Process. SSRN Electronic Journal, 0, , .	0.4	0
1474	Shati/Nat8l Overexpression Improves Cognitive Decline by Upregulating Neuronal Trophic Factor in Alzheimer's Disease Model Mice. Neurochemical Research, 2022, 47, 2805-2814.	1.6	2
1475	Glucose enrichment impair neurotransmission and induce $\hat{Al^2}$ oligomerization that cannot be reversed by manipulating O- \hat{l}^2 -GlcNAcylation in the C. elegans model of Alzheimer's disease. Journal of Nutritional Biochemistry, 2022, 108, 109100.	1.9	8
1476	Aspartic Acid-Modified Phospholipids Regulate Cell Response and Rescue Memory Deficits in APP/PS1 Transgenic Mice. ACS Chemical Neuroscience, 2022, 13, 2154-2163.	1.7	1
1478	Sphingosine 1â€phosphate attenuates neuronal dysfunction induced by amyloidâ€Î² oligomers through endocytic internalization of <scp>NMDA</scp> receptors. FEBS Journal, 2023, 290, 112-133.	2.2	4
1479	Conformational and functional changes of the native neuropeptide somatostatin occur in the presence of copper and amyloid- \hat{l}^2 . Nature Chemistry, 2022, 14, 1021-1030.	6.6	7
1480	Extracellular transglutaminase-2, nude or associated with astrocytic extracellular vesicles, modulates neuronal calcium homeostasis. Progress in Neurobiology, 2022, 216, 102313.	2.8	7
1481	Beyond Amyloid Fibers: Accumulation, Biological Relevance, and Regulation of Higher-Order Prion Architectures. Viruses, 2022, 14, 1635.	1.5	4
1482	Relationship between Brain Metabolic Disorders and Cognitive Impairment: LDL Receptor Defect. International Journal of Molecular Sciences, 2022, 23, 8384.	1.8	12
1483	Elucidating the Oligomerization and Cellular Interactions of a Trimer Derived from $\hat{Al^2}$ through Fluorescence and Mass Spectrometric Studies. ACS Chemical Neuroscience, 2022, 13, 2473-2482.	1.7	2
1484	A quantitative biology approach correlates neuronal toxicity with the largest inclusions of TDP-43. Science Advances, 2022, 8, .	4.7	12
1485	Excited-State Intramolecular Hydrogen Transfer of Compact Molecules Controls Amyloid Aggregation Profiles. Jacs Au, 2022, 2, 2001-2012.	3.6	5
1486	Interactions of amyloid coaggregates with biomolecules and its relevance to neurodegeneration. FASEB Journal, 2022, 36, .	0.2	11
1487	$A\hat{l}^2$ < sub> 42 < /sub> peptides. Journal of the Chinese Chemical Society, 2022, 69, 1318-1325.	0.8	2
1488	Endoplasmic reticulum stress induces Alzheimer diseaseâ€like phenotypes in the neuron derived from the induced pluripotent stem cell with <scp>D678H</scp> mutation on amyloid precursor protein. Journal of Neurochemistry, 2022, 163, 26-39.	2.1	0

#	Article	IF	CITATIONS
1489	Protein Aggregation in Neurodegenerative Diseases. , 2022, , 26-58.		0
1490	Oligomeropathies, inflammation and prion protein binding. Frontiers in Neuroscience, $0,16,.$	1.4	3
1491	The Chemerin/CMKLR1 Axis Is Involved in the Recruitment of Microglia to ${\rm A\hat{I}^2}$ Deposition through p38 MAPK Pathway. International Journal of Molecular Sciences, 2022, 23, 9041.	1.8	7
1492	Should we lower or raise levels of amyloid- \hat{l}^2 in the brains of Alzheimer patients?. Pharmacological Research, 2022, 183, 106390.	3.1	3
1493	GC/MS-Based Urine Metabolomics Study on the Ameliorative Effect of Xanthoceras sorbifolia Extract on Alzheimer's Disease in Mice. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-13.	0.5	0
1494	The Impairment of Blood-Brain Barrier in Alzheimer's Disease: Challenges and Opportunities with Stem Cells. International Journal of Molecular Sciences, 2022, 23, 10136.	1.8	6
1495	Expression of the human herpesvirus 6A latency-associated transcript U94A impairs cytoskeletal functions in human neural cells. Molecular and Cellular Neurosciences, 2022, 123, 103770.	1.0	0
1496	Misfolded protein oligomers induce an increase of intracellular Ca2+ causing an escalation of reactive oxidative species. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	13
1497	Toward high-throughput oligomer detection and classification for early-stage aggregation of amyloidogenic protein. Frontiers in Chemistry, 0, 10 , .	1.8	0
1499	Melatonin Inhibits hIAPP Oligomerization by Preventing \hat{I}^2 -Sheet and Hydrogen Bond Formation of the Amyloidogenic Region Revealed by Replica-Exchange Molecular Dynamics Simulation. International Journal of Molecular Sciences, 2022, 23, 10264.	1.8	7
1501	Peroxiredoxin 2 Ameliorates AβO-Mediated Autophagy by Inhibiting ROS via the ROS–NRF2–p62 Pathway in N2a-APP Swedish Cells. Antioxidants, 2022, 11, 1889.	2.2	3
1502	Amyloid fibrils act as a reservoir of soluble oligomers, the main culprits in protein deposition diseases. BioEssays, 2022, 44, .	1.2	14
1503	The multiple functions of PrPC in physiological, cancer, and neurodegenerative contexts. Journal of Molecular Medicine, 2022, 100, 1405-1425.	1.7	5
1505	Mesenchymal stromal cells for the treatment of Alzheimer's disease: Strategies and limitations. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	7
1506	Interaction between autophagy and the NLRP3 inflammasome in Alzheimer's and Parkinson's disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	15
1507	Proteinopathies: Deciphering Physiology and Mechanisms to Develop Effective Therapies for Neurodegenerative Diseases. Molecular Neurobiology, 2022, 59, 7513-7540.	1.9	5
1508	Lysine-targeting inhibition of amyloid \hat{l}^2 oligomerization by a green perilla-derived metastable chalcone <i>in vitro</i> and <i>in vivo</i> . RSC Chemical Biology, 2022, 3, 1380-1396.	2.0	3
1509	Amphiphilic stilbene derivatives attenuate the neurotoxicity of soluble $\hat{Al^2}$ sub>42 (sub> oligomers by controlling their interactions with cell membranes. Chemical Science, 2022, 13, 12818-12830.	3.7	5

#	Article	IF	CITATIONS
1510	Synaptogenic effect of <i>APP</i> -Swedish mutation in familial Alzheimer's disease. Science Translational Medicine, 2022, 14, .	5.8	29
1512	Alzheimer's Disease: From Immune Homeostasis to Neuroinflammatory Condition. International Journal of Molecular Sciences, 2022, 23, 13008.	1.8	13
1513	The Hidden Role of Non-Canonical Amyloid β Isoforms in Alzheimer's Disease. Cells, 2022, 11, 3421.	1.8	3
1514	Preparation and Investigation of Crucial Oligomers in the Early Stages of Al 2 40 and Al 2 42 Aggregation. Methods in Molecular Biology, 2023, , 15-28.	0.4	0
1515	Fats, Friends or Foes: Investigating the Role of Short- and Medium-Chain Fatty Acids in Alzheimer's Disease. Biomedicines, 2022, 10, 2778.	1.4	4
1516	Inhibition of Amyloid Protein Aggregation Using Selected Peptidomimetics. ChemMedChem, 2023, 18, .	1.6	3
1517	Molecular Structure of Cu(II)-Bound Amyloid-β Monomer Implicated in Inhibition of Peptide Self-Assembly in Alzheimer's Disease. Jacs Au, 2022, 2, 2571-2584.	3.6	20
1518	Blood Selenium and Serum Glutathione Peroxidase Levels Were Associated with Serum \hat{l}^2 -Amyloid in Older Adults. Biological Trace Element Research, 2023, 201, 3679-3687.	1.9	5
1520	Alzheimer's disease – Where do we go from here?. Biochemical and Biophysical Research Communications, 2022, 633, 72-76.	1.0	10
1521	Infectious origin of Alzheimer's disease: Amyloid beta as a component of brain antimicrobial immunity. PLoS Pathogens, 2022, 18, e1010929.	2.1	22
1522	A cationic amphiphilic peptide chaperone rescues \hat{A}^2 sub>42 \langle sub> aggregation and cytotoxicity. RSC Medicinal Chemistry, 2023, 14, 332-340.	1.7	1
1523	Mitochondrial defects in pancreatic beta-cell dysfunction and neurodegenerative diseases: Pathogenesis and therapeutic applications. Life Sciences, 2023, 312, 121247.	2.0	2
1524	Borneol-driven meningeal lymphatic drainage clears amyloid- \hat{l}^2 peptide to attenuate Alzheimer-like phenotype in mice. Theranostics, 2023, 13, 106-124.	4.6	9
1525	Characterisation of Amyloid Aggregation and Inhibition by Diffusion-Based Single-Molecule Fluorescence Techniques. Biophysica, 2022, 2, 506-524.	0.6	0
1526	Differential compartmentalization of myeloid cell phenotypes and responses towards the CNS in Alzheimer's disease. Nature Communications, 2022, 13, .	5.8	7
1527	An Exploratory Study Provides Insights into MMP9 and $A\hat{l}^2$ Levels in the Vitreous and Blood across Different Ages and in a Subset of AMD Patients. International Journal of Molecular Sciences, 2022, 23, 14603.	1.8	0
1528	Perphenazine–Macrocycle Conjugates Rapidly Sequester the Aβ42 Monomer and Prevent Formation of Toxic Oligomers and Amyloid. ACS Chemical Neuroscience, 2023, 14, 87-98.	1.7	1
1529	Simple, Reliable Protocol for High-Yield Solubilization of Seedless Amyloid- \hat{I}^2 Monomer. ACS Chemical Neuroscience, 0, , .	1.7	O

#	ARTICLE	IF	CITATIONS
1530	Differentiation of subnucleus-sized oligomers and nucleation-competent assemblies of the A <mml:math altimg="si1.gif" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>\hat{l}^2</mml:mi></mml:mrow></mml:math> peptide. Biophysical Journal, 2023, 122, 269-278.	0.2	1
1531	Applications of Carbon Dots for the Treatment of Alzheimer's Disease. International Journal of Nanomedicine, 0, Volume 17, 6621-6638.	3.3	4
1532	Accumulation of amyloid- \hat{l}^2 in the brain of mouse models of Alzheimer's disease is modified by altered gene expression in the presence of human apoE isoforms during aging. Neurobiology of Aging, 2023, 123, 63-74.	1.5	2
1533	A dualâ€functional BODIPYâ€based molecular rotor probe reveals different viscosity of protein aggregates in live cells. Aggregate, 2023, 4, .	5.2	20
1535	The cellular model for Alzheimer's disease research: PC12 cells. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	14
1537	Distinct effects of <scp>SDC3</scp> and <scp>FGFRL1</scp> on selective neurodegeneration in <scp>AD</scp> and <scp>PD</scp> . FASEB Journal, 2023, 37, .	0.2	2
1538	Prion Protein Complex with mGluR5 Mediates Amyloid-ß Synaptic Loss in Alzheimer's Disease. , 2023, , 467-481.		0
1540	Elevated Plasma Oligomeric Amyloid \hat{l}^2 -42 Is Associated with Cognitive Impairments in Cerebral Small Vessel Disease. Biosensors, 2023, 13, 110.	2.3	3
1541	Regulatory mechanism of icariin in cardiovascular and neurological diseases. Biomedicine and Pharmacotherapy, 2023, 158, 114156.	2.5	4
1542	Diagnostic models and predictive drugs associated with cuproptosis hub genes in Alzheimer's disease. Frontiers in Neurology, 0, 13, .	1.1	6
1543	Methods for the isolation and analysis of $\hat{A^2}$ from postmortem brain. Frontiers in Neuroscience, 0, 17, .	1.4	0
1544	Formation kinetics and physicochemical properties of mesoscopic Alpha-Synuclein assemblies modulated by sodium chloride and a distinct pulsed electric field. Soft Matter, 0, , .	1.2	1
1545	Gut-derived β-amyloid: Likely a centerpiece of the gut–brain axis contributing to Alzheimer's pathogenesis. Gut Microbes, 2023, 15, .	4.3	16
1546	Mechanistic Insights of TiO ₂ Nanoparticles with Different Surface Charges on Aβ ₄₂ Peptide Early Aggregation: An In Vitro and In Silico Study. Langmuir, 2023, 39, 1997-2007.	1.6	3
1547	Liquid–liquid phase separation of amyloid-β oligomers modulates amyloid fibrils formation. Journal of Biological Chemistry, 2023, 299, 102926.	1.6	11
1548	Potential Protective Function of $\hat{Al}^2 < \text{sub} > 42 < /\text{sub} > Monomer on Tauopathies. Journal of the American Society for Mass Spectrometry, 2023, 34, 472-483.$	1.2	1
1549	Aggregation of Disordered Proteins Associated with Neurodegeneration. International Journal of Molecular Sciences, 2023, 24, 3380.	1.8	16
1550	Mixed pathology as a rule, not exception: Time to reconsider disease nosology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 57-71.	1.0	6

#	ARTICLE	IF	Citations
1551	Hyperoside alleviates toxicity of \hat{l}^2 -amyloid via endoplasmic reticulum-mitochondrial calcium signal transduction cascade in APP/PS1 double transgenic Alzheimer's disease mice. Redox Biology, 2023, 61, 102637.	3.9	5
1552	Pathogenesis of Alzheimer's Disease. , 2022, , 1709-1728.		0
1553	Probing Interfacial Charge Transfer between Amyloid- \hat{l}^2 and Graphene during Amyloid Fibrillization Using Raman Spectroscopy. ACS Nano, 2023, 17, 4834-4842.	7.3	4
1554	A peptide rich in glycine–serine–alanine repeats ameliorates Alzheimerâ€type neurodegeneration. British Journal of Pharmacology, 2023, 180, 1878-1896.	2.7	4
1555	Revealing the Nanoarchitectonics of Amyloid βâ€Aggregation on Twoâ€Dimensional Biomimetic Membranes by Surfaceâ€Enhanced Infrared Absorption Spectroscopy. ChemistryOpen, 2023, 12, .	0.9	3
1556	Amyloid oligomers as on-pathway precursors or off-pathway competitors of fibrils. Frontiers in Molecular Biosciences, 0 , 10 , .	1.6	6
1557	Interplay between APP and glypican-1 processing and α-synuclein aggregation in undifferentiated and differentiated human neural progenitor cells. Glycobiology, 2023, 33, 325-341.	1.3	2
1558	The shift to a proteinopenia paradigm in neurodegeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 23-32.	1.0	6
1559	Activation of the IL-17/TRAF6/NF-lºB pathway is implicated in Al̂2-induced neurotoxicity. BMC Neuroscience, 2023, 24, .	0.8	4
1560	Soluble and insoluble protein aggregates, endoplasmic reticulum stress, and vascular dysfunction in Alzheimer's disease and cardiovascular diseases. GeroScience, 2023, 45, 1411-1438.	2.1	5
1561	Protective Potential of \hat{l}^2 -Hydroxybutyrate against Glucose-Deprivation-Induced Neurotoxicity Involving the Modulation of Autophagic Flux and the Monomeric A \hat{l}^2 Level in Neuro-2a Cells. Biomedicines, 2023, 11, 698.	1.4	2
1562	Imaging Amyloidâ€Î² Membrane Interactions: Ionâ€Channel Pores and Lipidâ€Bilayer Permeability in Alzheimer's Disease. Angewandte Chemie, 2023, 135, .	1.6	0
1563	Imaging Amyloidâ€Î² Membrane Interactions: Ionâ€Channel Pores and Lipidâ€Bilayer Permeability in Alzheimer's Disease. Angewandte Chemie - International Edition, 2023, 62, .	7.2	9
1564	Protein Oligomer Engineering: A New Frontier for Studying Protein Structure, Function, and Toxicity. Angewandte Chemie - International Edition, 2023, 62, .	7.2	3
1565	Protein Oligomer Engineering: A New Frontier for Studying Protein Structure, Function, and Toxicity. Angewandte Chemie, 2023, 135, .	1.6	0
1566	<scp>MicroRNA</scp> â€128 suppresses tau phosphorylation and reduces amyloidâ€beta accumulation by inhibiting the expression of <scp>GSK3β</scp> , <scp>APPBP2</scp> , and <scp>mTOR</scp> in Alzheimer's disease. CNS Neuroscience and Therapeutics, 2023, 29, 1848-1864.	1.9	7
1567	Alpha Synuclein: Neurodegeneration and Inflammation. International Journal of Molecular Sciences, 2023, 24, 5914.	1.8	11
1568	Amyloid inhibition by molecular chaperones <i>in vitro</i> can be translated to Alzheimer's pathology <i>in vivo</i> . RSC Medicinal Chemistry, 2023, 14, 848-857.	1.7	10

#	Article	IF	CITATIONS
1569	S100B chaperone multimers suppress the formation of oligomers during Al̂^242 aggregation. Frontiers in Neuroscience, 0, 17, .	1.4	7
1570	Dityrosine cross-linking and its potential roles in Alzheimer's disease. Frontiers in Neuroscience, 0, 17,	1.4	2
1571	Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation. Cells, 2023, 12, 960.	1.8	0
1572	Regulation of betaâ€amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds. Medicinal Research Reviews, 2023, 43, 1091-1140.	5.0	6
1573	Learnings about Aβ from human brain recommend the use of a live-neuron bioassay for the discovery of next generation Alzheimer's disease immunotherapeutics. Acta Neuropathologica Communications, 2023, 11, .	2.4	2
1574	Protein fibril length in cerebrospinal fluid is increased in Alzheimer's disease. Communications Biology, 2023, 6, .	2.0	2
1576	Release of frustration drives corneal amyloid disaggregation by brain chaperone. Communications Biology, 2023, 6, .	2.0	0
1577	Rab11A Depletion in Microglia-Derived Extracellular Vesicle Proteome upon Beta-Amyloid Treatment. Cell Biochemistry and Biophysics, 2023, 81, 337-347.	0.9	0
1578	Brain <scp>p3â€Alcî²</scp> peptide restores neuronal viability impaired by Alzheimer's amyloid βâ€peptide. EMBO Molecular Medicine, 0, , .	3 . 3	3
1579	Enhanced therapeutic window for antimicrobial Pept-ins by investigating their structure-activity relationship. PLoS ONE, 2023, 18, e0283674.	1.1	0
1580	A new class of monoclonal $\hat{Al^2}$ antibodies selectively targets and triggers deposition of $\hat{Al^2}$ protofibrils. Journal of Neurochemistry, 2023, 165, 860-873.	2.1	2
1581	Lowering levels of reelin in entorhinal cortex layer II-neurons results in lowered levels of intracellular amyloid- \hat{l}^2 . Brain Communications, 2023, 5, .	1.5	3
1582	Cognitive decline in diabetic mice predisposed to Alzheimer's disease is greater than in wild type. Life Science Alliance, 2023, 6, e202201789.	1.3	2
1585	Structural Dynamics of Amyloid-Î ² Protofibrils and Actions of Anti-Amyloid-Î ² Antibodies as Observed by High-Speed Atomic Force Microscopy. Nano Letters, 2023, 23, 6259-6268.	4.5	4
1594	Recent Advances in Photoelectrochemical Sensing of Alzheimer's Biomarkers. Biochip Journal, 2023, 17, 218-229.	2.5	0
1595	High-Throughput Searches for Natural Products as Aggregation Modulators of Amyloidogenic Proteins., 2023,, 313-332.		0
1604	Recent developments in the chemical biology of amyloid- \hat{l}^2 oligomer targeting. Organic and Biomolecular Chemistry, 2023, 21, 4540-4552.	1.5	5
1611	Amyloid peptide hydrogels <i>via</i> formation of coordination polymers with Ag ⁺ by its core peptide equipped with a C-cysteine. Chemical Communications, 2023, 59, 9599-9602.	2.2	2

#	Article	IF	CITATIONS
1613	Alzheimer's Research Gains Momentum and Spreads Out. , 2023, , 285-307.		0
1622	Molecular pathology of neurodegenerative diseases by cryo-EM of amyloids. Nature, 2023, 621, 701-710.	13.7	18
1634	Assessment of Amyloid Morphology Using Electron Microscopy. Springer Protocols, 2023, , 129-133.	0.1	0
1653	Introduction: Molecular Chaperones and Protein Quality Control. , 2023, , 1-37.		O
1675	Amyloids as endogenous toxicants in neurodegenerative diseases. , 2024, , 1059-1081.		0